1	24	36	Introduction	introduction	NNP	_	_	B-cesDoc	B-head	_
2	45	48	The	the	DT	_	_	I-cesDoc	_	B-p
3	49	56	concept	concept	NN	_	_	I-cesDoc	_	I-p
4	57	59	of	of	IN	_	_	I-cesDoc	_	I-p
5	60	64	lung	lung	NN	_	_	I-cesDoc	_	I-p
6	65	76	fibroblasts	fibroblast	NNS	_	_	I-cesDoc	_	I-p
7	77	79	as	as	IN	_	_	I-cesDoc	_	I-p
8	80	88	effector	effector	NN	_	_	I-cesDoc	_	I-p
9	89	94	cells	cell	NNS	_	_	I-cesDoc	_	I-p
10	95	97	in	in	IN	_	_	I-cesDoc	_	I-p
11	98	101	the	the	DT	_	_	I-cesDoc	_	I-p
12	110	122	pathogenesis	pathogenesis	NNS	_	_	I-cesDoc	_	I-p
13	123	125	of	of	IN	_	_	I-cesDoc	_	I-p
14	126	136	idiopathic	idiopathic	JJ	_	_	I-cesDoc	_	I-p
15	137	146	pulmonary	pulmonary	JJ	_	_	I-cesDoc	_	I-p
16	147	155	fibrosis	fibrosis	NNS	_	_	I-cesDoc	_	I-p
17	156	157	(	(	(	_	_	I-cesDoc	_	I-p
18	157	160	IPF	ipf	NNP	_	_	I-cesDoc	_	I-p
19	160	161	)	)	)	_	_	I-cesDoc	_	I-p
20	162	165	has	have	VBZ	_	_	I-cesDoc	_	I-p
21	174	182	recently	recently	RB	_	_	I-cesDoc	_	I-p
22	183	190	evolved	evolve	VBN	_	_	I-cesDoc	_	I-p
23	191	192	[	[	NN	_	_	I-cesDoc	_	I-p
24	193	194	1	1	CD	_	_	I-cesDoc	_	I-p
25	195	196	2	2	CD	_	_	I-cesDoc	_	I-p
26	197	198	]	]	NN	_	_	I-cesDoc	_	I-p
27	199	200	.	.	.	_	_	I-cesDoc	_	I-p
28	201	205	Lung	lung	NNP	_	_	I-cesDoc	_	I-p
29	206	217	fibroblasts	fibroblast	NNS	_	_	I-cesDoc	_	I-p
30	218	225	respond	respond	VBP	_	_	I-cesDoc	_	I-p
31	225	226	,	,	,	_	_	I-cesDoc	_	I-p
32	236	238	in	in	IN	_	_	I-cesDoc	_	I-p
33	239	244	vitro	vitro	NN	_	_	I-cesDoc	_	I-p
34	245	246	,	,	,	_	_	I-cesDoc	_	I-p
35	247	249	to	to	TO	_	_	I-cesDoc	_	I-p
36	250	262	inflammatory	inflammatory	JJ	_	_	I-cesDoc	_	I-p
37	263	272	cytokines	cytokine	NNS	_	_	I-cesDoc	_	I-p
38	281	283	by	by	IN	_	_	I-cesDoc	_	I-p
39	284	293	producing	produce	VBG	_	_	I-cesDoc	_	I-p
40	294	300	growth	growth	NN	_	_	I-cesDoc	_	I-p
41	301	308	factors	factor	NNS	_	_	I-cesDoc	_	I-p
42	309	312	and	and	CC	_	_	I-cesDoc	_	I-p
43	313	321	collagen	collagen	NN	_	_	I-cesDoc	_	I-p
44	321	322	,	,	,	_	_	I-cesDoc	_	I-p
45	323	332	resulting	result	VBG	_	_	I-cesDoc	_	I-p
46	333	335	in	in	IN	_	_	I-cesDoc	_	I-p
47	344	354	fibroblast	fibroblast	NN	_	_	I-cesDoc	_	I-p
48	355	368	proliferation	proliferation	NN	_	_	I-cesDoc	_	I-p
49	369	372	and	and	CC	_	_	I-cesDoc	_	I-p
50	373	386	extracellular	extracellular	NN	_	_	I-cesDoc	_	I-p
51	387	393	matrix	matrix	NN	_	_	I-cesDoc	_	I-p
52	402	412	deposition	deposition	NN	_	_	I-cesDoc	_	I-p
53	413	414	[	[	NN	_	_	I-cesDoc	_	I-p
54	415	416	2	2	CD	_	_	I-cesDoc	_	I-p
55	417	418	3	3	CD	_	_	I-cesDoc	_	I-p
56	419	420	4	4	CD	_	_	I-cesDoc	_	I-p
57	421	422	]	]	NN	_	_	I-cesDoc	_	I-p
58	423	424	.	.	.	_	_	I-cesDoc	_	I-p
59	425	427	In	in	IN	_	_	I-cesDoc	_	I-p
60	428	436	addition	addition	NN	_	_	I-cesDoc	_	I-p
61	436	437	,	,	,	_	_	I-cesDoc	_	I-p
62	438	447	activated	activate	VBN	_	_	I-cesDoc	_	I-p
63	448	452	lung	lung	NN	_	_	I-cesDoc	_	I-p
64	461	472	fibroblasts	fibroblast	NNS	_	_	I-cesDoc	_	I-p
65	473	477	have	have	VBP	_	_	I-cesDoc	_	I-p
66	478	482	been	be	VBN	_	_	I-cesDoc	_	I-p
67	483	488	shown	show	VBN	_	_	I-cesDoc	_	I-p
68	489	491	to	to	TO	_	_	I-cesDoc	_	I-p
69	492	499	produce	produce	VB	_	_	I-cesDoc	_	I-p
70	500	505	large	large	JJ	_	_	I-cesDoc	_	I-p
71	506	513	amounts	amount	NNS	_	_	I-cesDoc	_	I-p
72	514	516	of	of	IN	_	_	I-cesDoc	_	I-p
73	525	537	inflammatory	inflammatory	JJ	_	_	I-cesDoc	_	I-p
74	538	547	cytokines	cytokine	NNS	_	_	I-cesDoc	_	I-p
75	548	551	and	and	CC	_	_	I-cesDoc	_	I-p
76	552	562	chemokines	chemokine	NNS	_	_	I-cesDoc	_	I-p
77	562	563	,	,	,	_	_	I-cesDoc	_	I-p
78	573	575	in	in	IN	_	_	I-cesDoc	_	I-p
79	576	581	vitro	vitro	NN	_	_	I-cesDoc	_	I-p
80	582	583	,	,	,	_	_	I-cesDoc	_	I-p
81	584	587	and	and	CC	_	_	I-cesDoc	_	I-p
82	588	593	hence	hence	RB	_	_	I-cesDoc	_	I-p
83	593	594	,	,	,	_	_	I-cesDoc	_	I-p
84	595	600	these	these	DT	_	_	I-cesDoc	_	I-p
85	601	606	cells	cell	NNS	_	_	I-cesDoc	_	I-p
86	607	610	may	may	MD	_	_	I-cesDoc	_	I-p
87	619	623	also	also	RB	_	_	I-cesDoc	_	I-p
88	624	628	have	have	VB	_	_	I-cesDoc	_	I-p
89	629	630	a	a	DT	_	_	I-cesDoc	_	I-p
90	631	635	role	role	NN	_	_	I-cesDoc	_	I-p
91	636	638	as	as	IN	_	_	I-cesDoc	_	I-p
92	639	647	effector	effector	NN	_	_	I-cesDoc	_	I-p
93	647	648	-	-	-	_	_	I-cesDoc	_	I-p
94	648	660	inflammatory	inflammatory	JJ	_	_	I-cesDoc	_	I-p
95	661	666	cells	cell	NNS	_	_	I-cesDoc	_	I-p
96	667	668	[	[	NN	_	_	I-cesDoc	_	I-p
97	669	670	1	1	CD	_	_	I-cesDoc	_	I-p
98	671	672	2	2	CD	_	_	I-cesDoc	_	I-p
99	673	674	]	]	NN	_	_	I-cesDoc	_	I-p
100	675	676	.	.	.	_	_	I-cesDoc	_	I-p
101	685	689	This	this	DT	_	_	I-cesDoc	_	I-p
102	690	698	capacity	capacity	NN	_	_	I-cesDoc	_	I-p
103	699	701	to	to	TO	_	_	I-cesDoc	_	I-p
104	702	709	produce	produce	VB	_	_	I-cesDoc	_	I-p
105	710	714	both	both	DT	_	_	I-cesDoc	_	I-p
106	715	727	inflammatory	inflammatory	JJ	_	_	I-cesDoc	_	I-p
107	728	731	and	and	CC	_	_	I-cesDoc	_	I-p
108	732	740	fibrotic	fibrotic	JJ	_	_	I-cesDoc	_	I-p
109	749	756	factors	factor	NNS	_	_	I-cesDoc	_	I-p
110	757	762	could	could	MD	_	_	I-cesDoc	_	I-p
111	763	767	mean	mean	VB	_	_	I-cesDoc	_	I-p
112	768	772	that	that	IN	_	_	I-cesDoc	_	I-p
113	773	787	phenotypically	phenotypically	RB	_	_	I-cesDoc	_	I-p
114	788	795	altered	alter	VBN	_	_	I-cesDoc	_	I-p
115	796	800	lung	lung	NN	_	_	I-cesDoc	_	I-p
116	809	820	fibroblasts	fibroblast	NNS	_	_	I-cesDoc	_	I-p
117	821	824	act	act	VBP	_	_	I-cesDoc	_	I-p
118	825	839	simultaneously	simultaneously	RB	_	_	I-cesDoc	_	I-p
119	840	842	as	as	IN	_	_	I-cesDoc	_	I-p
120	843	851	effector	effector	NN	_	_	I-cesDoc	_	I-p
121	852	855	and	and	CC	_	_	I-cesDoc	_	I-p
122	856	862	target	target	NN	_	_	I-cesDoc	_	I-p
123	871	876	cells	cell	NNS	_	_	I-cesDoc	_	I-p
124	876	877	,	,	,	_	_	I-cesDoc	_	I-p
125	878	881	via	via	IN	_	_	I-cesDoc	_	I-p
126	882	891	paracrine	paracrine	NN	_	_	I-cesDoc	_	I-p
127	892	895	and	and	CC	_	_	I-cesDoc	_	I-p
128	896	905	autocrine	autocrine	NN	_	_	I-cesDoc	_	I-p
129	906	916	mechanisms	mechanism	NNS	_	_	I-cesDoc	_	I-p
130	916	917	,	,	,	_	_	I-cesDoc	_	I-p
131	918	930	perpetuating	perpetuate	VBG	_	_	I-cesDoc	_	I-p
132	939	942	the	the	DT	_	_	I-cesDoc	_	I-p
133	943	951	fibrotic	fibrotic	JJ	_	_	I-cesDoc	_	I-p
134	952	959	process	process	NN	_	_	I-cesDoc	_	I-p
135	960	961	[	[	NN	_	_	I-cesDoc	_	I-p
136	962	963	2	2	CD	_	_	I-cesDoc	_	I-p
137	964	965	]	]	NN	_	_	I-cesDoc	_	I-p
138	966	967	.	.	.	_	_	I-cesDoc	_	I-p
139	976	987	Prostanoids	prostanoids	NNP	_	_	I-cesDoc	_	I-p
140	988	991	are	be	VBP	_	_	I-cesDoc	_	I-p
141	992	1001	important	important	JJ	_	_	I-cesDoc	_	I-p
142	1002	1012	regulators	regulator	NNS	_	_	I-cesDoc	_	I-p
143	1013	1015	of	of	IN	_	_	I-cesDoc	_	I-p
144	1016	1026	fibroblast	fibroblast	NN	_	_	I-cesDoc	_	I-p
145	1035	1043	function	function	NN	_	_	I-cesDoc	_	I-p
146	1044	1045	[	[	NN	_	_	I-cesDoc	_	I-p
147	1046	1047	5	5	CD	_	_	I-cesDoc	_	I-p
148	1048	1049	6	6	CD	_	_	I-cesDoc	_	I-p
149	1050	1051	7	7	CD	_	_	I-cesDoc	_	I-p
150	1052	1053	8	8	CD	_	_	I-cesDoc	_	I-p
151	1054	1055	9	9	CD	_	_	I-cesDoc	_	I-p
152	1056	1057	]	]	NN	_	_	I-cesDoc	_	I-p
153	1058	1059	.	.	.	_	_	I-cesDoc	_	I-p
154	1060	1073	Prostaglandin	prostaglandin	NNP	_	_	I-cesDoc	_	I-p
155	1074	1075	(	(	(	_	_	I-cesDoc	_	I-p
156	1075	1077	PG	pg	NNP	_	_	I-cesDoc	_	I-p
157	1077	1078	)	)	)	_	_	I-cesDoc	_	I-p
158	1078	1079	E	e	NN	_	_	I-cesDoc	_	I-p
159	1089	1090	2	2	CD	_	_	I-cesDoc	_	I-p
160	1091	1093	is	be	VBZ	_	_	I-cesDoc	_	I-p
161	1094	1101	thought	think	VBN	_	_	I-cesDoc	_	I-p
162	1102	1104	to	to	TO	_	_	I-cesDoc	_	I-p
163	1105	1109	have	have	VB	_	_	I-cesDoc	_	I-p
164	1110	1122	antifibrotic	antifibrotic	JJ	_	_	I-cesDoc	_	I-p
165	1131	1141	properties	property	NNS	_	_	I-cesDoc	_	I-p
166	1151	1153	in	in	IN	_	_	I-cesDoc	_	I-p
167	1154	1159	vitro	vitro	NN	_	_	I-cesDoc	_	I-p
168	1160	1161	,	,	,	_	_	I-cesDoc	_	I-p
169	1162	1165	but	but	CC	_	_	I-cesDoc	_	I-p
170	1166	1170	also	also	RB	_	_	I-cesDoc	_	I-p
171	1171	1174	can	can	MD	_	_	I-cesDoc	_	I-p
172	1175	1179	have	have	VB	_	_	I-cesDoc	_	I-p
173	1188	1203	proinflammatory	proinflammatory	NN	_	_	I-cesDoc	_	I-p
174	1204	1211	effects	effect	NNS	_	_	I-cesDoc	_	I-p
175	1212	1216	both	both	DT	_	_	I-cesDoc	_	I-p
176	1226	1228	in	in	IN	_	_	I-cesDoc	_	I-p
177	1229	1233	vivo	vivo	NN	_	_	I-cesDoc	_	I-p
178	1234	1237	and	and	CC	_	_	I-cesDoc	_	I-p
179	1247	1249	in	in	IN	_	_	I-cesDoc	_	I-p
180	1250	1255	vitro	vitro	NN	_	_	I-cesDoc	_	I-p
181	1256	1257	[	[	NN	_	_	I-cesDoc	_	I-p
182	1258	1260	10	10	CD	_	_	I-cesDoc	_	I-p
183	1261	1263	11	11	CD	_	_	I-cesDoc	_	I-p
184	1264	1266	12	12	CD	_	_	I-cesDoc	_	I-p
185	1267	1268	]	]	NN	_	_	I-cesDoc	_	I-p
186	1269	1270	.	.	.	_	_	I-cesDoc	_	I-p
187	1271	1282	Thromboxane	thromboxane	NNP	_	_	I-cesDoc	_	I-p
188	1291	1292	(	(	(	_	_	I-cesDoc	_	I-p
189	1292	1294	TX	tx	NNP	_	_	I-cesDoc	_	I-p
190	1294	1295	)	)	)	_	_	I-cesDoc	_	I-p
191	1295	1296	A	a	DT	_	_	I-cesDoc	_	I-p
192	1306	1307	2	2	CD	_	_	I-cesDoc	_	I-p
193	1308	1317	increases	increase	NNS	_	_	I-cesDoc	_	I-p
194	1318	1331	proliferation	proliferation	NN	_	_	I-cesDoc	_	I-p
195	1331	1332	,	,	,	_	_	I-cesDoc	_	I-p
196	1333	1336	and	and	CC	_	_	I-cesDoc	_	I-p
197	1337	1340	DNA	dna	NNP	_	_	I-cesDoc	_	I-p
198	1341	1344	and	and	CC	_	_	I-cesDoc	_	I-p
199	1353	1356	RNA	rna	NNP	_	_	I-cesDoc	_	I-p
200	1357	1366	synthesis	synthesis	NN	_	_	I-cesDoc	_	I-p
201	1367	1369	in	in	IN	_	_	I-cesDoc	_	I-p
202	1370	1377	several	several	JJ	_	_	I-cesDoc	_	I-p
203	1378	1382	cell	cell	NN	_	_	I-cesDoc	_	I-p
204	1383	1388	types	type	NNS	_	_	I-cesDoc	_	I-p
205	1388	1389	,	,	,	_	_	I-cesDoc	_	I-p
206	1390	1399	including	include	VBG	_	_	I-cesDoc	_	I-p
207	1400	1411	fibroblasts	fibroblast	NNS	_	_	I-cesDoc	_	I-p
208	1420	1423	and	and	CC	_	_	I-cesDoc	_	I-p
209	1424	1430	smooth	smooth	JJ	_	_	I-cesDoc	_	I-p
210	1431	1437	muscle	muscle	NN	_	_	I-cesDoc	_	I-p
211	1438	1442	like	like	IN	_	_	I-cesDoc	_	I-p
212	1443	1453	glomerular	glomerular	NN	_	_	I-cesDoc	_	I-p
213	1454	1463	mesangial	mesangial	NN	_	_	I-cesDoc	_	I-p
214	1464	1469	cells	cell	NNS	_	_	I-cesDoc	_	I-p
215	1470	1471	[	[	NN	_	_	I-cesDoc	_	I-p
216	1472	1474	13	13	CD	_	_	I-cesDoc	_	I-p
217	1475	1477	14	14	CD	_	_	I-cesDoc	_	I-p
218	1486	1488	15	15	CD	_	_	I-cesDoc	_	I-p
219	1489	1491	16	16	CD	_	_	I-cesDoc	_	I-p
220	1492	1493	]	]	NN	_	_	I-cesDoc	_	I-p
221	1494	1495	.	.	.	_	_	I-cesDoc	_	I-p
222	1496	1506	Conversely	conversely	RB	_	_	I-cesDoc	_	I-p
223	1506	1507	,	,	,	_	_	I-cesDoc	_	I-p
224	1508	1520	prostacyclin	prostacyclin	NN	_	_	I-cesDoc	_	I-p
225	1521	1522	(	(	(	_	_	I-cesDoc	_	I-p
226	1522	1525	PGI	pgi	NNP	_	_	I-cesDoc	_	I-p
227	1535	1536	2	2	CD	_	_	I-cesDoc	_	I-p
228	1537	1538	)	)	)	_	_	I-cesDoc	_	I-p
229	1539	1548	decreases	decrease	NNS	_	_	I-cesDoc	_	I-p
230	1549	1555	smooth	smooth	JJ	_	_	I-cesDoc	_	I-p
231	1556	1562	muscle	muscle	NN	_	_	I-cesDoc	_	I-p
232	1563	1567	cell	cell	NN	_	_	I-cesDoc	_	I-p
233	1576	1589	proliferation	proliferation	NN	_	_	I-cesDoc	_	I-p
234	1590	1593	and	and	CC	_	_	I-cesDoc	_	I-p
235	1594	1602	collagen	collagen	NN	_	_	I-cesDoc	_	I-p
236	1603	1612	synthesis	synthesis	NN	_	_	I-cesDoc	_	I-p
237	1613	1614	[	[	NN	_	_	I-cesDoc	_	I-p
238	1615	1617	17	17	CD	_	_	I-cesDoc	_	I-p
239	1618	1620	18	18	CD	_	_	I-cesDoc	_	I-p
240	1621	1622	]	]	NN	_	_	I-cesDoc	_	I-p
241	1623	1624	.	.	.	_	_	I-cesDoc	_	I-p
242	1633	1637	Many	many	JJ	_	_	I-cesDoc	_	I-p
243	1638	1642	cell	cell	NN	_	_	I-cesDoc	_	I-p
244	1643	1648	types	type	NNS	_	_	I-cesDoc	_	I-p
245	1648	1649	,	,	,	_	_	I-cesDoc	_	I-p
246	1650	1659	including	include	VBG	_	_	I-cesDoc	_	I-p
247	1660	1664	lung	lung	NN	_	_	I-cesDoc	_	I-p
248	1665	1676	fibroblasts	fibroblast	NNS	_	_	I-cesDoc	_	I-p
249	1676	1677	,	,	,	_	_	I-cesDoc	_	I-p
250	1678	1685	contain	contain	VB	_	_	I-cesDoc	_	I-p
251	1694	1708	cyclooxygenase	cyclooxygenase	NN	_	_	I-cesDoc	_	I-p
252	1709	1710	(	(	(	_	_	I-cesDoc	_	I-p
253	1710	1713	COX	cox	NNP	_	_	I-cesDoc	_	I-p
254	1713	1714	)	)	)	_	_	I-cesDoc	_	I-p
255	1714	1715	,	,	,	_	_	I-cesDoc	_	I-p
256	1716	1717	a	a	DT	_	_	I-cesDoc	_	I-p
257	1718	1726	proximal	proximal	NN	_	_	I-cesDoc	_	I-p
258	1727	1733	enzyme	enzyme	NN	_	_	I-cesDoc	_	I-p
259	1734	1736	in	in	IN	_	_	I-cesDoc	_	I-p
260	1737	1747	prostanoid	prostanoid	NN	_	_	I-cesDoc	_	I-p
261	1756	1766	production	production	NN	_	_	I-cesDoc	_	I-p
262	1766	1767	,	,	,	_	_	I-cesDoc	_	I-p
263	1768	1771	and	and	CC	_	_	I-cesDoc	_	I-p
264	1772	1775	can	can	MD	_	_	I-cesDoc	_	I-p
265	1776	1784	generate	generate	VB	_	_	I-cesDoc	_	I-p
266	1785	1796	prostanoids	prostanoid	NNS	_	_	I-cesDoc	_	I-p
267	1797	1798	[	[	NN	_	_	I-cesDoc	_	I-p
268	1799	1801	19	19	CD	_	_	I-cesDoc	_	I-p
269	1802	1803	]	]	NN	_	_	I-cesDoc	_	I-p
270	1804	1805	.	.	.	_	_	I-cesDoc	_	I-p
271	1806	1808	It	it	PRP	_	_	I-cesDoc	_	I-p
272	1809	1812	has	have	VBZ	_	_	I-cesDoc	_	I-p
273	1821	1825	been	be	VBN	_	_	I-cesDoc	_	I-p
274	1826	1836	previously	previously	RB	_	_	I-cesDoc	_	I-p
275	1837	1845	reported	report	VBN	_	_	I-cesDoc	_	I-p
276	1846	1850	that	that	IN	_	_	I-cesDoc	_	I-p
277	1851	1854	IPF	ipf	NNP	_	_	I-cesDoc	_	I-p
278	1855	1859	lung	lung	NN	_	_	I-cesDoc	_	I-p
279	1860	1871	fibroblasts	fibroblast	NNS	_	_	I-cesDoc	_	I-p
280	1872	1876	have	have	VBP	_	_	I-cesDoc	_	I-p
281	1885	1894	decreased	decrease	VBN	_	_	I-cesDoc	_	I-p
282	1895	1900	COX-2	cox-2	NNP	_	_	I-cesDoc	_	I-p
283	1901	1911	expression	expression	NN	_	_	I-cesDoc	_	I-p
284	1912	1920	compared	compare	VBN	_	_	I-cesDoc	_	I-p
285	1921	1923	to	to	TO	_	_	I-cesDoc	_	I-p
286	1924	1930	normal	normal	JJ	_	_	I-cesDoc	_	I-p
287	1931	1935	lung	lung	NN	_	_	I-cesDoc	_	I-p
288	1944	1955	fibroblasts	fibroblast	NNS	_	_	I-cesDoc	_	I-p
289	1956	1959	and	and	CC	_	_	I-cesDoc	_	I-p
290	1959	1960	,	,	,	_	_	I-cesDoc	_	I-p
291	1961	1966	hence	hence	RB	_	_	I-cesDoc	_	I-p
292	1966	1967	,	,	,	_	_	I-cesDoc	_	I-p
293	1968	1972	have	have	VBP	_	_	I-cesDoc	_	I-p
294	1973	1982	decreased	decrease	VBN	_	_	I-cesDoc	_	I-p
295	1983	1986	PGE	pge	NNP	_	_	I-cesDoc	_	I-p
296	1996	1997	2	2	CD	_	_	I-cesDoc	_	I-p
297	1998	2008	production	production	NN	_	_	I-cesDoc	_	I-p
298	2009	2010	[	[	NN	_	_	I-cesDoc	_	I-p
299	2011	2013	12	12	CD	_	_	I-cesDoc	_	I-p
300	2014	2016	20	20	CD	_	_	I-cesDoc	_	I-p
301	2017	2019	21	21	CD	_	_	I-cesDoc	_	I-p
302	2020	2021	]	]	NN	_	_	I-cesDoc	_	I-p
303	2022	2023	.	.	.	_	_	I-cesDoc	_	I-p
304	2024	2031	Because	because	IN	_	_	I-cesDoc	_	I-p
305	2032	2034	of	of	IN	_	_	I-cesDoc	_	I-p
306	2043	2048	these	these	DT	_	_	I-cesDoc	_	I-p
307	2049	2057	findings	finding	NNS	_	_	I-cesDoc	_	I-p
308	2058	2061	and	and	CC	_	_	I-cesDoc	_	I-p
309	2062	2065	the	the	DT	_	_	I-cesDoc	_	I-p
310	2066	2070	fact	fact	NN	_	_	I-cesDoc	_	I-p
311	2071	2075	that	that	IN	_	_	I-cesDoc	_	I-p
312	2076	2079	PGs	pgs	NNP	_	_	I-cesDoc	_	I-p
313	2080	2083	are	be	VBP	_	_	I-cesDoc	_	I-p
314	2084	2093	important	important	JJ	_	_	I-cesDoc	_	I-p
315	2102	2112	fibroblast	fibroblast	NN	_	_	I-cesDoc	_	I-p
316	2113	2123	regulators	regulator	NNS	_	_	I-cesDoc	_	I-p
317	2123	2124	,	,	,	_	_	I-cesDoc	_	I-p
318	2125	2127	we	we	PRP	_	_	I-cesDoc	_	I-p
319	2128	2134	sought	seek	VBD	_	_	I-cesDoc	_	I-p
320	2135	2137	to	to	TO	_	_	I-cesDoc	_	I-p
321	2138	2149	investigate	investigate	VB	_	_	I-cesDoc	_	I-p
322	2150	2157	whether	whether	IN	_	_	I-cesDoc	_	I-p
323	2166	2179	abnormalities	abnormality	NNS	_	_	I-cesDoc	_	I-p
324	2180	2182	in	in	IN	_	_	I-cesDoc	_	I-p
325	2183	2188	COX-2	cox-2	NNP	_	_	I-cesDoc	_	I-p
326	2189	2199	expression	expression	NN	_	_	I-cesDoc	_	I-p
327	2200	2205	could	could	MD	_	_	I-cesDoc	_	I-p
328	2206	2208	be	be	VB	_	_	I-cesDoc	_	I-p
329	2209	2219	associated	associate	VBN	_	_	I-cesDoc	_	I-p
330	2220	2224	with	with	IN	_	_	I-cesDoc	_	I-p
331	2233	2235	an	an	DT	_	_	I-cesDoc	_	I-p
332	2236	2243	altered	alter	VBN	_	_	I-cesDoc	_	I-p
333	2244	2251	balance	balance	NN	_	_	I-cesDoc	_	I-p
334	2252	2259	between	between	IN	_	_	I-cesDoc	_	I-p
335	2260	2271	profibrotic	profibrotic	JJ	_	_	I-cesDoc	_	I-p
336	2272	2275	and	and	CC	_	_	I-cesDoc	_	I-p
337	2276	2288	antifibrotic	antifibrotic	JJ	_	_	I-cesDoc	_	I-p
338	2297	2300	PGs	pgs	NNP	_	_	I-cesDoc	_	I-p
339	2300	2301	.	.	.	_	_	I-cesDoc	_	I-p
340	2302	2304	We	we	PRP	_	_	I-cesDoc	_	I-p
341	2305	2317	hypothesized	hypothesize	VBN	_	_	I-cesDoc	_	I-p
342	2318	2322	that	that	IN	_	_	I-cesDoc	_	I-p
343	2323	2334	fibroblasts	fibroblast	NNS	_	_	I-cesDoc	_	I-p
344	2335	2339	from	from	IN	_	_	I-cesDoc	_	I-p
345	2340	2343	the	the	DT	_	_	I-cesDoc	_	I-p
346	2344	2349	lungs	lung	NNS	_	_	I-cesDoc	_	I-p
347	2350	2352	of	of	IN	_	_	I-cesDoc	_	I-p
348	2361	2369	patients	patient	NNS	_	_	I-cesDoc	_	I-p
349	2370	2374	with	with	IN	_	_	I-cesDoc	_	I-p
350	2375	2378	IPF	ipf	NNP	_	_	I-cesDoc	_	I-p
351	2379	2380	(	(	(	_	_	I-cesDoc	_	I-p
352	2380	2386	HF-IPF	hf-ipf	NNP	_	_	I-cesDoc	_	I-p
353	2386	2387	)	)	)	_	_	I-cesDoc	_	I-p
354	2388	2392	have	have	VBP	_	_	I-cesDoc	_	I-p
355	2393	2395	an	an	DT	_	_	I-cesDoc	_	I-p
356	2396	2403	altered	alter	VBN	_	_	I-cesDoc	_	I-p
357	2404	2406	PG	pg	NNP	_	_	I-cesDoc	_	I-p
358	2407	2414	balance	balance	NN	_	_	I-cesDoc	_	I-p
359	2423	2431	compared	compare	VBN	_	_	I-cesDoc	_	I-p
360	2432	2434	to	to	TO	_	_	I-cesDoc	_	I-p
361	2435	2441	normal	normal	JJ	_	_	I-cesDoc	_	I-p
362	2442	2446	lung	lung	NN	_	_	I-cesDoc	_	I-p
363	2447	2458	fibroblasts	fibroblast	NNS	_	_	I-cesDoc	_	I-p
364	2459	2460	(	(	(	_	_	I-cesDoc	_	I-p
365	2460	2465	HF-NL	hf-nl	NNP	_	_	I-cesDoc	_	I-p
366	2465	2466	)	)	)	_	_	I-cesDoc	_	I-p
367	2466	2467	.	.	.	_	_	I-cesDoc	_	I-p
368	2468	2472	This	this	DT	_	_	I-cesDoc	_	I-p
369	2481	2493	phenotypical	phenotypical	JJ	_	_	I-cesDoc	_	I-p
370	2494	2505	abnormality	abnormality	NN	_	_	I-cesDoc	_	I-p
371	2506	2511	could	could	MD	_	_	I-cesDoc	_	I-p
372	2512	2514	be	be	VB	_	_	I-cesDoc	_	I-p
373	2515	2517	an	an	DT	_	_	I-cesDoc	_	I-p
374	2518	2527	important	important	JJ	_	_	I-cesDoc	_	I-p
375	2528	2534	factor	factor	NN	_	_	I-cesDoc	_	I-p
376	2535	2537	in	in	IN	_	_	I-cesDoc	_	I-p
377	2546	2549	the	the	DT	_	_	I-cesDoc	_	I-p
378	2550	2562	pathogenesis	pathogenesis	NNS	_	_	I-cesDoc	_	I-p
379	2563	2565	of	of	IN	_	_	I-cesDoc	_	I-p
380	2566	2569	IPF	ipf	NNP	_	_	I-cesDoc	_	I-p
381	2569	2570	.	.	.	_	_	I-cesDoc	_	I-p
382	2593	2602	Materials	material	NNS	_	_	I-cesDoc	B-head	_
383	2603	2606	and	and	CC	_	_	I-cesDoc	I-head	_
384	2607	2614	methods	method	NNS	_	_	I-cesDoc	I-head	_
385	2634	2641	Primary	primary	JJ	_	_	I-cesDoc	B-head	_
386	2642	2646	lung	lung	NN	_	_	I-cesDoc	I-head	_
387	2647	2658	fibroblasts	fibroblast	NNS	_	_	I-cesDoc	I-head	_
388	2669	2680	Fibroblasts	fibroblasts	NNP	_	_	I-cesDoc	_	B-p
389	2681	2685	from	from	IN	_	_	I-cesDoc	_	I-p
390	2686	2689	the	the	DT	_	_	I-cesDoc	_	I-p
391	2690	2695	lungs	lung	NNS	_	_	I-cesDoc	_	I-p
392	2696	2698	of	of	IN	_	_	I-cesDoc	_	I-p
393	2699	2704	seven	seven	CD	_	_	I-cesDoc	_	I-p
394	2705	2713	patients	patient	NNS	_	_	I-cesDoc	_	I-p
395	2714	2715	(	(	(	_	_	I-cesDoc	_	I-p
396	2715	2716	6	6	CD	_	_	I-cesDoc	_	I-p
397	2717	2722	males	male	NNS	_	_	I-cesDoc	_	I-p
398	2722	2723	)	)	)	_	_	I-cesDoc	_	I-p
399	2734	2738	with	with	IN	_	_	I-cesDoc	_	I-p
400	2739	2742	IPF	ipf	NNP	_	_	I-cesDoc	_	I-p
401	2743	2744	(	(	(	_	_	I-cesDoc	_	I-p
402	2744	2750	HF-IPF	hf-ipf	NNP	_	_	I-cesDoc	_	I-p
403	2750	2751	)	)	)	_	_	I-cesDoc	_	I-p
404	2752	2756	were	be	VBD	_	_	I-cesDoc	_	I-p
405	2757	2766	harvested	harvest	VBN	_	_	I-cesDoc	_	I-p
406	2766	2767	:	:	:	_	_	I-cesDoc	_	I-p
407	2768	2769	a	a	DT	_	_	I-cesDoc	_	I-p
408	2769	2770	)	)	)	_	_	I-cesDoc	_	I-p
409	2771	2775	from	from	IN	_	_	I-cesDoc	_	I-p
410	2776	2783	excised	excise	VBD	_	_	I-cesDoc	_	I-p
411	2784	2788	lung	lung	NN	_	_	I-cesDoc	_	I-p
412	2789	2791	at	at	IN	_	_	I-cesDoc	_	I-p
413	2802	2805	the	the	DT	_	_	I-cesDoc	_	I-p
414	2806	2810	time	time	NN	_	_	I-cesDoc	_	I-p
415	2811	2813	of	of	IN	_	_	I-cesDoc	_	I-p
416	2814	2818	lung	lung	NN	_	_	I-cesDoc	_	I-p
417	2819	2834	transplantation	transplantation	NN	_	_	I-cesDoc	_	I-p
418	2834	2835	;	;	:	_	_	I-cesDoc	_	I-p
419	2836	2837	b	b	SYM	_	_	I-cesDoc	_	I-p
420	2837	2838	)	)	)	_	_	I-cesDoc	_	I-p
421	2839	2845	during	during	IN	_	_	I-cesDoc	_	I-p
422	2846	2848	an	an	DT	_	_	I-cesDoc	_	I-p
423	2849	2856	autopsy	autopsy	NN	_	_	I-cesDoc	_	I-p
424	2867	2876	performed	perform	VBN	_	_	I-cesDoc	_	I-p
425	2877	2883	within	within	IN	_	_	I-cesDoc	_	I-p
426	2884	2885	4	4	CD	_	_	I-cesDoc	_	I-p
427	2886	2891	hours	hour	NNS	_	_	I-cesDoc	_	I-p
428	2892	2896	from	from	IN	_	_	I-cesDoc	_	I-p
429	2897	2902	death	death	NN	_	_	I-cesDoc	_	I-p
430	2902	2903	;	;	:	_	_	I-cesDoc	_	I-p
431	2904	2906	or	or	CC	_	_	I-cesDoc	_	I-p
432	2907	2908	c	c	SYM	_	_	I-cesDoc	_	I-p
433	2908	2909	)	)	)	_	_	I-cesDoc	_	I-p
434	2910	2916	during	during	IN	_	_	I-cesDoc	_	I-p
435	2917	2921	open	open	NN	_	_	I-cesDoc	_	I-p
436	2922	2924	or	or	CC	_	_	I-cesDoc	_	I-p
437	2935	2949	transbronchial	transbronchial	NN	_	_	I-cesDoc	_	I-p
438	2950	2954	lung	lung	NN	_	_	I-cesDoc	_	I-p
439	2955	2963	biopsies	biopsy	NNS	_	_	I-cesDoc	_	I-p
440	2964	2966	at	at	IN	_	_	I-cesDoc	_	I-p
441	2967	2970	the	the	DT	_	_	I-cesDoc	_	I-p
442	2971	2975	time	time	NN	_	_	I-cesDoc	_	I-p
443	2976	2978	of	of	IN	_	_	I-cesDoc	_	I-p
444	2979	2988	diagnosis	diagnosis	NN	_	_	I-cesDoc	_	I-p
445	2988	2989	.	.	.	_	_	I-cesDoc	_	I-p
446	2990	2992	Of	of	IN	_	_	I-cesDoc	_	I-p
447	3003	3006	the	the	DT	_	_	I-cesDoc	_	I-p
448	3007	3012	seven	seven	CD	_	_	I-cesDoc	_	I-p
449	3013	3021	patients	patient	NNS	_	_	I-cesDoc	_	I-p
450	3021	3022	,	,	,	_	_	I-cesDoc	_	I-p
451	3023	3027	five	five	CD	_	_	I-cesDoc	_	I-p
452	3028	3036	subjects	subject	NNS	_	_	I-cesDoc	_	I-p
453	3037	3040	had	have	VBD	_	_	I-cesDoc	_	I-p
454	3041	3049	advanced	advance	VBN	_	_	I-cesDoc	_	I-p
455	3050	3054	lung	lung	NN	_	_	I-cesDoc	_	I-p
456	3065	3073	fibrosis	fibrosis	NNS	_	_	I-cesDoc	_	I-p
457	3074	3077	and	and	CC	_	_	I-cesDoc	_	I-p
458	3078	3082	were	be	VBD	_	_	I-cesDoc	_	I-p
459	3083	3092	receiving	receive	VBG	_	_	I-cesDoc	_	I-p
460	3093	3103	prednisone	prednisone	NN	_	_	I-cesDoc	_	I-p
461	3104	3105	±	±	NN	_	_	I-cesDoc	_	I-p
462	3116	3133	immunosuppressive	immunosuppressive	JJ	_	_	I-cesDoc	_	I-p
463	3134	3140	agents	agent	NNS	_	_	I-cesDoc	_	I-p
464	3140	3141	;	;	:	_	_	I-cesDoc	_	I-p
465	3142	3143	2	2	CD	_	_	I-cesDoc	_	I-p
466	3144	3152	patients	patient	NNS	_	_	I-cesDoc	_	I-p
467	3153	3157	were	be	VBD	_	_	I-cesDoc	_	I-p
468	3158	3160	at	at	IN	_	_	I-cesDoc	_	I-p
469	3161	3163	an	an	DT	_	_	I-cesDoc	_	I-p
470	3164	3171	earlier	earlier	JJR	_	_	I-cesDoc	_	I-p
471	3182	3187	stage	stage	NN	_	_	I-cesDoc	_	I-p
472	3188	3190	of	of	IN	_	_	I-cesDoc	_	I-p
473	3191	3196	their	their	PRP$	_	_	I-cesDoc	_	I-p
474	3197	3204	disease	disease	NN	_	_	I-cesDoc	_	I-p
475	3205	3208	and	and	CC	_	_	I-cesDoc	_	I-p
476	3209	3213	were	be	VBD	_	_	I-cesDoc	_	I-p
477	3214	3217	not	not	RB	_	_	I-cesDoc	_	I-p
478	3218	3227	receiving	receive	VBG	_	_	I-cesDoc	_	I-p
479	3238	3255	immunosuppressive	immunosuppressive	JJ	_	_	I-cesDoc	_	I-p
480	3256	3261	drugs	drug	NNS	_	_	I-cesDoc	_	I-p
481	3261	3262	.	.	.	_	_	I-cesDoc	_	I-p
482	3263	3266	The	the	DT	_	_	I-cesDoc	_	I-p
483	3267	3271	mean	mean	JJ	_	_	I-cesDoc	_	I-p
484	3272	3275	age	age	NN	_	_	I-cesDoc	_	I-p
485	3276	3278	of	of	IN	_	_	I-cesDoc	_	I-p
486	3279	3282	the	the	DT	_	_	I-cesDoc	_	I-p
487	3283	3291	patients	patient	NNS	_	_	I-cesDoc	_	I-p
488	3292	3295	was	be	VBD	_	_	I-cesDoc	_	I-p
489	3306	3308	59	59	CD	_	_	I-cesDoc	_	I-p
490	3309	3310	(	(	(	_	_	I-cesDoc	_	I-p
491	3310	3315	range	range	NN	_	_	I-cesDoc	_	I-p
492	3316	3318	43	43	CD	_	_	I-cesDoc	_	I-p
493	3318	3319	-	-	-	_	_	I-cesDoc	_	I-p
494	3319	3321	71	71	CD	_	_	I-cesDoc	_	I-p
495	3321	3322	)	)	)	_	_	I-cesDoc	_	I-p
496	3322	3323	]	]	NN	_	_	I-cesDoc	_	I-p
497	3323	3324	.	.	.	_	_	I-cesDoc	_	I-p
498	3325	3330	HF-NL	hf-nl	NNP	_	_	I-cesDoc	_	I-p
499	3331	3335	were	be	VBD	_	_	I-cesDoc	_	I-p
500	3336	3344	cultured	cultured	JJ	_	_	I-cesDoc	_	I-p
501	3345	3349	from	from	IN	_	_	I-cesDoc	_	I-p
502	3350	3354	five	five	CD	_	_	I-cesDoc	_	I-p
503	3355	3360	human	human	JJ	_	_	I-cesDoc	_	I-p
504	3371	3376	lungs	lung	NNS	_	_	I-cesDoc	_	I-p
505	3377	3381	that	that	WDT	_	_	I-cesDoc	_	I-p
506	3382	3389	arrived	arrive	VBD	_	_	I-cesDoc	_	I-p
507	3390	3392	at	at	IN	_	_	I-cesDoc	_	I-p
508	3393	3396	our	our	PRP$	_	_	I-cesDoc	_	I-p
509	3397	3407	transplant	transplant	NN	_	_	I-cesDoc	_	I-p
510	3408	3414	center	center	NN	_	_	I-cesDoc	_	I-p
511	3415	3419	with	with	IN	_	_	I-cesDoc	_	I-p
512	3420	3423	the	the	DT	_	_	I-cesDoc	_	I-p
513	3434	3443	intention	intention	NN	_	_	I-cesDoc	_	I-p
514	3444	3446	of	of	IN	_	_	I-cesDoc	_	I-p
515	3447	3452	being	be	VBG	_	_	I-cesDoc	_	I-p
516	3453	3457	used	use	VBN	_	_	I-cesDoc	_	I-p
517	3458	3461	for	for	IN	_	_	I-cesDoc	_	I-p
518	3462	3477	transplantation	transplantation	NN	_	_	I-cesDoc	_	I-p
519	3477	3478	,	,	,	_	_	I-cesDoc	_	I-p
520	3479	3482	but	but	CC	_	_	I-cesDoc	_	I-p
521	3483	3486	for	for	IN	_	_	I-cesDoc	_	I-p
522	3497	3504	various	various	JJ	_	_	I-cesDoc	_	I-p
523	3505	3512	reasons	reason	NNS	_	_	I-cesDoc	_	I-p
524	3513	3518	could	could	MD	_	_	I-cesDoc	_	I-p
525	3519	3522	not	not	RB	_	_	I-cesDoc	_	I-p
526	3523	3525	be	be	VB	_	_	I-cesDoc	_	I-p
527	3526	3538	transplanted	transplant	VBN	_	_	I-cesDoc	_	I-p
528	3538	3539	;	;	:	_	_	I-cesDoc	_	I-p
529	3540	3545	these	these	DT	_	_	I-cesDoc	_	I-p
530	3546	3550	were	be	VBD	_	_	I-cesDoc	_	I-p
531	3561	3576	macroscopically	macroscopically	RB	_	_	I-cesDoc	_	I-p
532	3577	3580	and	and	CC	_	_	I-cesDoc	_	I-p
533	3581	3596	microscopically	microscopically	RB	_	_	I-cesDoc	_	I-p
534	3597	3603	normal	normal	JJ	_	_	I-cesDoc	_	I-p
535	3603	3604	.	.	.	_	_	I-cesDoc	_	I-p
536	3605	3608	The	the	DT	_	_	I-cesDoc	_	I-p
537	3609	3614	cells	cell	NNS	_	_	I-cesDoc	_	I-p
538	3625	3629	were	be	VBD	_	_	I-cesDoc	_	I-p
539	3630	3639	harvested	harvest	VBN	_	_	I-cesDoc	_	I-p
540	3640	3643	and	and	CC	_	_	I-cesDoc	_	I-p
541	3644	3652	cultured	cultured	JJ	_	_	I-cesDoc	_	I-p
542	3653	3655	as	as	IN	_	_	I-cesDoc	_	I-p
543	3656	3659	per	per	IN	_	_	I-cesDoc	_	I-p
544	3660	3663	the	the	DT	_	_	I-cesDoc	_	I-p
545	3664	3672	protocol	protocol	NN	_	_	I-cesDoc	_	I-p
546	3673	3682	described	describe	VBN	_	_	I-cesDoc	_	I-p
547	3693	3695	by	by	IN	_	_	I-cesDoc	_	I-p
548	3696	3701	Kumar	kumar	NNP	_	_	I-cesDoc	_	I-p
549	3713	3715	et	et	CC	_	_	I-cesDoc	_	I-p
550	3716	3719	al.	al.	NN	_	_	I-cesDoc	_	I-p
551	3720	3721	[	[	NN	_	_	I-cesDoc	_	I-p
552	3722	3724	22	22	CD	_	_	I-cesDoc	_	I-p
553	3725	3726	]	]	NN	_	_	I-cesDoc	_	I-p
554	3727	3728	.	.	.	_	_	I-cesDoc	_	I-p
555	3729	3736	Briefly	briefly	NNP	_	_	I-cesDoc	_	I-p
556	3736	3737	,	,	,	_	_	I-cesDoc	_	I-p
557	3738	3742	lung	lung	NN	_	_	I-cesDoc	_	I-p
558	3753	3759	tissue	tissue	NN	_	_	I-cesDoc	_	I-p
559	3760	3768	sections	section	NNS	_	_	I-cesDoc	_	I-p
560	3769	3773	were	be	VBD	_	_	I-cesDoc	_	I-p
561	3774	3780	finely	finely	RB	_	_	I-cesDoc	_	I-p
562	3781	3784	cut	cut	VB	_	_	I-cesDoc	_	I-p
563	3785	3789	with	with	IN	_	_	I-cesDoc	_	I-p
564	3790	3797	sterile	sterile	JJ	_	_	I-cesDoc	_	I-p
565	3798	3806	scissors	scissors	NNS	_	_	I-cesDoc	_	I-p
566	3807	3810	and	and	CC	_	_	I-cesDoc	_	I-p
567	3821	3830	incubated	incubated	JJ	_	_	I-cesDoc	_	I-p
568	3831	3835	with	with	IN	_	_	I-cesDoc	_	I-p
569	3836	3841	serum	serum	NN	_	_	I-cesDoc	_	I-p
570	3842	3846	free	free	JJ	_	_	I-cesDoc	_	I-p
571	3847	3851	DMEM	dmem	NNP	_	_	I-cesDoc	_	I-p
572	3852	3862	containing	contain	VBG	_	_	I-cesDoc	_	I-p
573	3863	3870	trypsin	trypsin	NN	_	_	I-cesDoc	_	I-p
574	3870	3871	,	,	,	_	_	I-cesDoc	_	I-p
575	3872	3877	DNAse	dnase	NNP	_	_	I-cesDoc	_	I-p
576	3888	3891	and	and	CC	_	_	I-cesDoc	_	I-p
577	3892	3903	collagenase	collagenase	NN	_	_	I-cesDoc	_	I-p
578	3904	3907	for	for	IN	_	_	I-cesDoc	_	I-p
579	3908	3910	30	30	CD	_	_	I-cesDoc	_	I-p
580	3911	3915	min.	min.	NN	_	_	I-cesDoc	_	I-p
581	3916	3919	The	the	DT	_	_	I-cesDoc	_	I-p
582	3920	3929	procedure	procedure	NN	_	_	I-cesDoc	_	I-p
583	3930	3933	was	be	VBD	_	_	I-cesDoc	_	I-p
584	3934	3942	repeated	repeat	VBN	_	_	I-cesDoc	_	I-p
585	3953	3958	twice	twice	RB	_	_	I-cesDoc	_	I-p
586	3958	3959	,	,	,	_	_	I-cesDoc	_	I-p
587	3960	3963	and	and	CC	_	_	I-cesDoc	_	I-p
588	3964	3967	the	the	DT	_	_	I-cesDoc	_	I-p
589	3968	3980	supernatants	supernatant	NNS	_	_	I-cesDoc	_	I-p
590	3981	3985	were	be	VBD	_	_	I-cesDoc	_	I-p
591	3986	3992	pooled	pool	VBN	_	_	I-cesDoc	_	I-p
592	3993	3996	and	and	CC	_	_	I-cesDoc	_	I-p
593	3997	4005	cultured	cultured	JJ	_	_	I-cesDoc	_	I-p
594	4006	4008	in	in	IN	_	_	I-cesDoc	_	I-p
595	4019	4022	one	one	CD	_	_	I-cesDoc	_	I-p
596	4023	4026	100	100	CD	_	_	I-cesDoc	_	I-p
597	4027	4029	mm	mm	NN	_	_	I-cesDoc	_	I-p
598	4030	4035	plate	plate	NN	_	_	I-cesDoc	_	I-p
599	4036	4039	and	and	CC	_	_	I-cesDoc	_	I-p
600	4040	4049	incubated	incubated	JJ	_	_	I-cesDoc	_	I-p
601	4050	4052	at	at	IN	_	_	I-cesDoc	_	I-p
602	4053	4055	37	37	CD	_	_	I-cesDoc	_	I-p
603	4055	4056	°	°	NN	_	_	I-cesDoc	_	I-p
604	4056	4057	C	c	NNP	_	_	I-cesDoc	_	I-p
605	4058	4060	in	in	IN	_	_	I-cesDoc	_	I-p
606	4061	4062	a	a	DT	_	_	I-cesDoc	_	I-p
607	4063	4064	5	5	CD	_	_	I-cesDoc	_	I-p
608	4064	4065	%	%	NN	_	_	I-cesDoc	_	I-p
609	4066	4068	CO	co	NNP	_	_	I-cesDoc	_	I-p
610	4080	4081	2	2	CD	_	_	I-cesDoc	_	I-p
611	4082	4092	humidified	humidified	JJ	_	_	I-cesDoc	_	I-p
612	4093	4103	atmosphere	atmosphere	NN	_	_	I-cesDoc	_	I-p
613	4103	4104	.	.	.	_	_	I-cesDoc	_	I-p
614	4105	4112	Culture	culture	NNP	_	_	I-cesDoc	_	I-p
615	4123	4129	medium	medium	NN	_	_	I-cesDoc	_	I-p
616	4130	4131	(	(	(	_	_	I-cesDoc	_	I-p
617	4131	4135	DMEM	dmem	NNP	_	_	I-cesDoc	_	I-p
618	4136	4140	with	with	IN	_	_	I-cesDoc	_	I-p
619	4141	4142	5	5	CD	_	_	I-cesDoc	_	I-p
620	4142	4143	%	%	NN	_	_	I-cesDoc	_	I-p
621	4144	4149	fetal	fetal	JJ	_	_	I-cesDoc	_	I-p
622	4150	4156	bovine	bovine	JJ	_	_	I-cesDoc	_	I-p
623	4157	4162	serum	serum	NN	_	_	I-cesDoc	_	I-p
624	4163	4164	[	[	NN	_	_	I-cesDoc	_	I-p
625	4164	4167	FBS	fbs	NNP	_	_	I-cesDoc	_	I-p
626	4167	4168	]	]	NN	_	_	I-cesDoc	_	I-p
627	4169	4172	and	and	CC	_	_	I-cesDoc	_	I-p
628	4183	4193	penicillin	penicillin	NN	_	_	I-cesDoc	_	I-p
629	4193	4194	/	/	NN	_	_	I-cesDoc	_	I-p
630	4194	4206	streptomycin	streptomycin	NN	_	_	I-cesDoc	_	I-p
631	4206	4207	)	)	)	_	_	I-cesDoc	_	I-p
632	4208	4211	was	be	VBD	_	_	I-cesDoc	_	I-p
633	4212	4220	replaced	replace	VBN	_	_	I-cesDoc	_	I-p
634	4221	4226	three	three	CD	_	_	I-cesDoc	_	I-p
635	4227	4232	times	time	NNS	_	_	I-cesDoc	_	I-p
636	4233	4236	per	per	IN	_	_	I-cesDoc	_	I-p
637	4247	4251	week	week	NN	_	_	I-cesDoc	_	I-p
638	4252	4255	and	and	CC	_	_	I-cesDoc	_	I-p
639	4256	4267	fibroblasts	fibroblast	NNS	_	_	I-cesDoc	_	I-p
640	4268	4272	were	be	VBD	_	_	I-cesDoc	_	I-p
641	4273	4279	passed	pass	VBN	_	_	I-cesDoc	_	I-p
642	4280	4281	(	(	(	_	_	I-cesDoc	_	I-p
643	4281	4282	1	1	CD	_	_	I-cesDoc	_	I-p
644	4282	4283	:	:	:	_	_	I-cesDoc	_	I-p
645	4283	4284	2	2	CD	_	_	I-cesDoc	_	I-p
646	4285	4290	split	split	NN	_	_	I-cesDoc	_	I-p
647	4290	4291	)	)	)	_	_	I-cesDoc	_	I-p
648	4292	4294	at	at	IN	_	_	I-cesDoc	_	I-p
649	4295	4298	the	the	DT	_	_	I-cesDoc	_	I-p
650	4299	4303	time	time	NN	_	_	I-cesDoc	_	I-p
651	4314	4318	they	they	PRP	_	_	I-cesDoc	_	I-p
652	4319	4325	became	become	VBD	_	_	I-cesDoc	_	I-p
653	4326	4335	confluent	confluent	NN	_	_	I-cesDoc	_	I-p
654	4335	4336	.	.	.	_	_	I-cesDoc	_	I-p
655	4337	4339	On	on	IN	_	_	I-cesDoc	_	I-p
656	4340	4347	passage	passage	NN	_	_	I-cesDoc	_	I-p
657	4348	4349	4	4	CD	_	_	I-cesDoc	_	I-p
658	4350	4353	the	the	DT	_	_	I-cesDoc	_	I-p
659	4354	4359	cells	cell	NNS	_	_	I-cesDoc	_	I-p
660	4360	4364	were	be	VBD	_	_	I-cesDoc	_	I-p
661	4375	4386	resuspended	resuspended	JJ	_	_	I-cesDoc	_	I-p
662	4387	4389	in	in	IN	_	_	I-cesDoc	_	I-p
663	4390	4391	1	1	CD	_	_	I-cesDoc	_	I-p
664	4392	4394	ml	ml	NN	_	_	I-cesDoc	_	I-p
665	4395	4397	of	of	IN	_	_	I-cesDoc	_	I-p
666	4398	4402	DMEM	dmem	NNP	_	_	I-cesDoc	_	I-p
667	4403	4407	with	with	IN	_	_	I-cesDoc	_	I-p
668	4408	4410	20	20	CD	_	_	I-cesDoc	_	I-p
669	4410	4411	%	%	NN	_	_	I-cesDoc	_	I-p
670	4412	4415	FBS	fbs	NNP	_	_	I-cesDoc	_	I-p
671	4416	4419	and	and	CC	_	_	I-cesDoc	_	I-p
672	4420	4424	DMSO	dmso	NNP	_	_	I-cesDoc	_	I-p
673	4425	4428	and	and	CC	_	_	I-cesDoc	_	I-p
674	4439	4445	frozen	freeze	VBN	_	_	I-cesDoc	_	I-p
675	4446	4448	at	at	IN	_	_	I-cesDoc	_	I-p
676	4449	4450	-	-	:	_	_	I-cesDoc	_	I-p
677	4450	4452	70	70	CD	_	_	I-cesDoc	_	I-p
678	4452	4453	°	°	NN	_	_	I-cesDoc	_	I-p
679	4453	4455	C.	C.	NN	_	_	I-cesDoc	_	I-p
680	4456	4459	For	for	IN	_	_	I-cesDoc	_	I-p
681	4460	4464	each	each	DT	_	_	I-cesDoc	_	I-p
682	4465	4475	experiment	experiment	NN	_	_	I-cesDoc	_	I-p
683	4476	4485	described	describe	VBD	_	_	I-cesDoc	_	I-p
684	4486	4491	below	below	IN	_	_	I-cesDoc	_	I-p
685	4492	4495	the	the	DT	_	_	I-cesDoc	_	I-p
686	4506	4511	cells	cell	NNS	_	_	I-cesDoc	_	I-p
687	4512	4516	were	be	VBD	_	_	I-cesDoc	_	I-p
688	4517	4523	thawed	thawed	JJ	_	_	I-cesDoc	_	I-p
689	4523	4524	,	,	,	_	_	I-cesDoc	_	I-p
690	4525	4533	cultured	cultured	JJ	_	_	I-cesDoc	_	I-p
691	4534	4537	and	and	CC	_	_	I-cesDoc	_	I-p
692	4538	4544	passed	pass	VBN	_	_	I-cesDoc	_	I-p
693	4545	4547	at	at	IN	_	_	I-cesDoc	_	I-p
694	4548	4553	least	least	JJS	_	_	I-cesDoc	_	I-p
695	4554	4558	once	once	RB	_	_	I-cesDoc	_	I-p
696	4558	4559	.	.	.	_	_	I-cesDoc	_	I-p
697	4560	4563	All	all	DT	_	_	I-cesDoc	_	I-p
698	4574	4577	the	the	DT	_	_	I-cesDoc	_	I-p
699	4578	4589	experiments	experiment	NNS	_	_	I-cesDoc	_	I-p
700	4590	4594	were	be	VBD	_	_	I-cesDoc	_	I-p
701	4595	4604	conducted	conduct	VBN	_	_	I-cesDoc	_	I-p
702	4605	4609	with	with	IN	_	_	I-cesDoc	_	I-p
703	4610	4615	cells	cell	NNS	_	_	I-cesDoc	_	I-p
704	4616	4618	at	at	IN	_	_	I-cesDoc	_	I-p
705	4619	4627	passages	passage	NNS	_	_	I-cesDoc	_	I-p
706	4628	4629	6	6	CD	_	_	I-cesDoc	_	I-p
707	4640	4642	to	to	TO	_	_	I-cesDoc	_	I-p
708	4643	4644	8	8	CD	_	_	I-cesDoc	_	I-p
709	4644	4645	.	.	.	_	_	I-cesDoc	_	I-p
710	4674	4683	Inducible	inducible	NNP	_	_	I-cesDoc	B-head	_
711	4684	4698	cyclooxygenase	cyclooxygenase	NN	_	_	I-cesDoc	I-head	_
712	4699	4706	(COX)-2	(cox)-2	NNP	_	_	I-cesDoc	I-head	_
713	4707	4717	expression	expression	NN	_	_	I-cesDoc	I-head	_
714	4718	4721	and	and	CC	_	_	I-cesDoc	I-head	_
715	4732	4742	eicosanoid	eicosanoid	NN	_	_	I-cesDoc	I-head	_
716	4743	4753	production	production	NN	_	_	I-cesDoc	I-head	_
717	4764	4769	COX-2	cox-2	NNP	_	_	I-cesDoc	_	B-p
718	4770	4778	activity	activity	NN	_	_	I-cesDoc	_	I-p
719	4779	4782	was	be	VBD	_	_	I-cesDoc	_	I-p
720	4783	4793	determined	determine	VBN	_	_	I-cesDoc	_	I-p
721	4794	4796	by	by	IN	_	_	I-cesDoc	_	I-p
722	4797	4806	measuring	measure	VBG	_	_	I-cesDoc	_	I-p
723	4807	4810	PGE	pge	NNP	_	_	I-cesDoc	_	I-p
724	4822	4823	2	2	CD	_	_	I-cesDoc	_	I-p
725	4824	4825	,	,	,	_	_	I-cesDoc	_	I-p
726	4826	4836	6-keto-PGF	6-keto-PGF	NN	_	_	I-cesDoc	_	I-p
727	4848	4849	1	1	CD	_	_	I-cesDoc	_	I-p
728	4849	4850	?	?	NN	_	_	I-cesDoc	_	I-p
729	4851	4852	(	(	(	_	_	I-cesDoc	_	I-p
730	4852	4858	stable	stable	JJ	_	_	I-cesDoc	_	I-p
731	4859	4862	PGI	pgi	NNP	_	_	I-cesDoc	_	I-p
732	4874	4875	2	2	CD	_	_	I-cesDoc	_	I-p
733	4876	4886	metabolite	metabolite	NN	_	_	I-cesDoc	_	I-p
734	4886	4887	)	)	)	_	_	I-cesDoc	_	I-p
735	4887	4888	,	,	,	_	_	I-cesDoc	_	I-p
736	4889	4892	TXB	txb	NNP	_	_	I-cesDoc	_	I-p
737	4904	4905	2	2	CD	_	_	I-cesDoc	_	I-p
738	4906	4907	(	(	(	_	_	I-cesDoc	_	I-p
739	4907	4913	stable	stable	JJ	_	_	I-cesDoc	_	I-p
740	4914	4917	TXA	txa	NNP	_	_	I-cesDoc	_	I-p
741	4929	4930	2	2	CD	_	_	I-cesDoc	_	I-p
742	4931	4941	metabolite	metabolite	NN	_	_	I-cesDoc	_	I-p
743	4941	4942	)	)	)	_	_	I-cesDoc	_	I-p
744	4942	4943	,	,	,	_	_	I-cesDoc	_	I-p
745	4944	4947	and	and	CC	_	_	I-cesDoc	_	I-p
746	4948	4951	PGF	pgf	NNP	_	_	I-cesDoc	_	I-p
747	4963	4964	2	2	CD	_	_	I-cesDoc	_	I-p
748	4964	4965	?	?	NN	_	_	I-cesDoc	_	I-p
749	4966	4976	production	production	NN	_	_	I-cesDoc	_	I-p
750	4977	4979	in	in	IN	_	_	I-cesDoc	_	I-p
751	4980	4990	stimulated	stimulate	VBN	_	_	I-cesDoc	_	I-p
752	5001	5012	fibroblasts	fibroblast	NNS	_	_	I-cesDoc	_	I-p
753	5012	5013	.	.	.	_	_	I-cesDoc	_	I-p
754	5014	5020	HF-IPF	hf-ipf	NNP	_	_	I-cesDoc	_	I-p
755	5021	5022	(	(	(	_	_	I-cesDoc	_	I-p
756	5022	5023	n	n	NN	_	_	I-cesDoc	_	I-p
757	5024	5025	=	=	SYM	_	_	I-cesDoc	_	I-p
758	5026	5027	7	7	CD	_	_	I-cesDoc	_	I-p
759	5027	5028	)	)	)	_	_	I-cesDoc	_	I-p
760	5029	5032	and	and	CC	_	_	I-cesDoc	_	I-p
761	5033	5038	HF-NL	hf-nl	NNP	_	_	I-cesDoc	_	I-p
762	5039	5040	(	(	(	_	_	I-cesDoc	_	I-p
763	5040	5041	n	n	NN	_	_	I-cesDoc	_	I-p
764	5042	5043	=	=	SYM	_	_	I-cesDoc	_	I-p
765	5044	5045	5	5	CD	_	_	I-cesDoc	_	I-p
766	5045	5046	)	)	)	_	_	I-cesDoc	_	I-p
767	5047	5051	were	be	VBD	_	_	I-cesDoc	_	I-p
768	5062	5069	brought	bring	VBN	_	_	I-cesDoc	_	I-p
769	5070	5072	to	to	TO	_	_	I-cesDoc	_	I-p
770	5073	5074	>	>	NN	_	_	I-cesDoc	_	I-p
771	5074	5076	90	90	CD	_	_	I-cesDoc	_	I-p
772	5076	5077	%	%	NN	_	_	I-cesDoc	_	I-p
773	5078	5088	confluency	confluency	NN	_	_	I-cesDoc	_	I-p
774	5089	5091	in	in	IN	_	_	I-cesDoc	_	I-p
775	5092	5095	100	100	CD	_	_	I-cesDoc	_	I-p
776	5095	5097	mm	mm	NN	_	_	I-cesDoc	_	I-p
777	5098	5104	plates	plate	NNS	_	_	I-cesDoc	_	I-p
778	5105	5108	and	and	CC	_	_	I-cesDoc	_	I-p
779	5109	5113	then	then	RB	_	_	I-cesDoc	_	I-p
780	5124	5130	placed	place	VBN	_	_	I-cesDoc	_	I-p
781	5131	5133	on	on	IN	_	_	I-cesDoc	_	I-p
782	5134	5139	serum	serum	NN	_	_	I-cesDoc	_	I-p
783	5140	5144	free	free	JJ	_	_	I-cesDoc	_	I-p
784	5145	5149	DMEM	dmem	NNP	_	_	I-cesDoc	_	I-p
785	5150	5153	for	for	IN	_	_	I-cesDoc	_	I-p
786	5154	5156	24	24	CD	_	_	I-cesDoc	_	I-p
787	5157	5162	hours	hour	NNS	_	_	I-cesDoc	_	I-p
788	5163	5165	to	to	TO	_	_	I-cesDoc	_	I-p
789	5166	5172	render	render	VB	_	_	I-cesDoc	_	I-p
790	5173	5177	them	them	PRP	_	_	I-cesDoc	_	I-p
791	5188	5197	quiescent	quiescent	JJ	_	_	I-cesDoc	_	I-p
792	5197	5198	.	.	.	_	_	I-cesDoc	_	I-p
793	5199	5210	Fibroblasts	fibroblasts	NNP	_	_	I-cesDoc	_	I-p
794	5211	5215	were	be	VBD	_	_	I-cesDoc	_	I-p
795	5216	5220	then	then	RB	_	_	I-cesDoc	_	I-p
796	5221	5230	incubated	incubated	JJ	_	_	I-cesDoc	_	I-p
797	5231	5233	in	in	IN	_	_	I-cesDoc	_	I-p
798	5234	5238	DMEM	dmem	NNP	_	_	I-cesDoc	_	I-p
799	5239	5243	with	with	IN	_	_	I-cesDoc	_	I-p
800	5254	5255	5	5	CD	_	_	I-cesDoc	_	I-p
801	5255	5256	%	%	NN	_	_	I-cesDoc	_	I-p
802	5257	5260	FBS	fbs	NNP	_	_	I-cesDoc	_	I-p
803	5261	5266	alone	alone	RB	_	_	I-cesDoc	_	I-p
804	5267	5269	or	or	CC	_	_	I-cesDoc	_	I-p
805	5270	5272	in	in	IN	_	_	I-cesDoc	_	I-p
806	5273	5276	the	the	DT	_	_	I-cesDoc	_	I-p
807	5277	5281	same	same	JJ	_	_	I-cesDoc	_	I-p
808	5282	5288	medium	medium	NN	_	_	I-cesDoc	_	I-p
809	5289	5293	with	with	IN	_	_	I-cesDoc	_	I-p
810	5294	5299	IL-1?	il-1?	NNP	_	_	I-cesDoc	_	I-p
811	5300	5301	(	(	(	_	_	I-cesDoc	_	I-p
812	5301	5304	2.5	2.5	CD	_	_	I-cesDoc	_	I-p
813	5305	5307	ng	ng	NN	_	_	I-cesDoc	_	I-p
814	5307	5308	/	/	NN	_	_	I-cesDoc	_	I-p
815	5308	5310	ml	ml	NN	_	_	I-cesDoc	_	I-p
816	5310	5311	)	)	)	_	_	I-cesDoc	_	I-p
817	5322	5325	for	for	IN	_	_	I-cesDoc	_	I-p
818	5326	5328	24	24	CD	_	_	I-cesDoc	_	I-p
819	5329	5334	hours	hour	NNS	_	_	I-cesDoc	_	I-p
820	5334	5335	.	.	.	_	_	I-cesDoc	_	I-p
821	5336	5338	At	at	IN	_	_	I-cesDoc	_	I-p
822	5339	5342	the	the	DT	_	_	I-cesDoc	_	I-p
823	5343	5346	end	end	NN	_	_	I-cesDoc	_	I-p
824	5347	5349	of	of	IN	_	_	I-cesDoc	_	I-p
825	5350	5353	the	the	DT	_	_	I-cesDoc	_	I-p
826	5354	5364	incubation	incubation	NN	_	_	I-cesDoc	_	I-p
827	5365	5371	period	period	NN	_	_	I-cesDoc	_	I-p
828	5372	5375	the	the	DT	_	_	I-cesDoc	_	I-p
829	5386	5397	supernatant	supernatant	NN	_	_	I-cesDoc	_	I-p
830	5398	5401	was	be	VBD	_	_	I-cesDoc	_	I-p
831	5402	5411	aspirated	aspirated	JJ	_	_	I-cesDoc	_	I-p
832	5412	5415	and	and	CC	_	_	I-cesDoc	_	I-p
833	5416	5421	fresh	fresh	JJ	_	_	I-cesDoc	_	I-p
834	5422	5427	media	media	NNS	_	_	I-cesDoc	_	I-p
835	5428	5438	containing	contain	VBG	_	_	I-cesDoc	_	I-p
836	5439	5441	30	30	CD	_	_	I-cesDoc	_	I-p
837	5452	5454	?M	?m	NN	_	_	I-cesDoc	_	I-p
838	5455	5457	of	of	IN	_	_	I-cesDoc	_	I-p
839	5458	5469	arachidonic	arachidonic	JJ	_	_	I-cesDoc	_	I-p
840	5470	5474	acid	acid	NN	_	_	I-cesDoc	_	I-p
841	5475	5478	was	be	VBD	_	_	I-cesDoc	_	I-p
842	5479	5484	added	add	VBN	_	_	I-cesDoc	_	I-p
843	5485	5487	to	to	TO	_	_	I-cesDoc	_	I-p
844	5488	5491	the	the	DT	_	_	I-cesDoc	_	I-p
845	5492	5498	plates	plate	NNS	_	_	I-cesDoc	_	I-p
846	5498	5499	.	.	.	_	_	I-cesDoc	_	I-p
847	5500	5505	After	after	IN	_	_	I-cesDoc	_	I-p
848	5506	5508	30	30	CD	_	_	I-cesDoc	_	I-p
849	5519	5522	min	min	NN	_	_	I-cesDoc	_	I-p
850	5523	5525	of	of	IN	_	_	I-cesDoc	_	I-p
851	5526	5536	incubation	incubation	NN	_	_	I-cesDoc	_	I-p
852	5537	5540	the	the	DT	_	_	I-cesDoc	_	I-p
853	5541	5552	supernatant	supernatant	NN	_	_	I-cesDoc	_	I-p
854	5553	5556	was	be	VBD	_	_	I-cesDoc	_	I-p
855	5557	5566	collected	collect	VBN	_	_	I-cesDoc	_	I-p
856	5567	5570	and	and	CC	_	_	I-cesDoc	_	I-p
857	5571	5576	saved	save	VBN	_	_	I-cesDoc	_	I-p
858	5587	5589	at	at	IN	_	_	I-cesDoc	_	I-p
859	5590	5591	-	-	:	_	_	I-cesDoc	_	I-p
860	5591	5593	70	70	CD	_	_	I-cesDoc	_	I-p
861	5593	5594	°	°	NN	_	_	I-cesDoc	_	I-p
862	5594	5595	C	c	NNP	_	_	I-cesDoc	_	I-p
863	5596	5599	for	for	IN	_	_	I-cesDoc	_	I-p
864	5600	5605	later	later	RB	_	_	I-cesDoc	_	I-p
865	5606	5616	eicosanoid	eicosanoid	NN	_	_	I-cesDoc	_	I-p
866	5617	5625	analysis	analysis	NN	_	_	I-cesDoc	_	I-p
867	5625	5626	.	.	.	_	_	I-cesDoc	_	I-p
868	5627	5630	The	the	DT	_	_	I-cesDoc	_	I-p
869	5631	5636	cells	cell	NNS	_	_	I-cesDoc	_	I-p
870	5637	5641	were	be	VBD	_	_	I-cesDoc	_	I-p
871	5652	5656	then	then	RB	_	_	I-cesDoc	_	I-p
872	5657	5668	resuspended	resuspended	JJ	_	_	I-cesDoc	_	I-p
873	5669	5672	and	and	CC	_	_	I-cesDoc	_	I-p
874	5673	5680	divided	divide	VBN	_	_	I-cesDoc	_	I-p
875	5681	5685	into	into	IN	_	_	I-cesDoc	_	I-p
876	5686	5689	two	two	CD	_	_	I-cesDoc	_	I-p
877	5690	5698	aliquots	aliquot	NNS	_	_	I-cesDoc	_	I-p
878	5698	5699	,	,	,	_	_	I-cesDoc	_	I-p
879	5700	5705	which	which	WDT	_	_	I-cesDoc	_	I-p
880	5716	5720	were	be	VBD	_	_	I-cesDoc	_	I-p
881	5721	5725	used	use	VBN	_	_	I-cesDoc	_	I-p
882	5726	5729	for	for	IN	_	_	I-cesDoc	_	I-p
883	5730	5733	RNA	rna	NNP	_	_	I-cesDoc	_	I-p
884	5734	5737	and	and	CC	_	_	I-cesDoc	_	I-p
885	5738	5745	protein	protein	NN	_	_	I-cesDoc	_	I-p
886	5746	5757	extractions	extraction	NNS	_	_	I-cesDoc	_	I-p
887	5757	5758	,	,	,	_	_	I-cesDoc	_	I-p
888	5759	5771	respectively	respectively	RB	_	_	I-cesDoc	_	I-p
889	5771	5772	.	.	.	_	_	I-cesDoc	_	I-p
890	5783	5786	The	the	DT	_	_	I-cesDoc	_	I-p
891	5787	5792	above	above	IN	_	_	I-cesDoc	_	I-p
892	5793	5804	experiments	experiment	NNS	_	_	I-cesDoc	_	I-p
893	5805	5809	were	be	VBD	_	_	I-cesDoc	_	I-p
894	5810	5818	repeated	repeat	VBN	_	_	I-cesDoc	_	I-p
895	5819	5821	in	in	IN	_	_	I-cesDoc	_	I-p
896	5822	5828	HF-IPF	hf-ipf	NNP	_	_	I-cesDoc	_	I-p
897	5829	5830	(	(	(	_	_	I-cesDoc	_	I-p
898	5830	5831	n	n	NN	_	_	I-cesDoc	_	I-p
899	5832	5833	=	=	SYM	_	_	I-cesDoc	_	I-p
900	5834	5835	2	2	CD	_	_	I-cesDoc	_	I-p
901	5835	5836	)	)	)	_	_	I-cesDoc	_	I-p
902	5837	5840	and	and	CC	_	_	I-cesDoc	_	I-p
903	5851	5856	HF-NL	hf-nl	NNP	_	_	I-cesDoc	_	I-p
904	5857	5858	(	(	(	_	_	I-cesDoc	_	I-p
905	5858	5859	n	n	NN	_	_	I-cesDoc	_	I-p
906	5860	5861	=	=	SYM	_	_	I-cesDoc	_	I-p
907	5862	5863	2	2	CD	_	_	I-cesDoc	_	I-p
908	5863	5864	)	)	)	_	_	I-cesDoc	_	I-p
909	5865	5870	using	use	VBG	_	_	I-cesDoc	_	I-p
910	5871	5876	serum	serum	NN	_	_	I-cesDoc	_	I-p
911	5877	5881	free	free	JJ	_	_	I-cesDoc	_	I-p
912	5882	5887	media	media	NNS	_	_	I-cesDoc	_	I-p
913	5888	5898	conditions	condition	NNS	_	_	I-cesDoc	_	I-p
914	5898	5899	.	.	.	_	_	I-cesDoc	_	I-p
915	5910	5921	Prostanoids	prostanoids	NNP	_	_	I-cesDoc	_	I-p
916	5922	5926	were	be	VBD	_	_	I-cesDoc	_	I-p
917	5927	5935	measured	measure	VBN	_	_	I-cesDoc	_	I-p
918	5936	5938	by	by	IN	_	_	I-cesDoc	_	I-p
919	5939	5947	modified	modify	VBN	_	_	I-cesDoc	_	I-p
920	5948	5954	stable	stable	JJ	_	_	I-cesDoc	_	I-p
921	5955	5962	isotope	isotope	NN	_	_	I-cesDoc	_	I-p
922	5973	5981	dilution	dilution	NN	_	_	I-cesDoc	_	I-p
923	5982	5988	assays	assay	NNS	_	_	I-cesDoc	_	I-p
924	5989	5993	that	that	WDT	_	_	I-cesDoc	_	I-p
925	5994	5998	used	use	VBD	_	_	I-cesDoc	_	I-p
926	5999	6002	gas	gas	NN	_	_	I-cesDoc	_	I-p
927	6003	6017	chromatography	chromatography	NN	_	_	I-cesDoc	_	I-p
928	6017	6018	-	-	-	_	_	I-cesDoc	_	I-p
929	6018	6026	negative	negative	JJ	_	_	I-cesDoc	_	I-p
930	6037	6040	ion	ion	NN	_	_	I-cesDoc	_	I-p
931	6040	6041	-	-	-	_	_	I-cesDoc	_	I-p
932	6041	6049	chemical	chemical	JJ	_	_	I-cesDoc	_	I-p
933	6050	6060	ionization	ionization	NN	_	_	I-cesDoc	_	I-p
934	6061	6065	mass	mass	NN	_	_	I-cesDoc	_	I-p
935	6066	6078	spectrometry	spectrometry	NN	_	_	I-cesDoc	_	I-p
936	6079	6081	as	as	RB	_	_	I-cesDoc	_	I-p
937	6082	6092	previously	previously	RB	_	_	I-cesDoc	_	I-p
938	6103	6112	described	describe	VBD	_	_	I-cesDoc	_	I-p
939	6113	6114	[	[	NN	_	_	I-cesDoc	_	I-p
940	6115	6117	23	23	CD	_	_	I-cesDoc	_	I-p
941	6118	6119	]	]	NN	_	_	I-cesDoc	_	I-p
942	6120	6121	.	.	.	_	_	I-cesDoc	_	I-p
943	6122	6129	Briefly	briefly	NNP	_	_	I-cesDoc	_	I-p
944	6129	6130	,	,	,	_	_	I-cesDoc	_	I-p
945	6131	6140	deuterium	deuterium	NN	_	_	I-cesDoc	_	I-p
946	6140	6141	-	-	-	_	_	I-cesDoc	_	I-p
947	6141	6148	labeled	label	JJ	_	_	I-cesDoc	_	I-p
948	6149	6157	internal	internal	JJ	_	_	I-cesDoc	_	I-p
949	6168	6177	standards	standard	NNS	_	_	I-cesDoc	_	I-p
950	6178	6180	of	of	IN	_	_	I-cesDoc	_	I-p
951	6181	6184	PGE	pge	NNP	_	_	I-cesDoc	_	I-p
952	6196	6197	2	2	CD	_	_	I-cesDoc	_	I-p
953	6198	6199	,	,	,	_	_	I-cesDoc	_	I-p
954	6200	6203	PGF	pgf	NNP	_	_	I-cesDoc	_	I-p
955	6215	6216	2	2	CD	_	_	I-cesDoc	_	I-p
956	6216	6217	?	?	NN	_	_	I-cesDoc	_	I-p
957	6218	6219	,	,	,	_	_	I-cesDoc	_	I-p
958	6220	6223	TXB	txb	NNP	_	_	I-cesDoc	_	I-p
959	6235	6236	2	2	CD	_	_	I-cesDoc	_	I-p
960	6237	6238	,	,	,	_	_	I-cesDoc	_	I-p
961	6239	6242	and	and	CC	_	_	I-cesDoc	_	I-p
962	6243	6253	6-keto-PGF	6-keto-PGF	NN	_	_	I-cesDoc	_	I-p
963	6265	6266	1	1	CD	_	_	I-cesDoc	_	I-p
964	6266	6267	?	?	NN	_	_	I-cesDoc	_	I-p
965	6268	6272	were	be	VBD	_	_	I-cesDoc	_	I-p
966	6273	6278	added	add	VBN	_	_	I-cesDoc	_	I-p
967	6279	6281	to	to	TO	_	_	I-cesDoc	_	I-p
968	6282	6285	the	the	DT	_	_	I-cesDoc	_	I-p
969	6286	6298	supernatants	supernatant	NNS	_	_	I-cesDoc	_	I-p
970	6299	6303	with	with	IN	_	_	I-cesDoc	_	I-p
971	6314	6323	isopropyl	isopropyl	NN	_	_	I-cesDoc	_	I-p
972	6324	6331	alcohol	alcohol	NN	_	_	I-cesDoc	_	I-p
973	6331	6332	.	.	.	_	_	I-cesDoc	_	I-p
974	6333	6342	Isopropyl	isopropyl	NNP	_	_	I-cesDoc	_	I-p
975	6343	6350	alcohol	alcohol	NN	_	_	I-cesDoc	_	I-p
976	6351	6354	was	be	VBD	_	_	I-cesDoc	_	I-p
977	6355	6362	removed	remove	VBN	_	_	I-cesDoc	_	I-p
978	6363	6365	by	by	IN	_	_	I-cesDoc	_	I-p
979	6376	6387	evaporation	evaporation	NN	_	_	I-cesDoc	_	I-p
980	6388	6393	under	under	IN	_	_	I-cesDoc	_	I-p
981	6394	6402	nitrogen	nitrogen	NN	_	_	I-cesDoc	_	I-p
982	6402	6403	.	.	.	_	_	I-cesDoc	_	I-p
983	6404	6409	After	after	IN	_	_	I-cesDoc	_	I-p
984	6410	6423	acidification	acidification	NN	_	_	I-cesDoc	_	I-p
985	6424	6426	to	to	TO	_	_	I-cesDoc	_	I-p
986	6427	6429	pH	ph	NN	_	_	I-cesDoc	_	I-p
987	6440	6443	3.5	3.5	CD	_	_	I-cesDoc	_	I-p
988	6443	6444	,	,	,	_	_	I-cesDoc	_	I-p
989	6445	6448	the	the	DT	_	_	I-cesDoc	_	I-p
990	6449	6456	samples	sample	NNS	_	_	I-cesDoc	_	I-p
991	6457	6461	were	be	VBD	_	_	I-cesDoc	_	I-p
992	6462	6471	extracted	extract	VBN	_	_	I-cesDoc	_	I-p
993	6472	6474	on	on	IN	_	_	I-cesDoc	_	I-p
994	6475	6489	preconditioned	preconditioned	JJ	_	_	I-cesDoc	_	I-p
995	6490	6494	C-18	c-18	NNP	_	_	I-cesDoc	_	I-p
996	6505	6512	PrepSep	prepsep	NNP	_	_	I-cesDoc	_	I-p
997	6513	6520	columns	column	NNS	_	_	I-cesDoc	_	I-p
998	6521	6522	(	(	(	_	_	I-cesDoc	_	I-p
999	6522	6528	Fisher	fisher	NNP	_	_	I-cesDoc	_	I-p
1000	6529	6539	Scientific	scientific	NNP	_	_	I-cesDoc	_	I-p
1001	6539	6540	,	,	,	_	_	I-cesDoc	_	I-p
1002	6541	6545	Fair	fair	NNP	_	_	I-cesDoc	_	I-p
1003	6546	6550	Lawn	lawn	NNP	_	_	I-cesDoc	_	I-p
1004	6550	6551	,	,	,	_	_	I-cesDoc	_	I-p
1005	6552	6554	NJ	nj	NNP	_	_	I-cesDoc	_	I-p
1006	6554	6555	)	)	)	_	_	I-cesDoc	_	I-p
1007	6555	6556	,	,	,	_	_	I-cesDoc	_	I-p
1008	6557	6560	and	and	CC	_	_	I-cesDoc	_	I-p
1009	6571	6577	eluted	eluted	JJ	_	_	I-cesDoc	_	I-p
1010	6578	6582	with	with	IN	_	_	I-cesDoc	_	I-p
1011	6583	6588	ethyl	ethyl	NN	_	_	I-cesDoc	_	I-p
1012	6589	6596	acetate	acetate	NN	_	_	I-cesDoc	_	I-p
1013	6596	6597	.	.	.	_	_	I-cesDoc	_	I-p
1014	6598	6601	The	the	DT	_	_	I-cesDoc	_	I-p
1015	6602	6609	extract	extract	NN	_	_	I-cesDoc	_	I-p
1016	6610	6613	was	be	VBD	_	_	I-cesDoc	_	I-p
1017	6614	6618	then	then	RB	_	_	I-cesDoc	_	I-p
1018	6619	6628	converted	convert	VBN	_	_	I-cesDoc	_	I-p
1019	6639	6641	to	to	TO	_	_	I-cesDoc	_	I-p
1020	6642	6643	a	a	DT	_	_	I-cesDoc	_	I-p
1021	6644	6661	pentafluorobenzyl	pentafluorobenzyl	NN	_	_	I-cesDoc	_	I-p
1022	6662	6667	ester	ester	NN	_	_	I-cesDoc	_	I-p
1023	6668	6670	by	by	IN	_	_	I-cesDoc	_	I-p
1024	6671	6680	treatment	treatment	NN	_	_	I-cesDoc	_	I-p
1025	6681	6685	with	with	IN	_	_	I-cesDoc	_	I-p
1026	6686	6687	a	a	DT	_	_	I-cesDoc	_	I-p
1027	6688	6695	mixture	mixture	NN	_	_	I-cesDoc	_	I-p
1028	6706	6708	of	of	IN	_	_	I-cesDoc	_	I-p
1029	6709	6713	12.5	12.5	CD	_	_	I-cesDoc	_	I-p
1030	6713	6714	%	%	NN	_	_	I-cesDoc	_	I-p
1031	6715	6732	pentafluorobenzyl	pentafluorobenzyl	NN	_	_	I-cesDoc	_	I-p
1032	6733	6740	bromide	bromide	NN	_	_	I-cesDoc	_	I-p
1033	6741	6743	in	in	IN	_	_	I-cesDoc	_	I-p
1034	6744	6756	acetonitrile	acetonitrile	NN	_	_	I-cesDoc	_	I-p
1035	6757	6760	and	and	CC	_	_	I-cesDoc	_	I-p
1036	6771	6791	disopropylethylamine	disopropylethylamine	NN	_	_	I-cesDoc	_	I-p
1037	6792	6794	at	at	IN	_	_	I-cesDoc	_	I-p
1038	6795	6799	room	room	NN	_	_	I-cesDoc	_	I-p
1039	6800	6811	temperature	temperature	NN	_	_	I-cesDoc	_	I-p
1040	6812	6815	for	for	IN	_	_	I-cesDoc	_	I-p
1041	6816	6818	30	30	CD	_	_	I-cesDoc	_	I-p
1042	6819	6823	min.	min.	NN	_	_	I-cesDoc	_	I-p
1043	6834	6839	After	after	IN	_	_	I-cesDoc	_	I-p
1044	6840	6851	evaporation	evaporation	NN	_	_	I-cesDoc	_	I-p
1045	6852	6854	of	of	IN	_	_	I-cesDoc	_	I-p
1046	6855	6863	reagents	reagent	NNS	_	_	I-cesDoc	_	I-p
1047	6863	6864	,	,	,	_	_	I-cesDoc	_	I-p
1048	6865	6868	the	the	DT	_	_	I-cesDoc	_	I-p
1049	6869	6876	residue	residue	NN	_	_	I-cesDoc	_	I-p
1050	6877	6880	was	be	VBD	_	_	I-cesDoc	_	I-p
1051	6881	6890	subjected	subject	VBN	_	_	I-cesDoc	_	I-p
1052	6901	6903	to	to	TO	_	_	I-cesDoc	_	I-p
1053	6904	6907	TLC	tlc	NNP	_	_	I-cesDoc	_	I-p
1054	6908	6914	plates	plate	NNS	_	_	I-cesDoc	_	I-p
1055	6914	6915	,	,	,	_	_	I-cesDoc	_	I-p
1056	6916	6921	using	use	VBG	_	_	I-cesDoc	_	I-p
1057	6922	6925	the	the	DT	_	_	I-cesDoc	_	I-p
1058	6926	6933	solvent	solvent	JJ	_	_	I-cesDoc	_	I-p
1059	6934	6940	system	system	NN	_	_	I-cesDoc	_	I-p
1060	6951	6961	chloroform	chloroform	NN	_	_	I-cesDoc	_	I-p
1061	6961	6962	/	/	NN	_	_	I-cesDoc	_	I-p
1062	6962	6969	ethanol	ethanol	NN	_	_	I-cesDoc	_	I-p
1063	6970	6971	(	(	(	_	_	I-cesDoc	_	I-p
1064	6971	6973	93	93	CD	_	_	I-cesDoc	_	I-p
1065	6973	6974	:	:	:	_	_	I-cesDoc	_	I-p
1066	6974	6975	7	7	CD	_	_	I-cesDoc	_	I-p
1067	6975	6976	,	,	,	_	_	I-cesDoc	_	I-p
1068	6977	6980	vol	vol	NN	_	_	I-cesDoc	_	I-p
1069	6980	6981	/	/	NN	_	_	I-cesDoc	_	I-p
1070	6981	6984	vol	vol	NN	_	_	I-cesDoc	_	I-p
1071	6984	6985	)	)	)	_	_	I-cesDoc	_	I-p
1072	6986	6989	for	for	IN	_	_	I-cesDoc	_	I-p
1073	6990	6993	PGF	pgf	NNP	_	_	I-cesDoc	_	I-p
1074	7005	7006	2	2	CD	_	_	I-cesDoc	_	I-p
1075	7006	7007	?	?	NN	_	_	I-cesDoc	_	I-p
1076	7008	7011	and	and	CC	_	_	I-cesDoc	_	I-p
1077	7012	7015	TXB	txb	NNP	_	_	I-cesDoc	_	I-p
1078	7027	7028	2	2	CD	_	_	I-cesDoc	_	I-p
1079	7029	7030	,	,	,	_	_	I-cesDoc	_	I-p
1080	7031	7034	and	and	CC	_	_	I-cesDoc	_	I-p
1081	7035	7040	ethyl	ethyl	NN	_	_	I-cesDoc	_	I-p
1082	7041	7048	acetate	acetate	NN	_	_	I-cesDoc	_	I-p
1083	7048	7049	/	/	NN	_	_	I-cesDoc	_	I-p
1084	7049	7057	methanol	methanol	NN	_	_	I-cesDoc	_	I-p
1085	7058	7059	(	(	(	_	_	I-cesDoc	_	I-p
1086	7059	7061	93	93	CD	_	_	I-cesDoc	_	I-p
1087	7061	7062	:	:	:	_	_	I-cesDoc	_	I-p
1088	7062	7063	2	2	CD	_	_	I-cesDoc	_	I-p
1089	7063	7064	,	,	,	_	_	I-cesDoc	_	I-p
1090	7075	7078	vol	vol	NN	_	_	I-cesDoc	_	I-p
1091	7078	7079	/	/	NN	_	_	I-cesDoc	_	I-p
1092	7079	7082	vol	vol	NN	_	_	I-cesDoc	_	I-p
1093	7082	7083	)	)	)	_	_	I-cesDoc	_	I-p
1094	7084	7087	for	for	IN	_	_	I-cesDoc	_	I-p
1095	7088	7098	6-keto-PGF	6-keto-PGF	NN	_	_	I-cesDoc	_	I-p
1096	7110	7111	1	1	CD	_	_	I-cesDoc	_	I-p
1097	7111	7112	?	?	NN	_	_	I-cesDoc	_	I-p
1098	7113	7116	and	and	CC	_	_	I-cesDoc	_	I-p
1099	7117	7120	PGE	pge	NNP	_	_	I-cesDoc	_	I-p
1100	7132	7133	2	2	CD	_	_	I-cesDoc	_	I-p
1101	7134	7135	.	.	.	_	_	I-cesDoc	_	I-p
1102	7136	7140	Then	then	RB	_	_	I-cesDoc	_	I-p
1103	7141	7144	PGF	pgf	NNP	_	_	I-cesDoc	_	I-p
1104	7156	7157	2	2	CD	_	_	I-cesDoc	_	I-p
1105	7157	7158	?	?	NN	_	_	I-cesDoc	_	I-p
1106	7159	7162	was	be	VBD	_	_	I-cesDoc	_	I-p
1107	7163	7172	converted	convert	VBN	_	_	I-cesDoc	_	I-p
1108	7173	7175	to	to	TO	_	_	I-cesDoc	_	I-p
1109	7176	7190	trimethylsilyl	trimethylsilyl	NN	_	_	I-cesDoc	_	I-p
1110	7201	7206	ether	ether	NN	_	_	I-cesDoc	_	I-p
1111	7207	7217	derivative	derivative	JJ	_	_	I-cesDoc	_	I-p
1112	7218	7220	by	by	IN	_	_	I-cesDoc	_	I-p
1113	7221	7230	treatment	treatment	NN	_	_	I-cesDoc	_	I-p
1114	7231	7235	with	with	IN	_	_	I-cesDoc	_	I-p
1115	7236	7243	N,O-bis	n,o-bis	NNP	_	_	I-cesDoc	_	I-p
1116	7254	7255	(	(	(	_	_	I-cesDoc	_	I-p
1117	7255	7269	trimethylsilyl	trimethylsilyl	NN	_	_	I-cesDoc	_	I-p
1118	7269	7270	)	)	)	_	_	I-cesDoc	_	I-p
1119	7271	7289	trifluoroacetamide	trifluoroacetamide	NN	_	_	I-cesDoc	_	I-p
1120	7290	7293	and	and	CC	_	_	I-cesDoc	_	I-p
1121	7304	7321	dimethylformamide	dimethylformamide	NN	_	_	I-cesDoc	_	I-p
1122	7321	7322	.	.	.	_	_	I-cesDoc	_	I-p
1123	7323	7326	The	the	DT	_	_	I-cesDoc	_	I-p
1124	7327	7336	methoxime	methoxime	NN	_	_	I-cesDoc	_	I-p
1125	7337	7347	derivative	derivative	NN	_	_	I-cesDoc	_	I-p
1126	7348	7350	of	of	IN	_	_	I-cesDoc	_	I-p
1127	7351	7354	TXB	txb	NNP	_	_	I-cesDoc	_	I-p
1128	7366	7367	2	2	CD	_	_	I-cesDoc	_	I-p
1129	7368	7369	,	,	,	_	_	I-cesDoc	_	I-p
1130	7370	7373	PGE	pge	NNP	_	_	I-cesDoc	_	I-p
1131	7385	7386	2	2	CD	_	_	I-cesDoc	_	I-p
1132	7387	7390	and	and	CC	_	_	I-cesDoc	_	I-p
1133	7391	7401	6-keto-PGF	6-keto-PGF	NN	_	_	I-cesDoc	_	I-p
1134	7413	7414	1	1	CD	_	_	I-cesDoc	_	I-p
1135	7414	7415	?	?	NN	_	_	I-cesDoc	_	I-p
1136	7416	7419	was	be	VBD	_	_	I-cesDoc	_	I-p
1137	7420	7424	made	make	VBN	_	_	I-cesDoc	_	I-p
1138	7425	7427	by	by	IN	_	_	I-cesDoc	_	I-p
1139	7428	7437	treatment	treatment	NN	_	_	I-cesDoc	_	I-p
1140	7438	7442	with	with	IN	_	_	I-cesDoc	_	I-p
1141	7443	7444	2	2	CD	_	_	I-cesDoc	_	I-p
1142	7444	7445	%	%	NN	_	_	I-cesDoc	_	I-p
1143	7456	7467	methoxamine	methoxamine	NN	_	_	I-cesDoc	_	I-p
1144	7468	7481	hydrochloride	hydrochloride	NN	_	_	I-cesDoc	_	I-p
1145	7482	7484	in	in	IN	_	_	I-cesDoc	_	I-p
1146	7485	7493	pyridine	pyridine	NN	_	_	I-cesDoc	_	I-p
1147	7494	7496	at	at	IN	_	_	I-cesDoc	_	I-p
1148	7497	7499	70	70	CD	_	_	I-cesDoc	_	I-p
1149	7499	7500	°	°	NN	_	_	I-cesDoc	_	I-p
1150	7500	7501	C	c	NNP	_	_	I-cesDoc	_	I-p
1151	7502	7505	for	for	IN	_	_	I-cesDoc	_	I-p
1152	7506	7508	60	60	CD	_	_	I-cesDoc	_	I-p
1153	7509	7512	min	min	NN	_	_	I-cesDoc	_	I-p
1154	7512	7513	,	,	,	_	_	I-cesDoc	_	I-p
1155	7524	7532	followed	follow	VBN	_	_	I-cesDoc	_	I-p
1156	7533	7535	by	by	IN	_	_	I-cesDoc	_	I-p
1157	7536	7547	evaporation	evaporation	NN	_	_	I-cesDoc	_	I-p
1158	7548	7550	of	of	IN	_	_	I-cesDoc	_	I-p
1159	7551	7554	the	the	DT	_	_	I-cesDoc	_	I-p
1160	7555	7563	pyridine	pyridine	NN	_	_	I-cesDoc	_	I-p
1161	7563	7564	,	,	,	_	_	I-cesDoc	_	I-p
1162	7565	7573	addition	addition	NN	_	_	I-cesDoc	_	I-p
1163	7574	7576	of	of	IN	_	_	I-cesDoc	_	I-p
1164	7587	7592	water	water	NN	_	_	I-cesDoc	_	I-p
1165	7592	7593	,	,	,	_	_	I-cesDoc	_	I-p
1166	7594	7597	and	and	CC	_	_	I-cesDoc	_	I-p
1167	7598	7608	extraction	extraction	NN	_	_	I-cesDoc	_	I-p
1168	7609	7613	with	with	IN	_	_	I-cesDoc	_	I-p
1169	7614	7619	ethyl	ethyl	NN	_	_	I-cesDoc	_	I-p
1170	7620	7627	acetate	acetate	NN	_	_	I-cesDoc	_	I-p
1171	7627	7628	.	.	.	_	_	I-cesDoc	_	I-p
1172	7629	7643	Derivatization	derivatization	NNP	_	_	I-cesDoc	_	I-p
1173	7654	7657	was	be	VBD	_	_	I-cesDoc	_	I-p
1174	7658	7667	completed	complete	VBN	_	_	I-cesDoc	_	I-p
1175	7668	7670	by	by	IN	_	_	I-cesDoc	_	I-p
1176	7671	7680	formation	formation	NN	_	_	I-cesDoc	_	I-p
1177	7681	7683	of	of	IN	_	_	I-cesDoc	_	I-p
1178	7684	7687	the	the	DT	_	_	I-cesDoc	_	I-p
1179	7688	7702	trimethylsilyl	trimethylsilyl	NN	_	_	I-cesDoc	_	I-p
1180	7713	7724	derivatives	derivative	NNS	_	_	I-cesDoc	_	I-p
1181	7725	7727	by	by	IN	_	_	I-cesDoc	_	I-p
1182	7728	7737	treatment	treatment	NN	_	_	I-cesDoc	_	I-p
1183	7738	7742	with	with	IN	_	_	I-cesDoc	_	I-p
1184	7743	7750	N,O-bis	n,o-bis	NNP	_	_	I-cesDoc	_	I-p
1185	7751	7752	(	(	(	_	_	I-cesDoc	_	I-p
1186	7752	7766	trimethylsilyl	trimethylsilyl	NN	_	_	I-cesDoc	_	I-p
1187	7766	7767	)	)	)	_	_	I-cesDoc	_	I-p
1188	7778	7796	trifluoroacetamide	trifluoroacetamide	NN	_	_	I-cesDoc	_	I-p
1189	7797	7800	and	and	CC	_	_	I-cesDoc	_	I-p
1190	7801	7809	pyridine	pyridine	NN	_	_	I-cesDoc	_	I-p
1191	7809	7810	.	.	.	_	_	I-cesDoc	_	I-p
1192	7811	7822	Eicosanoids	eicosanoids	NNP	_	_	I-cesDoc	_	I-p
1193	7823	7827	were	be	VBD	_	_	I-cesDoc	_	I-p
1194	7838	7848	quantified	quantify	VBN	_	_	I-cesDoc	_	I-p
1195	7849	7851	by	by	IN	_	_	I-cesDoc	_	I-p
1196	7852	7861	measuring	measure	VBG	_	_	I-cesDoc	_	I-p
1197	7862	7865	the	the	DT	_	_	I-cesDoc	_	I-p
1198	7866	7871	ratio	ratio	NN	_	_	I-cesDoc	_	I-p
1199	7872	7874	of	of	IN	_	_	I-cesDoc	_	I-p
1200	7875	7878	the	the	DT	_	_	I-cesDoc	_	I-p
1201	7879	7888	intensity	intensity	NN	_	_	I-cesDoc	_	I-p
1202	7889	7891	of	of	IN	_	_	I-cesDoc	_	I-p
1203	7902	7906	ions	ion	NNS	_	_	I-cesDoc	_	I-p
1204	7907	7908	m	m	NN	_	_	I-cesDoc	_	I-p
1205	7908	7909	/	/	NN	_	_	I-cesDoc	_	I-p
1206	7909	7910	z	z	SYM	_	_	I-cesDoc	_	I-p
1207	7911	7918	569/573	569/573	CD	_	_	I-cesDoc	_	I-p
1208	7919	7922	for	for	IN	_	_	I-cesDoc	_	I-p
1209	7923	7926	PGF	pgf	NNP	_	_	I-cesDoc	_	I-p
1210	7938	7939	2	2	CD	_	_	I-cesDoc	_	I-p
1211	7939	7940	?	?	NN	_	_	I-cesDoc	_	I-p
1212	7941	7942	,	,	,	_	_	I-cesDoc	_	I-p
1213	7943	7944	m	m	NN	_	_	I-cesDoc	_	I-p
1214	7944	7945	/	/	NN	_	_	I-cesDoc	_	I-p
1215	7945	7946	z	z	SYM	_	_	I-cesDoc	_	I-p
1216	7947	7954	614/618	614/618	CD	_	_	I-cesDoc	_	I-p
1217	7955	7958	for	for	IN	_	_	I-cesDoc	_	I-p
1218	7959	7962	TXB	txb	NNP	_	_	I-cesDoc	_	I-p
1219	7974	7975	2	2	CD	_	_	I-cesDoc	_	I-p
1220	7976	7979	and	and	CC	_	_	I-cesDoc	_	I-p
1221	7980	7990	6-keto-PGF	6-keto-PGF	NN	_	_	I-cesDoc	_	I-p
1222	8002	8003	1	1	CD	_	_	I-cesDoc	_	I-p
1223	8003	8004	?	?	NN	_	_	I-cesDoc	_	I-p
1224	8005	8006	,	,	,	_	_	I-cesDoc	_	I-p
1225	8007	8010	and	and	CC	_	_	I-cesDoc	_	I-p
1226	8011	8012	m	m	NN	_	_	I-cesDoc	_	I-p
1227	8012	8013	/	/	NN	_	_	I-cesDoc	_	I-p
1228	8013	8014	z	z	SYM	_	_	I-cesDoc	_	I-p
1229	8015	8022	524/528	524/528	CD	_	_	I-cesDoc	_	I-p
1230	8023	8026	for	for	IN	_	_	I-cesDoc	_	I-p
1231	8027	8030	PGE	pge	NNP	_	_	I-cesDoc	_	I-p
1232	8042	8043	2	2	CD	_	_	I-cesDoc	_	I-p
1233	8044	8045	.	.	.	_	_	I-cesDoc	_	I-p
1234	8046	8048	An	an	DT	_	_	I-cesDoc	_	I-p
1235	8049	8059	analytical	analytical	JJ	_	_	I-cesDoc	_	I-p
1236	8060	8065	blank	blank	NN	_	_	I-cesDoc	_	I-p
1237	8066	8069	for	for	IN	_	_	I-cesDoc	_	I-p
1238	8070	8074	each	each	DT	_	_	I-cesDoc	_	I-p
1239	8075	8077	of	of	IN	_	_	I-cesDoc	_	I-p
1240	8088	8093	these	these	DT	_	_	I-cesDoc	_	I-p
1241	8094	8102	products	product	NNS	_	_	I-cesDoc	_	I-p
1242	8103	8106	was	be	VBD	_	_	I-cesDoc	_	I-p
1243	8107	8117	determined	determine	VBN	_	_	I-cesDoc	_	I-p
1244	8118	8120	by	by	IN	_	_	I-cesDoc	_	I-p
1245	8121	8130	measuring	measure	VBG	_	_	I-cesDoc	_	I-p
1246	8131	8134	the	the	DT	_	_	I-cesDoc	_	I-p
1247	8135	8141	amount	amount	NN	_	_	I-cesDoc	_	I-p
1248	8142	8144	of	of	IN	_	_	I-cesDoc	_	I-p
1249	8155	8168	nondeuterated	nondeuterated	JJ	_	_	I-cesDoc	_	I-p
1250	8169	8177	material	material	NN	_	_	I-cesDoc	_	I-p
1251	8177	8178	,	,	,	_	_	I-cesDoc	_	I-p
1252	8179	8187	detected	detect	VBD	_	_	I-cesDoc	_	I-p
1253	8188	8193	after	after	IN	_	_	I-cesDoc	_	I-p
1254	8194	8204	extracting	extract	VBG	_	_	I-cesDoc	_	I-p
1255	8205	8208	and	and	CC	_	_	I-cesDoc	_	I-p
1256	8219	8228	analyzing	analyze	VBG	_	_	I-cesDoc	_	I-p
1257	8229	8230	2	2	CD	_	_	I-cesDoc	_	I-p
1258	8231	8233	ml	ml	NN	_	_	I-cesDoc	_	I-p
1259	8234	8236	of	of	IN	_	_	I-cesDoc	_	I-p
1260	8237	8243	saline	saline	NN	_	_	I-cesDoc	_	I-p
1261	8244	8246	to	to	TO	_	_	I-cesDoc	_	I-p
1262	8247	8252	which	which	WDT	_	_	I-cesDoc	_	I-p
1263	8253	8256	the	the	DT	_	_	I-cesDoc	_	I-p
1264	8257	8274	deuterium-labeled	deuterium-labeled	JJ	_	_	I-cesDoc	_	I-p
1265	8285	8293	internal	internal	JJ	_	_	I-cesDoc	_	I-p
1266	8294	8303	standards	standard	NNS	_	_	I-cesDoc	_	I-p
1267	8304	8307	had	have	VBD	_	_	I-cesDoc	_	I-p
1268	8308	8312	been	be	VBN	_	_	I-cesDoc	_	I-p
1269	8313	8318	added	add	VBN	_	_	I-cesDoc	_	I-p
1270	8318	8319	.	.	.	_	_	I-cesDoc	_	I-p
1271	8348	8355	Western	western	JJ	_	_	I-cesDoc	B-head	_
1272	8356	8364	analysis	analysis	NN	_	_	I-cesDoc	I-head	_
1273	8375	8380	After	after	IN	_	_	I-cesDoc	_	B-p
1274	8381	8388	washing	wash	VBG	_	_	I-cesDoc	_	I-p
1275	8389	8393	with	with	IN	_	_	I-cesDoc	_	I-p
1276	8394	8397	PBS	pbs	NNP	_	_	I-cesDoc	_	I-p
1277	8398	8400	at	at	IN	_	_	I-cesDoc	_	I-p
1278	8401	8403	pH	ph	NN	_	_	I-cesDoc	_	I-p
1279	8404	8407	7.4	7.4	CD	_	_	I-cesDoc	_	I-p
1280	8407	8408	,	,	,	_	_	I-cesDoc	_	I-p
1281	8409	8416	pellets	pellet	NNS	_	_	I-cesDoc	_	I-p
1282	8417	8421	were	be	VBD	_	_	I-cesDoc	_	I-p
1283	8422	8427	lyzed	lyzed	JJ	_	_	I-cesDoc	_	I-p
1284	8438	8440	in	in	IN	_	_	I-cesDoc	_	I-p
1285	8441	8455	solubilization	solubilization	NN	_	_	I-cesDoc	_	I-p
1286	8456	8462	buffer	buffer	NN	_	_	I-cesDoc	_	I-p
1287	8463	8473	containing	contain	VBG	_	_	I-cesDoc	_	I-p
1288	8474	8476	50	50	CD	_	_	I-cesDoc	_	I-p
1289	8477	8479	mM	mm	NN	_	_	I-cesDoc	_	I-p
1290	8480	8484	TRIS	tris	NNP	_	_	I-cesDoc	_	I-p
1291	8485	8487	at	at	IN	_	_	I-cesDoc	_	I-p
1292	8488	8490	pH	ph	NN	_	_	I-cesDoc	_	I-p
1293	8491	8492	8	8	CD	_	_	I-cesDoc	_	I-p
1294	8492	8493	,	,	,	_	_	I-cesDoc	_	I-p
1295	8504	8505	1	1	CD	_	_	I-cesDoc	_	I-p
1296	8505	8506	%	%	NN	_	_	I-cesDoc	_	I-p
1297	8507	8512	Tween	tween	NNP	_	_	I-cesDoc	_	I-p
1298	8513	8515	20	20	CD	_	_	I-cesDoc	_	I-p
1299	8515	8516	,	,	,	_	_	I-cesDoc	_	I-p
1300	8517	8519	10	10	CD	_	_	I-cesDoc	_	I-p
1301	8520	8522	mM	mm	NN	_	_	I-cesDoc	_	I-p
1302	8523	8544	phenylmethylsulphonyl	phenylmethylsulphonyl	NN	_	_	I-cesDoc	_	I-p
1303	8545	8553	fluoride	fluoride	NN	_	_	I-cesDoc	_	I-p
1304	8553	8554	,	,	,	_	_	I-cesDoc	_	I-p
1305	8565	8586	diethyldithiocarbamic	diethyldithiocarbamic	JJ	_	_	I-cesDoc	_	I-p
1306	8587	8591	acid	acid	NN	_	_	I-cesDoc	_	I-p
1307	8591	8592	,	,	,	_	_	I-cesDoc	_	I-p
1308	8593	8602	leupeptin	leupeptin	NN	_	_	I-cesDoc	_	I-p
1309	8603	8606	and	and	CC	_	_	I-cesDoc	_	I-p
1310	8607	8616	pepstatin	pepstatin	NN	_	_	I-cesDoc	_	I-p
1311	8617	8618	A	a	DT	_	_	I-cesDoc	_	I-p
1312	8629	8630	(	(	(	_	_	I-cesDoc	_	I-p
1313	8630	8633	all	all	DT	_	_	I-cesDoc	_	I-p
1314	8634	8638	from	from	IN	_	_	I-cesDoc	_	I-p
1315	8639	8644	Sigma	sigma	NNP	_	_	I-cesDoc	_	I-p
1316	8645	8653	Chemical	chemical	NNP	_	_	I-cesDoc	_	I-p
1317	8653	8654	)	)	)	_	_	I-cesDoc	_	I-p
1318	8654	8655	,	,	,	_	_	I-cesDoc	_	I-p
1319	8656	8665	sonicated	sonicated	JJ	_	_	I-cesDoc	_	I-p
1320	8665	8666	,	,	,	_	_	I-cesDoc	_	I-p
1321	8667	8673	boiled	boil	VBD	_	_	I-cesDoc	_	I-p
1322	8674	8678	with	with	IN	_	_	I-cesDoc	_	I-p
1323	8679	8682	gel	gel	NN	_	_	I-cesDoc	_	I-p
1324	8693	8700	loading	loading	NN	_	_	I-cesDoc	_	I-p
1325	8701	8707	buffer	buffer	NN	_	_	I-cesDoc	_	I-p
1326	8708	8709	(	(	(	_	_	I-cesDoc	_	I-p
1327	8709	8713	62.5	62.5	CD	_	_	I-cesDoc	_	I-p
1328	8714	8716	mM	mm	NN	_	_	I-cesDoc	_	I-p
1329	8717	8725	TRIS-HCl	tris-hcl	NNP	_	_	I-cesDoc	_	I-p
1330	8725	8726	,	,	,	_	_	I-cesDoc	_	I-p
1331	8727	8729	at	at	IN	_	_	I-cesDoc	_	I-p
1332	8730	8732	pH	ph	NN	_	_	I-cesDoc	_	I-p
1333	8733	8736	6.8	6.8	CD	_	_	I-cesDoc	_	I-p
1334	8736	8737	,	,	,	_	_	I-cesDoc	_	I-p
1335	8738	8740	10	10	CD	_	_	I-cesDoc	_	I-p
1336	8740	8741	%	%	NN	_	_	I-cesDoc	_	I-p
1337	8752	8760	glycerol	glycerol	NN	_	_	I-cesDoc	_	I-p
1338	8760	8761	,	,	,	_	_	I-cesDoc	_	I-p
1339	8762	8763	2	2	CD	_	_	I-cesDoc	_	I-p
1340	8763	8764	%	%	NN	_	_	I-cesDoc	_	I-p
1341	8765	8768	SDS	sds	NNP	_	_	I-cesDoc	_	I-p
1342	8768	8769	,	,	,	_	_	I-cesDoc	_	I-p
1343	8770	8771	5	5	CD	_	_	I-cesDoc	_	I-p
1344	8771	8772	%	%	NN	_	_	I-cesDoc	_	I-p
1345	8773	8790	?-mercaptoethanol	?-mercaptoethanol	JJ	_	_	I-cesDoc	_	I-p
1346	8790	8791	,	,	,	_	_	I-cesDoc	_	I-p
1347	8792	8795	and	and	CC	_	_	I-cesDoc	_	I-p
1348	8796	8807	bromophenol	bromophenol	NN	_	_	I-cesDoc	_	I-p
1349	8818	8822	blue	blue	JJ	_	_	I-cesDoc	_	I-p
1350	8822	8823	)	)	)	_	_	I-cesDoc	_	I-p
1351	8823	8824	,	,	,	_	_	I-cesDoc	_	I-p
1352	8825	8828	and	and	CC	_	_	I-cesDoc	_	I-p
1353	8829	8840	centrifuged	centrifuged	JJ	_	_	I-cesDoc	_	I-p
1354	8841	8843	at	at	IN	_	_	I-cesDoc	_	I-p
1355	8844	8850	15,000	15,000	CD	_	_	I-cesDoc	_	I-p
1356	8851	8852	x	x	SYM	_	_	I-cesDoc	_	I-p
1357	8864	8865	g	g	SYM	_	_	I-cesDoc	_	I-p
1358	8866	8869	for	for	IN	_	_	I-cesDoc	_	I-p
1359	8870	8872	10	10	CD	_	_	I-cesDoc	_	I-p
1360	8873	8877	min.	min.	NN	_	_	I-cesDoc	_	I-p
1361	8878	8883	Equal	equal	NNP	_	_	I-cesDoc	_	I-p
1362	8884	8891	amounts	amount	NNS	_	_	I-cesDoc	_	I-p
1363	8892	8894	of	of	IN	_	_	I-cesDoc	_	I-p
1364	8905	8912	protein	protein	NN	_	_	I-cesDoc	_	I-p
1365	8913	8914	(	(	(	_	_	I-cesDoc	_	I-p
1366	8914	8916	70	70	CD	_	_	I-cesDoc	_	I-p
1367	8917	8919	to	to	TO	_	_	I-cesDoc	_	I-p
1368	8920	8923	100	100	CD	_	_	I-cesDoc	_	I-p
1369	8924	8926	?g	?g	NN	_	_	I-cesDoc	_	I-p
1370	8926	8927	)	)	)	_	_	I-cesDoc	_	I-p
1371	8928	8932	were	be	VBD	_	_	I-cesDoc	_	I-p
1372	8933	8942	separated	separate	VBN	_	_	I-cesDoc	_	I-p
1373	8943	8945	by	by	IN	_	_	I-cesDoc	_	I-p
1374	8946	8961	electrophoresis	electrophoresis	NNS	_	_	I-cesDoc	_	I-p
1375	8961	8962	.	.	.	_	_	I-cesDoc	_	I-p
1376	8973	8981	SDS-PAGE	sds-page	NNP	_	_	I-cesDoc	_	I-p
1377	8982	8985	was	be	VBD	_	_	I-cesDoc	_	I-p
1378	8986	8995	performed	perform	VBN	_	_	I-cesDoc	_	I-p
1379	8996	9001	using	use	VBG	_	_	I-cesDoc	_	I-p
1380	9002	9003	a	a	DT	_	_	I-cesDoc	_	I-p
1381	9004	9007	7.5	7.5	CD	_	_	I-cesDoc	_	I-p
1382	9007	9008	%	%	NN	_	_	I-cesDoc	_	I-p
1383	9009	9019	separating	separate	VBG	_	_	I-cesDoc	_	I-p
1384	9020	9023	gel	gel	NN	_	_	I-cesDoc	_	I-p
1385	9024	9028	with	with	IN	_	_	I-cesDoc	_	I-p
1386	9029	9030	a	a	DT	_	_	I-cesDoc	_	I-p
1387	9041	9042	4	4	CD	_	_	I-cesDoc	_	I-p
1388	9042	9043	%	%	NN	_	_	I-cesDoc	_	I-p
1389	9044	9052	stacking	stack	VBG	_	_	I-cesDoc	_	I-p
1390	9053	9056	gel	gel	NN	_	_	I-cesDoc	_	I-p
1391	9056	9057	.	.	.	_	_	I-cesDoc	_	I-p
1392	9058	9061	The	the	DT	_	_	I-cesDoc	_	I-p
1393	9062	9070	resolved	resolve	VBN	_	_	I-cesDoc	_	I-p
1394	9071	9079	proteins	protein	NNS	_	_	I-cesDoc	_	I-p
1395	9080	9084	were	be	VBD	_	_	I-cesDoc	_	I-p
1396	9085	9096	transferred	transfer	VBN	_	_	I-cesDoc	_	I-p
1397	9107	9126	electrophoretically	electrophoretically	RB	_	_	I-cesDoc	_	I-p
1398	9127	9129	to	to	TO	_	_	I-cesDoc	_	I-p
1399	9130	9144	nitrocellulose	nitrocellulose	NN	_	_	I-cesDoc	_	I-p
1400	9145	9154	membranes	membrane	NNS	_	_	I-cesDoc	_	I-p
1401	9165	9166	(	(	(	_	_	I-cesDoc	_	I-p
1402	9166	9173	Hybond-	hybond-	NNP	_	_	I-cesDoc	_	I-p
1403	9173	9176	ECL	ecl	NNP	_	_	I-cesDoc	_	I-p
1404	9176	9177	,	,	,	_	_	I-cesDoc	_	I-p
1405	9178	9186	Amersham	amersham	NNP	_	_	I-cesDoc	_	I-p
1406	9187	9191	Corp	corp	NNP	_	_	I-cesDoc	_	I-p
1407	9191	9192	.	.	.	_	_	I-cesDoc	_	I-p
1408	9192	9193	)	)	)	_	_	I-cesDoc	_	I-p
1409	9193	9194	.	.	.	_	_	I-cesDoc	_	I-p
1410	9195	9200	After	after	IN	_	_	I-cesDoc	_	I-p
1411	9201	9209	transfer	transfer	NN	_	_	I-cesDoc	_	I-p
1412	9209	9210	,	,	,	_	_	I-cesDoc	_	I-p
1413	9211	9214	the	the	DT	_	_	I-cesDoc	_	I-p
1414	9215	9222	filters	filter	NNS	_	_	I-cesDoc	_	I-p
1415	9233	9237	were	be	VBD	_	_	I-cesDoc	_	I-p
1416	9238	9247	incubated	incubated	JJ	_	_	I-cesDoc	_	I-p
1417	9248	9257	overnight	overnight	JJ	_	_	I-cesDoc	_	I-p
1418	9258	9260	at	at	IN	_	_	I-cesDoc	_	I-p
1419	9261	9262	4	4	CD	_	_	I-cesDoc	_	I-p
1420	9262	9263	°	°	NN	_	_	I-cesDoc	_	I-p
1421	9263	9264	C	c	NNP	_	_	I-cesDoc	_	I-p
1422	9265	9267	in	in	IN	_	_	I-cesDoc	_	I-p
1423	9268	9269	a	a	DT	_	_	I-cesDoc	_	I-p
1424	9270	9278	blocking	block	VBG	_	_	I-cesDoc	_	I-p
1425	9279	9287	solution	solution	NN	_	_	I-cesDoc	_	I-p
1426	9298	9299	(	(	(	_	_	I-cesDoc	_	I-p
1427	9299	9301	20	20	CD	_	_	I-cesDoc	_	I-p
1428	9302	9304	mM	mm	NN	_	_	I-cesDoc	_	I-p
1429	9305	9309	TRIS	tris	NNP	_	_	I-cesDoc	_	I-p
1430	9310	9314	base	base	NN	_	_	I-cesDoc	_	I-p
1431	9314	9315	,	,	,	_	_	I-cesDoc	_	I-p
1432	9316	9319	137	137	CD	_	_	I-cesDoc	_	I-p
1433	9320	9322	mM	mm	NN	_	_	I-cesDoc	_	I-p
1434	9323	9329	sodium	sodium	NN	_	_	I-cesDoc	_	I-p
1435	9330	9338	chloride	chloride	NN	_	_	I-cesDoc	_	I-p
1436	9339	9341	at	at	IN	_	_	I-cesDoc	_	I-p
1437	9342	9344	pH	ph	NN	_	_	I-cesDoc	_	I-p
1438	9345	9348	7.6	7.6	CD	_	_	I-cesDoc	_	I-p
1439	9348	9349	,	,	,	_	_	I-cesDoc	_	I-p
1440	9350	9351	5	5	CD	_	_	I-cesDoc	_	I-p
1441	9351	9352	%	%	NN	_	_	I-cesDoc	_	I-p
1442	9363	9371	powdered	powdered	JJ	_	_	I-cesDoc	_	I-p
1443	9372	9376	milk	milk	NN	_	_	I-cesDoc	_	I-p
1444	9376	9377	,	,	,	_	_	I-cesDoc	_	I-p
1445	9378	9379	3	3	CD	_	_	I-cesDoc	_	I-p
1446	9379	9380	%	%	NN	_	_	I-cesDoc	_	I-p
1447	9381	9384	BSA	bsa	NNP	_	_	I-cesDoc	_	I-p
1448	9384	9385	)	)	)	_	_	I-cesDoc	_	I-p
1449	9385	9386	,	,	,	_	_	I-cesDoc	_	I-p
1450	9387	9390	and	and	CC	_	_	I-cesDoc	_	I-p
1451	9391	9400	incubated	incubated	JJ	_	_	I-cesDoc	_	I-p
1452	9401	9405	with	with	IN	_	_	I-cesDoc	_	I-p
1453	9406	9413	primary	primary	JJ	_	_	I-cesDoc	_	I-p
1454	9424	9434	polyclonal	polyclonal	NN	_	_	I-cesDoc	_	I-p
1455	9435	9441	rabbit	rabbit	NN	_	_	I-cesDoc	_	I-p
1456	9442	9452	antibodies	antibody	NNS	_	_	I-cesDoc	_	I-p
1457	9453	9460	against	against	IN	_	_	I-cesDoc	_	I-p
1458	9461	9466	COX-2	cox-2	NNP	_	_	I-cesDoc	_	I-p
1459	9467	9469	at	at	IN	_	_	I-cesDoc	_	I-p
1460	9470	9471	a	a	DT	_	_	I-cesDoc	_	I-p
1461	9472	9480	dilution	dilution	NN	_	_	I-cesDoc	_	I-p
1462	9491	9492	1	1	CD	_	_	I-cesDoc	_	I-p
1463	9492	9493	:	:	:	_	_	I-cesDoc	_	I-p
1464	9493	9497	1000	1000	CD	_	_	I-cesDoc	_	I-p
1465	9498	9499	(	(	(	_	_	I-cesDoc	_	I-p
1466	9499	9505	Cayman	cayman	NNP	_	_	I-cesDoc	_	I-p
1467	9506	9514	Chemical	chemical	NNP	_	_	I-cesDoc	_	I-p
1468	9514	9515	,	,	,	_	_	I-cesDoc	_	I-p
1469	9516	9519	Ann	ann	NNP	_	_	I-cesDoc	_	I-p
1470	9520	9525	Arbor	arbor	NNP	_	_	I-cesDoc	_	I-p
1471	9525	9526	,	,	,	_	_	I-cesDoc	_	I-p
1472	9527	9529	MI	mi	NNP	_	_	I-cesDoc	_	I-p
1473	9529	9530	)	)	)	_	_	I-cesDoc	_	I-p
1474	9530	9531	,	,	,	_	_	I-cesDoc	_	I-p
1475	9532	9535	for	for	IN	_	_	I-cesDoc	_	I-p
1476	9536	9537	1	1	CD	_	_	I-cesDoc	_	I-p
1477	9538	9542	hour	hour	NN	_	_	I-cesDoc	_	I-p
1478	9543	9545	at	at	IN	_	_	I-cesDoc	_	I-p
1479	9556	9560	room	room	NN	_	_	I-cesDoc	_	I-p
1480	9561	9572	temperature	temperature	NN	_	_	I-cesDoc	_	I-p
1481	9572	9573	.	.	.	_	_	I-cesDoc	_	I-p
1482	9574	9577	The	the	DT	_	_	I-cesDoc	_	I-p
1483	9578	9585	filters	filter	NNS	_	_	I-cesDoc	_	I-p
1484	9586	9590	were	be	VBD	_	_	I-cesDoc	_	I-p
1485	9591	9597	washed	wash	VBN	_	_	I-cesDoc	_	I-p
1486	9598	9599	(	(	(	_	_	I-cesDoc	_	I-p
1487	9599	9602	TBS	tbs	NNP	_	_	I-cesDoc	_	I-p
1488	9602	9603	-	-	-	_	_	I-cesDoc	_	I-p
1489	9603	9606	0.1	0.1	CD	_	_	I-cesDoc	_	I-p
1490	9606	9607	%	%	NN	_	_	I-cesDoc	_	I-p
1491	9608	9613	Tween	tween	NNP	_	_	I-cesDoc	_	I-p
1492	9624	9626	20	20	CD	_	_	I-cesDoc	_	I-p
1493	9627	9629	at	at	IN	_	_	I-cesDoc	_	I-p
1494	9630	9632	pH	ph	NN	_	_	I-cesDoc	_	I-p
1495	9633	9636	7.6	7.6	CD	_	_	I-cesDoc	_	I-p
1496	9636	9637	)	)	)	_	_	I-cesDoc	_	I-p
1497	9638	9641	and	and	CC	_	_	I-cesDoc	_	I-p
1498	9642	9651	incubated	incubated	JJ	_	_	I-cesDoc	_	I-p
1499	9652	9656	with	with	IN	_	_	I-cesDoc	_	I-p
1500	9657	9668	horseradish	horseradish	NN	_	_	I-cesDoc	_	I-p
1501	9669	9679	peroxidase	peroxidase	NN	_	_	I-cesDoc	_	I-p
1502	9690	9696	linked	link	VBD	_	_	I-cesDoc	_	I-p
1503	9697	9706	secondary	secondary	JJ	_	_	I-cesDoc	_	I-p
1504	9707	9717	antibodies	antibody	NNS	_	_	I-cesDoc	_	I-p
1505	9718	9720	at	at	IN	_	_	I-cesDoc	_	I-p
1506	9721	9722	a	a	DT	_	_	I-cesDoc	_	I-p
1507	9723	9731	dilution	dilution	NN	_	_	I-cesDoc	_	I-p
1508	9732	9733	1	1	CD	_	_	I-cesDoc	_	I-p
1509	9733	9734	:	:	:	_	_	I-cesDoc	_	I-p
1510	9734	9738	4000	4000	CD	_	_	I-cesDoc	_	I-p
1511	9749	9750	(	(	(	_	_	I-cesDoc	_	I-p
1512	9750	9758	Amersham	amersham	NNP	_	_	I-cesDoc	_	I-p
1513	9758	9759	)	)	)	_	_	I-cesDoc	_	I-p
1514	9759	9760	.	.	.	_	_	I-cesDoc	_	I-p
1515	9761	9766	After	after	IN	_	_	I-cesDoc	_	I-p
1516	9767	9774	washing	wash	VBG	_	_	I-cesDoc	_	I-p
1517	9774	9775	,	,	,	_	_	I-cesDoc	_	I-p
1518	9776	9779	the	the	DT	_	_	I-cesDoc	_	I-p
1519	9780	9789	membranes	membrane	NNS	_	_	I-cesDoc	_	I-p
1520	9790	9794	were	be	VBD	_	_	I-cesDoc	_	I-p
1521	9795	9804	incubated	incubated	JJ	_	_	I-cesDoc	_	I-p
1522	9815	9819	with	with	IN	_	_	I-cesDoc	_	I-p
1523	9820	9827	luminol	luminol	NN	_	_	I-cesDoc	_	I-p
1524	9828	9833	based	base	VBD	_	_	I-cesDoc	_	I-p
1525	9834	9851	chemiluminescence	chemiluminescence	NN	_	_	I-cesDoc	_	I-p
1526	9852	9859	reagent	reagent	NN	_	_	I-cesDoc	_	I-p
1527	9860	9861	(	(	(	_	_	I-cesDoc	_	I-p
1528	9861	9867	DuPont	dupont	NNP	_	_	I-cesDoc	_	I-p
1529	9868	9871	NEN	nen	NNP	_	_	I-cesDoc	_	I-p
1530	9882	9890	Research	research	NNP	_	_	I-cesDoc	_	I-p
1531	9891	9899	Products	products	NNPS	_	_	I-cesDoc	_	I-p
1532	9899	9900	,	,	,	_	_	I-cesDoc	_	I-p
1533	9901	9907	Boston	boston	NNP	_	_	I-cesDoc	_	I-p
1534	9907	9908	,	,	,	_	_	I-cesDoc	_	I-p
1535	9909	9911	MA	ma	NNP	_	_	I-cesDoc	_	I-p
1536	9911	9912	)	)	)	_	_	I-cesDoc	_	I-p
1537	9912	9913	.	.	.	_	_	I-cesDoc	_	I-p
1538	9942	9950	Northern	northern	JJ	_	_	I-cesDoc	B-head	_
1539	9951	9959	analysis	analysis	NN	_	_	I-cesDoc	I-head	_
1540	9970	9974	Cell	cell	NNP	_	_	I-cesDoc	_	B-p
1541	9975	9982	pellets	pellet	NNS	_	_	I-cesDoc	_	I-p
1542	9983	9987	were	be	VBD	_	_	I-cesDoc	_	I-p
1543	9988	9993	lyzed	lyzed	JJ	_	_	I-cesDoc	_	I-p
1544	9994	9997	and	and	CC	_	_	I-cesDoc	_	I-p
1545	9998	10001	RNA	rna	NNP	_	_	I-cesDoc	_	I-p
1546	10002	10011	extracted	extract	VBD	_	_	I-cesDoc	_	I-p
1547	10012	10017	using	use	VBG	_	_	I-cesDoc	_	I-p
1548	10018	10021	the	the	DT	_	_	I-cesDoc	_	I-p
1549	10032	10038	RNeasy	rneasy	NNP	_	_	I-cesDoc	_	I-p
1550	10039	10045	method	method	NN	_	_	I-cesDoc	_	I-p
1551	10046	10047	®	®	NN	_	_	I-cesDoc	_	I-p
1552	10047	10048	(	(	(	_	_	I-cesDoc	_	I-p
1553	10048	10054	Qiagen	qiagen	NNP	_	_	I-cesDoc	_	I-p
1554	10054	10055	)	)	)	_	_	I-cesDoc	_	I-p
1555	10055	10056	,	,	,	_	_	I-cesDoc	_	I-p
1556	10057	10066	following	follow	VBG	_	_	I-cesDoc	_	I-p
1557	10067	10070	the	the	DT	_	_	I-cesDoc	_	I-p
1558	10071	10083	manufacturer	manufacturer	NN	_	_	I-cesDoc	_	I-p
1559	10083	10085	's	's	POS	_	_	I-cesDoc	_	I-p
1560	10096	10108	instructions	instruction	NNS	_	_	I-cesDoc	_	I-p
1561	10108	10109	.	.	.	_	_	I-cesDoc	_	I-p
1562	10110	10113	RNA	rna	NNP	_	_	I-cesDoc	_	I-p
1563	10114	10117	was	be	VBD	_	_	I-cesDoc	_	I-p
1564	10118	10128	quantified	quantify	VBN	_	_	I-cesDoc	_	I-p
1565	10129	10131	by	by	IN	_	_	I-cesDoc	_	I-p
1566	10132	10143	determining	determine	VBG	_	_	I-cesDoc	_	I-p
1567	10144	10149	light	light	JJ	_	_	I-cesDoc	_	I-p
1568	10160	10170	absorbance	absorbance	NN	_	_	I-cesDoc	_	I-p
1569	10171	10173	at	at	IN	_	_	I-cesDoc	_	I-p
1570	10174	10177	260	260	CD	_	_	I-cesDoc	_	I-p
1571	10178	10180	nm	nm	NN	_	_	I-cesDoc	_	I-p
1572	10181	10184	and	and	CC	_	_	I-cesDoc	_	I-p
1573	10185	10189	then	then	RB	_	_	I-cesDoc	_	I-p
1574	10190	10200	fractioned	fractioned	JJ	_	_	I-cesDoc	_	I-p
1575	10201	10203	by	by	IN	_	_	I-cesDoc	_	I-p
1576	10214	10229	electrophoresis	electrophoresis	NNS	_	_	I-cesDoc	_	I-p
1577	10230	10231	(	(	(	_	_	I-cesDoc	_	I-p
1578	10231	10233	10	10	CD	_	_	I-cesDoc	_	I-p
1579	10234	10236	?g	?g	NN	_	_	I-cesDoc	_	I-p
1580	10237	10240	per	per	IN	_	_	I-cesDoc	_	I-p
1581	10241	10245	lane	lane	NN	_	_	I-cesDoc	_	I-p
1582	10245	10246	)	)	)	_	_	I-cesDoc	_	I-p
1583	10247	10249	on	on	IN	_	_	I-cesDoc	_	I-p
1584	10250	10251	a	a	DT	_	_	I-cesDoc	_	I-p
1585	10252	10253	1	1	CD	_	_	I-cesDoc	_	I-p
1586	10253	10254	%	%	NN	_	_	I-cesDoc	_	I-p
1587	10255	10262	agarose	agarose	NN	_	_	I-cesDoc	_	I-p
1588	10273	10277	MOPS	mops	NNP	_	_	I-cesDoc	_	I-p
1589	10277	10278	/	/	NN	_	_	I-cesDoc	_	I-p
1590	10278	10290	formaldehyde	formaldehyde	NN	_	_	I-cesDoc	_	I-p
1591	10291	10294	gel	gel	NN	_	_	I-cesDoc	_	I-p
1592	10294	10295	.	.	.	_	_	I-cesDoc	_	I-p
1593	10296	10299	The	the	DT	_	_	I-cesDoc	_	I-p
1594	10300	10303	RNA	rna	NNP	_	_	I-cesDoc	_	I-p
1595	10304	10307	was	be	VBD	_	_	I-cesDoc	_	I-p
1596	10308	10317	denatured	denatured	JJ	_	_	I-cesDoc	_	I-p
1597	10318	10323	prior	prior	RB	_	_	I-cesDoc	_	I-p
1598	10324	10326	to	to	TO	_	_	I-cesDoc	_	I-p
1599	10337	10344	loading	loading	NN	_	_	I-cesDoc	_	I-p
1600	10345	10347	by	by	IN	_	_	I-cesDoc	_	I-p
1601	10348	10358	incubating	incubate	VBG	_	_	I-cesDoc	_	I-p
1602	10359	10362	the	the	DT	_	_	I-cesDoc	_	I-p
1603	10363	10366	RNA	rna	NNP	_	_	I-cesDoc	_	I-p
1604	10367	10369	at	at	IN	_	_	I-cesDoc	_	I-p
1605	10370	10372	65	65	CD	_	_	I-cesDoc	_	I-p
1606	10372	10373	°	°	NN	_	_	I-cesDoc	_	I-p
1607	10373	10374	C	c	NNP	_	_	I-cesDoc	_	I-p
1608	10375	10378	for	for	IN	_	_	I-cesDoc	_	I-p
1609	10379	10381	10	10	CD	_	_	I-cesDoc	_	I-p
1610	10382	10385	min	min	NN	_	_	I-cesDoc	_	I-p
1611	10386	10388	in	in	IN	_	_	I-cesDoc	_	I-p
1612	10389	10390	a	a	DT	_	_	I-cesDoc	_	I-p
1613	10401	10408	loading	loading	NN	_	_	I-cesDoc	_	I-p
1614	10409	10415	buffer	buffer	NN	_	_	I-cesDoc	_	I-p
1615	10416	10426	comprising	comprise	VBG	_	_	I-cesDoc	_	I-p
1616	10427	10428	1	1	CD	_	_	I-cesDoc	_	I-p
1617	10428	10429	X	x	NNP	_	_	I-cesDoc	_	I-p
1618	10430	10434	MOPS	mops	NNP	_	_	I-cesDoc	_	I-p
1619	10434	10435	,	,	,	_	_	I-cesDoc	_	I-p
1620	10436	10438	50	50	CD	_	_	I-cesDoc	_	I-p
1621	10438	10439	%	%	NN	_	_	I-cesDoc	_	I-p
1622	10440	10449	formamide	formamide	NN	_	_	I-cesDoc	_	I-p
1623	10449	10450	,	,	,	_	_	I-cesDoc	_	I-p
1624	10451	10454	6.5	6.5	CD	_	_	I-cesDoc	_	I-p
1625	10454	10455	%	%	NN	_	_	I-cesDoc	_	I-p
1626	10466	10478	formaldehyde	formaldehyde	NN	_	_	I-cesDoc	_	I-p
1627	10478	10479	,	,	,	_	_	I-cesDoc	_	I-p
1628	10480	10481	5	5	CD	_	_	I-cesDoc	_	I-p
1629	10481	10482	%	%	NN	_	_	I-cesDoc	_	I-p
1630	10483	10491	glycerol	glycerol	NN	_	_	I-cesDoc	_	I-p
1631	10491	10492	,	,	,	_	_	I-cesDoc	_	I-p
1632	10493	10496	0.1	0.1	CD	_	_	I-cesDoc	_	I-p
1633	10497	10499	mM	mm	NN	_	_	I-cesDoc	_	I-p
1634	10500	10504	EDTA	edta	NNP	_	_	I-cesDoc	_	I-p
1635	10504	10505	,	,	,	_	_	I-cesDoc	_	I-p
1636	10506	10511	0.025	0.025	CD	_	_	I-cesDoc	_	I-p
1637	10511	10512	%	%	NN	_	_	I-cesDoc	_	I-p
1638	10523	10534	bromophenol	bromophenol	NN	_	_	I-cesDoc	_	I-p
1639	10535	10539	blue	blue	JJ	_	_	I-cesDoc	_	I-p
1640	10539	10540	,	,	,	_	_	I-cesDoc	_	I-p
1641	10541	10546	0.025	0.025	CD	_	_	I-cesDoc	_	I-p
1642	10546	10547	%	%	NN	_	_	I-cesDoc	_	I-p
1643	10548	10554	xylene	xylene	NN	_	_	I-cesDoc	_	I-p
1644	10555	10561	cyanol	cyanol	NN	_	_	I-cesDoc	_	I-p
1645	10561	10562	.	.	.	_	_	I-cesDoc	_	I-p
1646	10563	10566	The	the	DT	_	_	I-cesDoc	_	I-p
1647	10567	10570	RNA	rna	NNP	_	_	I-cesDoc	_	I-p
1648	10571	10574	was	be	VBD	_	_	I-cesDoc	_	I-p
1649	10585	10596	transferred	transfer	VBN	_	_	I-cesDoc	_	I-p
1650	10597	10599	by	by	IN	_	_	I-cesDoc	_	I-p
1651	10600	10607	gravity	gravity	NN	_	_	I-cesDoc	_	I-p
1652	10607	10608	-	-	-	_	_	I-cesDoc	_	I-p
1653	10608	10616	assisted	assist	VBN	_	_	I-cesDoc	_	I-p
1654	10617	10626	capillary	capillary	JJ	_	_	I-cesDoc	_	I-p
1655	10627	10633	method	method	NN	_	_	I-cesDoc	_	I-p
1656	10634	10638	with	with	IN	_	_	I-cesDoc	_	I-p
1657	10639	10640	6	6	CD	_	_	I-cesDoc	_	I-p
1658	10640	10641	X	x	NNP	_	_	I-cesDoc	_	I-p
1659	10652	10655	SSC	ssc	NNP	_	_	I-cesDoc	_	I-p
1660	10656	10658	to	to	TO	_	_	I-cesDoc	_	I-p
1661	10659	10664	nylon	nylon	NN	_	_	I-cesDoc	_	I-p
1662	10665	10678	hybridization	hybridization	NN	_	_	I-cesDoc	_	I-p
1663	10679	10687	membrane	membrane	NN	_	_	I-cesDoc	_	I-p
1664	10687	10688	,	,	,	_	_	I-cesDoc	_	I-p
1665	10689	10692	and	and	CC	_	_	I-cesDoc	_	I-p
1666	10693	10697	then	then	RB	_	_	I-cesDoc	_	I-p
1667	10698	10703	fixed	fix	VBN	_	_	I-cesDoc	_	I-p
1668	10704	10706	to	to	TO	_	_	I-cesDoc	_	I-p
1669	10717	10720	the	the	DT	_	_	I-cesDoc	_	I-p
1670	10721	10729	membrane	membrane	NN	_	_	I-cesDoc	_	I-p
1671	10730	10732	by	by	IN	_	_	I-cesDoc	_	I-p
1672	10733	10735	UV	uv	NNP	_	_	I-cesDoc	_	I-p
1673	10736	10748	crosslinking	crosslink	VBG	_	_	I-cesDoc	_	I-p
1674	10749	10750	(	(	(	_	_	I-cesDoc	_	I-p
1675	10750	10762	Stratalinker	stratalinker	NNP	_	_	I-cesDoc	_	I-p
1676	10763	10767	1200	1200	CD	_	_	I-cesDoc	_	I-p
1677	10768	10770	?j	?j	NN	_	_	I-cesDoc	_	I-p
1678	10770	10771	/	/	NN	_	_	I-cesDoc	_	I-p
1679	10771	10773	cm	cm	NN	_	_	I-cesDoc	_	I-p
1680	10784	10785	2	2	CD	_	_	I-cesDoc	_	I-p
1681	10785	10786	)	)	)	_	_	I-cesDoc	_	I-p
1682	10786	10787	.	.	.	_	_	I-cesDoc	_	I-p
1683	10788	10804	Prehybridization	prehybridization	NNP	_	_	I-cesDoc	_	I-p
1684	10805	10808	and	and	CC	_	_	I-cesDoc	_	I-p
1685	10809	10822	hybridization	hybridization	NN	_	_	I-cesDoc	_	I-p
1686	10823	10827	were	be	VBD	_	_	I-cesDoc	_	I-p
1687	10828	10837	performed	perform	VBN	_	_	I-cesDoc	_	I-p
1688	10838	10840	at	at	IN	_	_	I-cesDoc	_	I-p
1689	10851	10853	42	42	CD	_	_	I-cesDoc	_	I-p
1690	10853	10854	°	°	NN	_	_	I-cesDoc	_	I-p
1691	10854	10855	C	c	NNP	_	_	I-cesDoc	_	I-p
1692	10856	10859	and	and	CC	_	_	I-cesDoc	_	I-p
1693	10860	10865	using	use	VBG	_	_	I-cesDoc	_	I-p
1694	10866	10871	Quick	quick	NNP	_	_	I-cesDoc	_	I-p
1695	10872	10875	Hyb	hyb	NNP	_	_	I-cesDoc	_	I-p
1696	10876	10877	®	®	NN	_	_	I-cesDoc	_	I-p
1697	10877	10878	(	(	(	_	_	I-cesDoc	_	I-p
1698	10878	10888	Stratagene	stratagene	NNP	_	_	I-cesDoc	_	I-p
1699	10888	10889	)	)	)	_	_	I-cesDoc	_	I-p
1700	10890	10892	as	as	IN	_	_	I-cesDoc	_	I-p
1701	10893	10906	hybridization	hybridization	NN	_	_	I-cesDoc	_	I-p
1702	10917	10925	solution	solution	NN	_	_	I-cesDoc	_	I-p
1703	10925	10926	.	.	.	_	_	I-cesDoc	_	I-p
1704	10927	10930	The	the	DT	_	_	I-cesDoc	_	I-p
1705	10931	10936	COX-2	cox-2	NNP	_	_	I-cesDoc	_	I-p
1706	10937	10942	probe	probe	NN	_	_	I-cesDoc	_	I-p
1707	10943	10946	was	be	VBD	_	_	I-cesDoc	_	I-p
1708	10947	10953	random	random	JJ	_	_	I-cesDoc	_	I-p
1709	10954	10960	primed	prime	VBN	_	_	I-cesDoc	_	I-p
1710	10961	10970	following	follow	VBG	_	_	I-cesDoc	_	I-p
1711	10971	10974	the	the	DT	_	_	I-cesDoc	_	I-p
1712	10985	10995	directions	direction	NNS	_	_	I-cesDoc	_	I-p
1713	10996	10998	of	of	IN	_	_	I-cesDoc	_	I-p
1714	10999	11002	the	the	DT	_	_	I-cesDoc	_	I-p
1715	11003	11015	manufacturer	manufacturer	NN	_	_	I-cesDoc	_	I-p
1716	11016	11017	(	(	(	_	_	I-cesDoc	_	I-p
1717	11017	11026	Megaprime	megaprime	NNP	_	_	I-cesDoc	_	I-p
1718	11027	11028	®	®	NN	_	_	I-cesDoc	_	I-p
1719	11028	11029	,	,	,	_	_	I-cesDoc	_	I-p
1720	11040	11048	Amersham	amersham	NNP	_	_	I-cesDoc	_	I-p
1721	11048	11049	/	/	NN	_	_	I-cesDoc	_	I-p
1722	11049	11058	Pharmacia	pharmacia	NNP	_	_	I-cesDoc	_	I-p
1723	11058	11059	)	)	)	_	_	I-cesDoc	_	I-p
1724	11059	11060	.	.	.	_	_	I-cesDoc	_	I-p
1725	11061	11064	The	the	DT	_	_	I-cesDoc	_	I-p
1726	11065	11073	membrane	membrane	NN	_	_	I-cesDoc	_	I-p
1727	11074	11077	was	be	VBD	_	_	I-cesDoc	_	I-p
1728	11078	11082	then	then	RB	_	_	I-cesDoc	_	I-p
1729	11083	11089	washed	wash	VBN	_	_	I-cesDoc	_	I-p
1730	11090	11092	at	at	IN	_	_	I-cesDoc	_	I-p
1731	11093	11094	a	a	DT	_	_	I-cesDoc	_	I-p
1732	11105	11110	final	final	JJ	_	_	I-cesDoc	_	I-p
1733	11111	11121	stringency	stringency	NN	_	_	I-cesDoc	_	I-p
1734	11122	11124	of	of	IN	_	_	I-cesDoc	_	I-p
1735	11125	11128	0.2	0.2	CD	_	_	I-cesDoc	_	I-p
1736	11128	11129	X	x	NNP	_	_	I-cesDoc	_	I-p
1737	11130	11133	SSC	ssc	NNP	_	_	I-cesDoc	_	I-p
1738	11133	11134	,	,	,	_	_	I-cesDoc	_	I-p
1739	11135	11138	0.1	0.1	CD	_	_	I-cesDoc	_	I-p
1740	11138	11139	%	%	NN	_	_	I-cesDoc	_	I-p
1741	11140	11143	SDS	sds	NNP	_	_	I-cesDoc	_	I-p
1742	11143	11144	,	,	,	_	_	I-cesDoc	_	I-p
1743	11145	11147	at	at	IN	_	_	I-cesDoc	_	I-p
1744	11148	11150	60	60	CD	_	_	I-cesDoc	_	I-p
1745	11150	11151	°	°	NN	_	_	I-cesDoc	_	I-p
1746	11151	11152	C	c	NNP	_	_	I-cesDoc	_	I-p
1747	11153	11156	for	for	IN	_	_	I-cesDoc	_	I-p
1748	11157	11159	30	30	CD	_	_	I-cesDoc	_	I-p
1749	11170	11174	min.	min.	NN	_	_	I-cesDoc	_	I-p
1750	11175	11178	The	the	DT	_	_	I-cesDoc	_	I-p
1751	11179	11187	membrane	membrane	NN	_	_	I-cesDoc	_	I-p
1752	11188	11191	was	be	VBD	_	_	I-cesDoc	_	I-p
1753	11192	11199	wrapped	wrap	VBN	_	_	I-cesDoc	_	I-p
1754	11200	11202	in	in	IN	_	_	I-cesDoc	_	I-p
1755	11203	11210	plastic	plastic	NN	_	_	I-cesDoc	_	I-p
1756	11211	11215	wrap	wrap	NN	_	_	I-cesDoc	_	I-p
1757	11216	11219	and	and	CC	_	_	I-cesDoc	_	I-p
1758	11220	11227	exposed	expose	VBN	_	_	I-cesDoc	_	I-p
1759	11238	11240	to	to	TO	_	_	I-cesDoc	_	I-p
1760	11241	11246	Kodak	kodak	NNP	_	_	I-cesDoc	_	I-p
1761	11247	11249	XR	xr	NNP	_	_	I-cesDoc	_	I-p
1762	11250	11254	film	film	NN	_	_	I-cesDoc	_	I-p
1763	11255	11257	at	at	IN	_	_	I-cesDoc	_	I-p
1764	11258	11259	-	-	:	_	_	I-cesDoc	_	I-p
1765	11259	11261	70	70	CD	_	_	I-cesDoc	_	I-p
1766	11261	11262	°	°	NN	_	_	I-cesDoc	_	I-p
1767	11262	11263	C	c	NNP	_	_	I-cesDoc	_	I-p
1768	11264	11268	with	with	IN	_	_	I-cesDoc	_	I-p
1769	11269	11280	intensifier	intensifier	NN	_	_	I-cesDoc	_	I-p
1770	11281	11287	screen	screen	NN	_	_	I-cesDoc	_	I-p
1771	11298	11307	overnight	overnight	JJ	_	_	I-cesDoc	_	I-p
1772	11307	11308	.	.	.	_	_	I-cesDoc	_	I-p
1773	11337	11348	Statistical	statistical	NNP	_	_	I-cesDoc	B-head	_
1774	11349	11356	methods	method	NNS	_	_	I-cesDoc	I-head	_
1775	11367	11370	All	all	DT	_	_	I-cesDoc	_	B-p
1776	11371	11378	results	result	NNS	_	_	I-cesDoc	_	I-p
1777	11379	11382	are	be	VBP	_	_	I-cesDoc	_	I-p
1778	11383	11392	presented	present	VBN	_	_	I-cesDoc	_	I-p
1779	11393	11395	as	as	IN	_	_	I-cesDoc	_	I-p
1780	11396	11403	medians	median	NNS	_	_	I-cesDoc	_	I-p
1781	11404	11408	with	with	IN	_	_	I-cesDoc	_	I-p
1782	11409	11414	their	their	PRP$	_	_	I-cesDoc	_	I-p
1783	11415	11420	range	range	NN	_	_	I-cesDoc	_	I-p
1784	11420	11421	.	.	.	_	_	I-cesDoc	_	I-p
1785	11432	11443	Comparisons	comparisons	NNP	_	_	I-cesDoc	_	I-p
1786	11444	11451	between	between	IN	_	_	I-cesDoc	_	I-p
1787	11452	11458	HF-IPF	hf-ipf	NNP	_	_	I-cesDoc	_	I-p
1788	11459	11462	and	and	CC	_	_	I-cesDoc	_	I-p
1789	11463	11468	HF-NL	hf-nl	NNP	_	_	I-cesDoc	_	I-p
1790	11469	11473	were	be	VBD	_	_	I-cesDoc	_	I-p
1791	11474	11478	done	do	VBN	_	_	I-cesDoc	_	I-p
1792	11479	11484	using	use	VBG	_	_	I-cesDoc	_	I-p
1793	11485	11488	the	the	DT	_	_	I-cesDoc	_	I-p
1794	11499	11503	Mann	mann	NNP	_	_	I-cesDoc	_	I-p
1795	11503	11504	-	-	-	_	_	I-cesDoc	_	I-p
1796	11504	11511	Whitney	whitney	NNP	_	_	I-cesDoc	_	I-p
1797	11512	11516	test	test	NN	_	_	I-cesDoc	_	I-p
1798	11516	11517	.	.	.	_	_	I-cesDoc	_	I-p
1799	11518	11519	A	a	DT	_	_	I-cesDoc	_	I-p
1800	11531	11532	P	p	NN	_	_	I-cesDoc	_	I-p
1801	11533	11538	value	value	NN	_	_	I-cesDoc	_	I-p
1802	11539	11541	of	of	IN	_	_	I-cesDoc	_	I-p
1803	11542	11543	<	<	NN	_	_	I-cesDoc	_	I-p
1804	11543	11547	0.05	0.05	CD	_	_	I-cesDoc	_	I-p
1805	11548	11551	was	be	VBD	_	_	I-cesDoc	_	I-p
1806	11552	11562	considered	consider	VBN	_	_	I-cesDoc	_	I-p
1807	11573	11584	significant	significant	JJ	_	_	I-cesDoc	_	I-p
1808	11584	11585	.	.	.	_	_	I-cesDoc	_	I-p
1809	11617	11624	Results	result	NNS	_	_	I-cesDoc	B-head	_
1810	11644	11652	Baseline	baseline	NNP	_	_	I-cesDoc	B-head	_
1811	11653	11656	and	and	CC	_	_	I-cesDoc	I-head	_
1812	11657	11667	stimulated	stimulate	VBN	_	_	I-cesDoc	I-head	_
1813	11668	11673	COX-2	cox-2	NNP	_	_	I-cesDoc	I-head	_
1814	11674	11682	activity	activity	NN	_	_	I-cesDoc	I-head	_
1815	11683	11685	in	in	IN	_	_	I-cesDoc	I-head	_
1816	11686	11692	HF-IPF	hf-ipf	NNP	_	_	I-cesDoc	I-head	_
1817	11703	11706	and	and	CC	_	_	I-cesDoc	I-head	_
1818	11707	11712	HF-NL	hf-nl	NNP	_	_	I-cesDoc	I-head	_
1819	11723	11735	Unstimulated	unstimulated	NNP	_	_	I-cesDoc	_	B-p
1820	11736	11746	eicosanoid	eicosanoid	NN	_	_	I-cesDoc	_	I-p
1821	11747	11757	production	production	NN	_	_	I-cesDoc	_	I-p
1822	11758	11761	was	be	VBD	_	_	I-cesDoc	_	I-p
1823	11762	11769	similar	similar	JJ	_	_	I-cesDoc	_	I-p
1824	11770	11772	in	in	IN	_	_	I-cesDoc	_	I-p
1825	11773	11777	both	both	DT	_	_	I-cesDoc	_	I-p
1826	11788	11794	HF-IPF	hf-ipf	NNP	_	_	I-cesDoc	_	I-p
1827	11795	11798	and	and	CC	_	_	I-cesDoc	_	I-p
1828	11799	11804	HF-NL	hf-nl	NNP	_	_	I-cesDoc	_	I-p
1829	11805	11806	(	(	(	_	_	I-cesDoc	_	I-p
1830	11806	11810	Fig.	Fig.	NN	_	_	I-cesDoc	_	I-p
1831	11811	11812	1	1	CD	_	_	I-cesDoc	_	I-p
1832	11812	11813	,	,	,	_	_	I-cesDoc	_	I-p
1833	11814	11817	a-d	a-d	JJ	_	_	I-cesDoc	_	I-p
1834	11817	11818	)	)	)	_	_	I-cesDoc	_	I-p
1835	11818	11819	.	.	.	_	_	I-cesDoc	_	I-p
1836	11820	11824	When	when	WRB	_	_	I-cesDoc	_	I-p
1837	11825	11836	fibroblasts	fibroblast	NNS	_	_	I-cesDoc	_	I-p
1838	11837	11841	were	be	VBD	_	_	I-cesDoc	_	I-p
1839	11852	11862	stimulated	stimulate	VBN	_	_	I-cesDoc	_	I-p
1840	11863	11867	with	with	IN	_	_	I-cesDoc	_	I-p
1841	11868	11873	IL-1?	il-1?	NNP	_	_	I-cesDoc	_	I-p
1842	11874	11879	there	there	EX	_	_	I-cesDoc	_	I-p
1843	11880	11883	was	be	VBD	_	_	I-cesDoc	_	I-p
1844	11884	11885	a	a	DT	_	_	I-cesDoc	_	I-p
1845	11886	11897	significant	significant	JJ	_	_	I-cesDoc	_	I-p
1846	11898	11901	and	and	CC	_	_	I-cesDoc	_	I-p
1847	11902	11909	similar	similar	JJ	_	_	I-cesDoc	_	I-p
1848	11920	11932	upregulation	upregulation	NN	_	_	I-cesDoc	_	I-p
1849	11933	11935	of	of	IN	_	_	I-cesDoc	_	I-p
1850	11936	11939	PGE	pge	NNP	_	_	I-cesDoc	_	I-p
1851	11951	11952	2	2	CD	_	_	I-cesDoc	_	I-p
1852	11953	11963	production	production	NN	_	_	I-cesDoc	_	I-p
1853	11964	11966	in	in	IN	_	_	I-cesDoc	_	I-p
1854	11967	11971	both	both	DT	_	_	I-cesDoc	_	I-p
1855	11972	11978	HF-IPF	hf-ipf	NNP	_	_	I-cesDoc	_	I-p
1856	11979	11982	and	and	CC	_	_	I-cesDoc	_	I-p
1857	11983	11988	HF-NL	hf-nl	NNP	_	_	I-cesDoc	_	I-p
1858	11999	12000	(	(	(	_	_	I-cesDoc	_	I-p
1859	12000	12005	28.35	28.35	CD	_	_	I-cesDoc	_	I-p
1860	12006	12007	[	[	NN	_	_	I-cesDoc	_	I-p
1861	12007	12012	range	range	NN	_	_	I-cesDoc	_	I-p
1862	12012	12013	:	:	:	_	_	I-cesDoc	_	I-p
1863	12014	12018	9.09	9.09	CD	_	_	I-cesDoc	_	I-p
1864	12018	12019	-	-	:	_	_	I-cesDoc	_	I-p
1865	12019	12024	89.09	89.09	CD	_	_	I-cesDoc	_	I-p
1866	12024	12025	]	]	NN	_	_	I-cesDoc	_	I-p
1867	12026	12032	versus	versus	CC	_	_	I-cesDoc	_	I-p
1868	12033	12038	17.12	17.12	CD	_	_	I-cesDoc	_	I-p
1869	12039	12040	[	[	NN	_	_	I-cesDoc	_	I-p
1870	12040	12044	8.58	8.58	CD	_	_	I-cesDoc	_	I-p
1871	12044	12045	-	-	:	_	_	I-cesDoc	_	I-p
1872	12045	12050	29.33	29.33	CD	_	_	I-cesDoc	_	I-p
1873	12050	12051	]	]	NN	_	_	I-cesDoc	_	I-p
1874	12062	12064	ng	ng	NN	_	_	I-cesDoc	_	I-p
1875	12064	12065	/	/	NN	_	_	I-cesDoc	_	I-p
1876	12065	12067	10	10	CD	_	_	I-cesDoc	_	I-p
1877	12068	12069	6	6	CD	_	_	I-cesDoc	_	I-p
1878	12069	12074	cells	cell	NNS	_	_	I-cesDoc	_	I-p
1879	12074	12075	/	/	NN	_	_	I-cesDoc	_	I-p
1880	12075	12077	30	30	CD	_	_	I-cesDoc	_	I-p
1881	12078	12081	min	min	NN	_	_	I-cesDoc	_	I-p
1882	12081	12082	,	,	,	_	_	I-cesDoc	_	I-p
1883	12083	12095	respectively	respectively	RB	_	_	I-cesDoc	_	I-p
1884	12095	12096	;	;	:	_	_	I-cesDoc	_	I-p
1885	12108	12109	P	p	NN	_	_	I-cesDoc	_	I-p
1886	12110	12111	=	=	SYM	_	_	I-cesDoc	_	I-p
1887	12112	12116	0.25	0.25	CD	_	_	I-cesDoc	_	I-p
1888	12116	12117	;	;	:	_	_	I-cesDoc	_	I-p
1889	12118	12119	[	[	NN	_	_	I-cesDoc	_	I-p
1890	12119	12123	Fig.	Fig.	NN	_	_	I-cesDoc	_	I-p
1891	12124	12125	1	1	CD	_	_	I-cesDoc	_	I-p
1892	12125	12126	a	a	DT	_	_	I-cesDoc	_	I-p
1893	12126	12127	]	]	NN	_	_	I-cesDoc	_	I-p
1894	12127	12128	)	)	)	_	_	I-cesDoc	_	I-p
1895	12128	12129	.	.	.	_	_	I-cesDoc	_	I-p
1896	12140	12156	IL-1?-stimulated	il-1?-stimulated	NNP	_	_	I-cesDoc	_	I-p
1897	12157	12167	production	production	NN	_	_	I-cesDoc	_	I-p
1898	12168	12170	of	of	IN	_	_	I-cesDoc	_	I-p
1899	12171	12174	TXB	txb	NNP	_	_	I-cesDoc	_	I-p
1900	12186	12187	2	2	CD	_	_	I-cesDoc	_	I-p
1901	12188	12189	(	(	(	_	_	I-cesDoc	_	I-p
1902	12189	12195	stable	stable	JJ	_	_	I-cesDoc	_	I-p
1903	12196	12206	metabolite	metabolite	NN	_	_	I-cesDoc	_	I-p
1904	12207	12209	of	of	IN	_	_	I-cesDoc	_	I-p
1905	12210	12213	the	the	DT	_	_	I-cesDoc	_	I-p
1906	12214	12220	active	active	JJ	_	_	I-cesDoc	_	I-p
1907	12221	12224	TXA	txa	NNP	_	_	I-cesDoc	_	I-p
1908	12246	12247	2	2	CD	_	_	I-cesDoc	_	B-p
1909	12248	12249	)	)	)	_	_	I-cesDoc	_	I-p
1910	12249	12250	,	,	,	_	_	I-cesDoc	_	I-p
1911	12251	12254	PGF	pgf	NNP	_	_	I-cesDoc	_	I-p
1912	12266	12267	2	2	CD	_	_	I-cesDoc	_	I-p
1913	12267	12268	?	?	NN	_	_	I-cesDoc	_	I-p
1914	12269	12270	,	,	,	_	_	I-cesDoc	_	I-p
1915	12271	12274	and	and	CC	_	_	I-cesDoc	_	I-p
1916	12275	12285	6-keto-PGF	6-keto-PGF	NN	_	_	I-cesDoc	_	I-p
1917	12297	12298	1	1	CD	_	_	I-cesDoc	_	I-p
1918	12298	12299	?	?	NN	_	_	I-cesDoc	_	I-p
1919	12300	12301	(	(	(	_	_	I-cesDoc	_	I-p
1920	12301	12307	stable	stable	JJ	_	_	I-cesDoc	_	I-p
1921	12308	12318	metabolite	metabolite	NN	_	_	I-cesDoc	_	I-p
1922	12319	12321	of	of	IN	_	_	I-cesDoc	_	I-p
1923	12322	12325	PGI	pgi	NNP	_	_	I-cesDoc	_	I-p
1924	12337	12338	2	2	CD	_	_	I-cesDoc	_	I-p
1925	12339	12340	)	)	)	_	_	I-cesDoc	_	I-p
1926	12341	12350	increased	increase	VBN	_	_	I-cesDoc	_	I-p
1927	12351	12359	modestly	modestly	RB	_	_	I-cesDoc	_	I-p
1928	12360	12362	in	in	IN	_	_	I-cesDoc	_	I-p
1929	12363	12368	every	every	DT	_	_	I-cesDoc	_	I-p
1930	12369	12373	case	case	NN	_	_	I-cesDoc	_	I-p
1931	12373	12374	,	,	,	_	_	I-cesDoc	_	I-p
1932	12385	12391	except	except	IN	_	_	I-cesDoc	_	I-p
1933	12392	12395	TXB	txb	NNP	_	_	I-cesDoc	_	I-p
1934	12407	12408	2	2	CD	_	_	I-cesDoc	_	I-p
1935	12409	12419	production	production	NN	_	_	I-cesDoc	_	I-p
1936	12420	12422	by	by	IN	_	_	I-cesDoc	_	I-p
1937	12423	12428	HF-NL	hf-nl	NNP	_	_	I-cesDoc	_	I-p
1938	12428	12429	,	,	,	_	_	I-cesDoc	_	I-p
1939	12430	12435	which	which	WDT	_	_	I-cesDoc	_	I-p
1940	12436	12445	decreased	decrease	VBD	_	_	I-cesDoc	_	I-p
1941	12456	12457	(	(	(	_	_	I-cesDoc	_	I-p
1942	12457	12461	0.75	0.75	CD	_	_	I-cesDoc	_	I-p
1943	12462	12463	[	[	NN	_	_	I-cesDoc	_	I-p
1944	12463	12467	0.15	0.15	CD	_	_	I-cesDoc	_	I-p
1945	12467	12468	-	-	:	_	_	I-cesDoc	_	I-p
1946	12468	12472	2.58	2.58	CD	_	_	I-cesDoc	_	I-p
1947	12472	12473	]	]	NN	_	_	I-cesDoc	_	I-p
1948	12474	12476	ng	ng	NN	_	_	I-cesDoc	_	I-p
1949	12476	12477	/	/	NN	_	_	I-cesDoc	_	I-p
1950	12477	12479	10	10	CD	_	_	I-cesDoc	_	I-p
1951	12480	12481	6	6	CD	_	_	I-cesDoc	_	I-p
1952	12481	12486	cells	cell	NNS	_	_	I-cesDoc	_	I-p
1953	12486	12487	/	/	NN	_	_	I-cesDoc	_	I-p
1954	12487	12489	30	30	CD	_	_	I-cesDoc	_	I-p
1955	12490	12493	min	min	NN	_	_	I-cesDoc	_	I-p
1956	12494	12496	at	at	IN	_	_	I-cesDoc	_	I-p
1957	12497	12505	baseline	baseline	NN	_	_	I-cesDoc	_	I-p
1958	12506	12512	versus	versus	CC	_	_	I-cesDoc	_	I-p
1959	12523	12527	0.61	0.61	CD	_	_	I-cesDoc	_	I-p
1960	12528	12529	[	[	NN	_	_	I-cesDoc	_	I-p
1961	12529	12533	0.21	0.21	CD	_	_	I-cesDoc	_	I-p
1962	12533	12534	-	-	:	_	_	I-cesDoc	_	I-p
1963	12534	12538	1.64	1.64	CD	_	_	I-cesDoc	_	I-p
1964	12538	12539	]	]	NN	_	_	I-cesDoc	_	I-p
1965	12540	12542	ng	ng	NN	_	_	I-cesDoc	_	I-p
1966	12542	12543	/	/	NN	_	_	I-cesDoc	_	I-p
1967	12543	12545	10	10	CD	_	_	I-cesDoc	_	I-p
1968	12546	12547	6	6	CD	_	_	I-cesDoc	_	I-p
1969	12547	12552	cells	cell	NNS	_	_	I-cesDoc	_	I-p
1970	12552	12553	/	/	NN	_	_	I-cesDoc	_	I-p
1971	12553	12555	30	30	CD	_	_	I-cesDoc	_	I-p
1972	12556	12559	min	min	NN	_	_	I-cesDoc	_	I-p
1973	12560	12564	with	with	IN	_	_	I-cesDoc	_	I-p
1974	12565	12570	IL-1?	il-1?	NNP	_	_	I-cesDoc	_	I-p
1975	12581	12592	stimulation	stimulation	NN	_	_	I-cesDoc	_	I-p
1976	12592	12593	)	)	)	_	_	I-cesDoc	_	I-p
1977	12594	12595	(	(	(	_	_	I-cesDoc	_	I-p
1978	12595	12599	Fig.	Fig.	NN	_	_	I-cesDoc	_	I-p
1979	12600	12601	1	1	CD	_	_	I-cesDoc	_	I-p
1980	12601	12602	b	b	SYM	_	_	I-cesDoc	_	I-p
1981	12602	12603	)	)	)	_	_	I-cesDoc	_	I-p
1982	12603	12604	.	.	.	_	_	I-cesDoc	_	I-p
1983	12605	12612	Results	result	NNS	_	_	I-cesDoc	_	I-p
1984	12613	12615	of	of	IN	_	_	I-cesDoc	_	I-p
1985	12616	12619	PGE	pge	NNP	_	_	I-cesDoc	_	I-p
1986	12631	12632	2	2	CD	_	_	I-cesDoc	_	I-p
1987	12633	12643	production	production	NN	_	_	I-cesDoc	_	I-p
1988	12644	12648	were	be	VBD	_	_	I-cesDoc	_	I-p
1989	12649	12656	similar	similar	JJ	_	_	I-cesDoc	_	I-p
1990	12657	12661	when	when	WRB	_	_	I-cesDoc	_	I-p
1991	12672	12683	experiments	experiment	NNS	_	_	I-cesDoc	_	I-p
1992	12684	12688	were	be	VBD	_	_	I-cesDoc	_	I-p
1993	12689	12698	conducted	conduct	VBN	_	_	I-cesDoc	_	I-p
1994	12699	12701	in	in	IN	_	_	I-cesDoc	_	I-p
1995	12702	12707	serum	serum	NN	_	_	I-cesDoc	_	I-p
1996	12708	12712	free	free	JJ	_	_	I-cesDoc	_	I-p
1997	12713	12718	media	media	NNS	_	_	I-cesDoc	_	I-p
1998	12719	12729	conditions	condition	NNS	_	_	I-cesDoc	_	I-p
1999	12740	12741	(	(	(	_	_	I-cesDoc	_	I-p
2000	12741	12748	results	result	NNS	_	_	I-cesDoc	_	I-p
2001	12749	12752	not	not	RB	_	_	I-cesDoc	_	I-p
2002	12753	12758	shown	show	VBN	_	_	I-cesDoc	_	I-p
2003	12758	12759	)	)	)	_	_	I-cesDoc	_	I-p
2004	12759	12760	.	.	.	_	_	I-cesDoc	_	I-p
2005	12771	12776	IL-1?	il-1?	NNP	_	_	I-cesDoc	_	I-p
2006	12777	12787	stimulated	stimulate	VBN	_	_	I-cesDoc	_	I-p
2007	12788	12791	TXB	txb	NNP	_	_	I-cesDoc	_	I-p
2008	12803	12804	2	2	CD	_	_	I-cesDoc	_	I-p
2009	12805	12815	production	production	NN	_	_	I-cesDoc	_	I-p
2010	12816	12819	was	be	VBD	_	_	I-cesDoc	_	I-p
2011	12820	12833	significantly	significantly	RB	_	_	I-cesDoc	_	I-p
2012	12834	12841	greater	greater	JJR	_	_	I-cesDoc	_	I-p
2013	12852	12854	in	in	IN	_	_	I-cesDoc	_	I-p
2014	12855	12861	HF-IPF	hf-ipf	NNP	_	_	I-cesDoc	_	I-p
2015	12862	12863	(	(	(	_	_	I-cesDoc	_	I-p
2016	12863	12867	1.92	1.92	CD	_	_	I-cesDoc	_	I-p
2017	12868	12869	[	[	NN	_	_	I-cesDoc	_	I-p
2018	12869	12873	1.27	1.27	CD	_	_	I-cesDoc	_	I-p
2019	12873	12874	-	-	:	_	_	I-cesDoc	_	I-p
2020	12874	12878	2.57	2.57	CD	_	_	I-cesDoc	_	I-p
2021	12878	12879	]	]	NN	_	_	I-cesDoc	_	I-p
2022	12880	12882	ng	ng	NN	_	_	I-cesDoc	_	I-p
2023	12882	12883	/	/	NN	_	_	I-cesDoc	_	I-p
2024	12883	12885	10	10	CD	_	_	I-cesDoc	_	I-p
2025	12886	12887	6	6	CD	_	_	I-cesDoc	_	I-p
2026	12887	12892	cells	cell	NNS	_	_	I-cesDoc	_	I-p
2027	12892	12893	/	/	NN	_	_	I-cesDoc	_	I-p
2028	12893	12895	30	30	CD	_	_	I-cesDoc	_	I-p
2029	12896	12899	min	min	NN	_	_	I-cesDoc	_	I-p
2030	12899	12900	)	)	)	_	_	I-cesDoc	_	I-p
2031	12901	12905	than	than	IN	_	_	I-cesDoc	_	I-p
2032	12906	12908	in	in	IN	_	_	I-cesDoc	_	I-p
2033	12919	12924	HF-NL	hf-nl	NNP	_	_	I-cesDoc	_	I-p
2034	12925	12926	(	(	(	_	_	I-cesDoc	_	I-p
2035	12926	12930	0.61	0.61	CD	_	_	I-cesDoc	_	I-p
2036	12931	12932	[	[	NN	_	_	I-cesDoc	_	I-p
2037	12932	12936	0.21	0.21	CD	_	_	I-cesDoc	_	I-p
2038	12936	12937	-	-	:	_	_	I-cesDoc	_	I-p
2039	12937	12941	1.64	1.64	CD	_	_	I-cesDoc	_	I-p
2040	12941	12942	]	]	NN	_	_	I-cesDoc	_	I-p
2041	12943	12945	ng	ng	NN	_	_	I-cesDoc	_	I-p
2042	12945	12946	/	/	NN	_	_	I-cesDoc	_	I-p
2043	12946	12948	10	10	CD	_	_	I-cesDoc	_	I-p
2044	12949	12950	6	6	CD	_	_	I-cesDoc	_	I-p
2045	12950	12955	cells	cell	NNS	_	_	I-cesDoc	_	I-p
2046	12955	12956	/	/	NN	_	_	I-cesDoc	_	I-p
2047	12956	12958	30	30	CD	_	_	I-cesDoc	_	I-p
2048	12959	12962	min	min	NN	_	_	I-cesDoc	_	I-p
2049	12962	12963	;	;	:	_	_	I-cesDoc	_	I-p
2050	12975	12976	P	p	NN	_	_	I-cesDoc	_	I-p
2051	12977	12978	=	=	SYM	_	_	I-cesDoc	_	I-p
2052	12979	12984	0.007	0.007	CD	_	_	I-cesDoc	_	I-p
2053	12984	12985	)	)	)	_	_	I-cesDoc	_	I-p
2054	12986	12987	(	(	(	_	_	I-cesDoc	_	I-p
2055	12987	12991	Fig.	Fig.	NN	_	_	I-cesDoc	_	I-p
2056	12992	12993	1	1	CD	_	_	I-cesDoc	_	I-p
2057	12993	12994	b	b	SYM	_	_	I-cesDoc	_	I-p
2058	12994	12995	)	)	)	_	_	I-cesDoc	_	I-p
2059	12995	12996	;	;	:	_	_	I-cesDoc	_	I-p
2060	12997	13005	baseline	baseline	NN	_	_	I-cesDoc	_	I-p
2061	13006	13009	TXB	txb	NNP	_	_	I-cesDoc	_	I-p
2062	13021	13022	2	2	CD	_	_	I-cesDoc	_	I-p
2063	13023	13033	production	production	NN	_	_	I-cesDoc	_	I-p
2064	13034	13037	was	be	VBD	_	_	I-cesDoc	_	I-p
2065	13038	13041	not	not	RB	_	_	I-cesDoc	_	I-p
2066	13042	13055	significantly	significantly	RB	_	_	I-cesDoc	_	I-p
2067	13066	13075	different	different	JJ	_	_	I-cesDoc	_	I-p
2068	13076	13083	between	between	IN	_	_	I-cesDoc	_	I-p
2069	13084	13087	the	the	DT	_	_	I-cesDoc	_	I-p
2070	13088	13091	two	two	CD	_	_	I-cesDoc	_	I-p
2071	13092	13096	cell	cell	NN	_	_	I-cesDoc	_	I-p
2072	13097	13103	groups	group	NNS	_	_	I-cesDoc	_	I-p
2073	13104	13105	(	(	(	_	_	I-cesDoc	_	I-p
2074	13105	13109	1.73	1.73	CD	_	_	I-cesDoc	_	I-p
2075	13110	13111	[	[	NN	_	_	I-cesDoc	_	I-p
2076	13111	13115	0.77	0.77	CD	_	_	I-cesDoc	_	I-p
2077	13115	13116	-	-	:	_	_	I-cesDoc	_	I-p
2078	13116	13120	2.53	2.53	CD	_	_	I-cesDoc	_	I-p
2079	13120	13121	]	]	NN	_	_	I-cesDoc	_	I-p
2080	13132	13138	versus	versus	CC	_	_	I-cesDoc	_	I-p
2081	13139	13143	0.75	0.75	CD	_	_	I-cesDoc	_	I-p
2082	13144	13145	[	[	NN	_	_	I-cesDoc	_	I-p
2083	13145	13149	0.15	0.15	CD	_	_	I-cesDoc	_	I-p
2084	13149	13150	-	-	:	_	_	I-cesDoc	_	I-p
2085	13150	13154	2.58	2.58	CD	_	_	I-cesDoc	_	I-p
2086	13154	13155	]	]	NN	_	_	I-cesDoc	_	I-p
2087	13156	13158	ng	ng	NN	_	_	I-cesDoc	_	I-p
2088	13158	13159	/	/	NN	_	_	I-cesDoc	_	I-p
2089	13159	13161	10	10	CD	_	_	I-cesDoc	_	I-p
2090	13162	13163	6	6	CD	_	_	I-cesDoc	_	I-p
2091	13163	13168	cells	cell	NNS	_	_	I-cesDoc	_	I-p
2092	13168	13169	/	/	NN	_	_	I-cesDoc	_	I-p
2093	13169	13171	30	30	CD	_	_	I-cesDoc	_	I-p
2094	13172	13175	min	min	NN	_	_	I-cesDoc	_	I-p
2095	13175	13176	,	,	,	_	_	I-cesDoc	_	I-p
2096	13177	13179	in	in	IN	_	_	I-cesDoc	_	I-p
2097	13180	13186	HF-IPF	hf-ipf	NNP	_	_	I-cesDoc	_	I-p
2098	13197	13200	and	and	CC	_	_	I-cesDoc	_	I-p
2099	13201	13206	HF-NL	hf-nl	NNP	_	_	I-cesDoc	_	I-p
2100	13206	13207	,	,	,	_	_	I-cesDoc	_	I-p
2101	13208	13220	respectively	respectively	RB	_	_	I-cesDoc	_	I-p
2102	13220	13221	;	;	:	_	_	I-cesDoc	_	I-p
2103	13233	13234	P	p	NN	_	_	I-cesDoc	_	I-p
2104	13235	13236	=	=	SYM	_	_	I-cesDoc	_	I-p
2105	13237	13241	0.17	0.17	CD	_	_	I-cesDoc	_	I-p
2106	13242	13243	[	[	NN	_	_	I-cesDoc	_	I-p
2107	13243	13247	Fig.	Fig.	NN	_	_	I-cesDoc	_	I-p
2108	13248	13249	1	1	CD	_	_	I-cesDoc	_	I-p
2109	13249	13250	b	b	SYM	_	_	I-cesDoc	_	I-p
2110	13250	13251	]	]	NN	_	_	I-cesDoc	_	I-p
2111	13251	13252	)	)	)	_	_	I-cesDoc	_	I-p
2112	13252	13253	.	.	.	_	_	I-cesDoc	_	I-p
2113	13254	13261	Because	because	IN	_	_	I-cesDoc	_	I-p
2114	13262	13265	PGI	pgi	NNP	_	_	I-cesDoc	_	I-p
2115	13277	13278	2	2	CD	_	_	I-cesDoc	_	I-p
2116	13279	13282	and	and	CC	_	_	I-cesDoc	_	I-p
2117	13283	13286	TXA	txa	NNP	_	_	I-cesDoc	_	I-p
2118	13298	13299	2	2	CD	_	_	I-cesDoc	_	I-p
2119	13300	13304	have	have	VBP	_	_	I-cesDoc	_	I-p
2120	13305	13313	opposing	oppose	VBG	_	_	I-cesDoc	_	I-p
2121	13314	13321	effects	effect	NNS	_	_	I-cesDoc	_	I-p
2122	13333	13335	in	in	IN	_	_	I-cesDoc	_	I-p
2123	13336	13340	vivo	vivo	NN	_	_	I-cesDoc	_	I-p
2124	13341	13342	,	,	,	_	_	I-cesDoc	_	I-p
2125	13343	13345	we	we	PRP	_	_	I-cesDoc	_	I-p
2126	13346	13356	calculated	calculate	VBD	_	_	I-cesDoc	_	I-p
2127	13357	13360	the	the	DT	_	_	I-cesDoc	_	I-p
2128	13361	13366	ratio	ratio	NN	_	_	I-cesDoc	_	I-p
2129	13377	13379	of	of	IN	_	_	I-cesDoc	_	I-p
2130	13380	13385	their	their	PRP$	_	_	I-cesDoc	_	I-p
2131	13386	13397	metabolites	metabolite	NNS	_	_	I-cesDoc	_	I-p
2132	13398	13399	(	(	(	_	_	I-cesDoc	_	I-p
2133	13399	13409	6-keto-PGF	6-keto-PGF	NN	_	_	I-cesDoc	_	I-p
2134	13421	13422	1	1	CD	_	_	I-cesDoc	_	I-p
2135	13422	13423	?	?	NN	_	_	I-cesDoc	_	I-p
2136	13424	13425	:	:	:	_	_	I-cesDoc	_	I-p
2137	13425	13428	TXB	txb	NNP	_	_	I-cesDoc	_	I-p
2138	13440	13441	2	2	CD	_	_	I-cesDoc	_	I-p
2139	13442	13443	)	)	)	_	_	I-cesDoc	_	I-p
2140	13444	13447	and	and	CC	_	_	I-cesDoc	_	I-p
2141	13448	13453	found	find	VBD	_	_	I-cesDoc	_	I-p
2142	13454	13455	a	a	DT	_	_	I-cesDoc	_	I-p
2143	13456	13469	significantly	significantly	RB	_	_	I-cesDoc	_	I-p
2144	13470	13475	lower	lower	JJR	_	_	I-cesDoc	_	I-p
2145	13486	13491	ratio	ratio	NN	_	_	I-cesDoc	_	I-p
2146	13492	13494	in	in	IN	_	_	I-cesDoc	_	I-p
2147	13495	13501	HF-IPF	hf-ipf	NNP	_	_	I-cesDoc	_	I-p
2148	13502	13504	at	at	IN	_	_	I-cesDoc	_	I-p
2149	13505	13513	baseline	baseline	NN	_	_	I-cesDoc	_	I-p
2150	13514	13515	(	(	(	_	_	I-cesDoc	_	I-p
2151	13515	13519	0.08	0.08	CD	_	_	I-cesDoc	_	I-p
2152	13520	13521	[	[	NN	_	_	I-cesDoc	_	I-p
2153	13521	13525	0.04	0.04	CD	_	_	I-cesDoc	_	I-p
2154	13525	13526	-	-	:	_	_	I-cesDoc	_	I-p
2155	13526	13530	0.52	0.52	CD	_	_	I-cesDoc	_	I-p
2156	13530	13531	]	]	NN	_	_	I-cesDoc	_	I-p
2157	13532	13538	versus	versus	CC	_	_	I-cesDoc	_	I-p
2158	13539	13543	0.12	0.12	CD	_	_	I-cesDoc	_	I-p
2159	13554	13555	[	[	NN	_	_	I-cesDoc	_	I-p
2160	13555	13559	0.11	0.11	CD	_	_	I-cesDoc	_	I-p
2161	13559	13560	-	-	:	_	_	I-cesDoc	_	I-p
2162	13560	13564	0.89	0.89	CD	_	_	I-cesDoc	_	I-p
2163	13564	13565	]	]	NN	_	_	I-cesDoc	_	I-p
2164	13566	13568	in	in	IN	_	_	I-cesDoc	_	I-p
2165	13569	13575	HF-IPF	hf-ipf	NNP	_	_	I-cesDoc	_	I-p
2166	13576	13579	and	and	CC	_	_	I-cesDoc	_	I-p
2167	13580	13585	HF-NL	hf-nl	NNP	_	_	I-cesDoc	_	I-p
2168	13585	13586	,	,	,	_	_	I-cesDoc	_	I-p
2169	13587	13599	respectively	respectively	RB	_	_	I-cesDoc	_	I-p
2170	13599	13600	;	;	:	_	_	I-cesDoc	_	I-p
2171	13612	13613	P	p	NN	_	_	I-cesDoc	_	I-p
2172	13614	13615	=	=	SYM	_	_	I-cesDoc	_	I-p
2173	13616	13621	0.028	0.028	CD	_	_	I-cesDoc	_	I-p
2174	13621	13622	)	)	)	_	_	I-cesDoc	_	I-p
2175	13623	13626	and	and	CC	_	_	I-cesDoc	_	I-p
2176	13627	13628	a	a	DT	_	_	I-cesDoc	_	I-p
2177	13629	13636	similar	similar	JJ	_	_	I-cesDoc	_	I-p
2178	13637	13642	trend	trend	NN	_	_	I-cesDoc	_	I-p
2179	13653	13658	under	under	IN	_	_	I-cesDoc	_	I-p
2180	13659	13669	stimulated	stimulate	VBN	_	_	I-cesDoc	_	I-p
2181	13670	13680	conditions	condition	NNS	_	_	I-cesDoc	_	I-p
2182	13681	13682	(	(	(	_	_	I-cesDoc	_	I-p
2183	13682	13686	0.24	0.24	CD	_	_	I-cesDoc	_	I-p
2184	13687	13688	[	[	NN	_	_	I-cesDoc	_	I-p
2185	13688	13692	0.05	0.05	CD	_	_	I-cesDoc	_	I-p
2186	13692	13693	-	-	:	_	_	I-cesDoc	_	I-p
2187	13693	13697	1.53	1.53	CD	_	_	I-cesDoc	_	I-p
2188	13697	13698	]	]	NN	_	_	I-cesDoc	_	I-p
2189	13699	13705	versus	versus	CC	_	_	I-cesDoc	_	I-p
2190	13706	13710	1.08	1.08	CD	_	_	I-cesDoc	_	I-p
2191	13721	13722	[	[	NN	_	_	I-cesDoc	_	I-p
2192	13722	13726	0.51	0.51	CD	_	_	I-cesDoc	_	I-p
2193	13726	13727	-	-	:	_	_	I-cesDoc	_	I-p
2194	13727	13731	3.79	3.79	CD	_	_	I-cesDoc	_	I-p
2195	13731	13732	]	]	NN	_	_	I-cesDoc	_	I-p
2196	13733	13735	in	in	IN	_	_	I-cesDoc	_	I-p
2197	13736	13742	HF-IPF	hf-ipf	NNP	_	_	I-cesDoc	_	I-p
2198	13743	13746	and	and	CC	_	_	I-cesDoc	_	I-p
2199	13747	13752	HF-NL	hf-nl	NNP	_	_	I-cesDoc	_	I-p
2200	13752	13753	,	,	,	_	_	I-cesDoc	_	I-p
2201	13754	13766	respectively	respectively	RB	_	_	I-cesDoc	_	I-p
2202	13766	13767	;	;	:	_	_	I-cesDoc	_	I-p
2203	13779	13780	P	p	NN	_	_	I-cesDoc	_	I-p
2204	13781	13782	=	=	SYM	_	_	I-cesDoc	_	I-p
2205	13783	13787	0.09	0.09	CD	_	_	I-cesDoc	_	I-p
2206	13788	13789	[	[	NN	_	_	I-cesDoc	_	I-p
2207	13789	13793	Fig.	Fig.	NN	_	_	I-cesDoc	_	I-p
2208	13794	13795	2	2	CD	_	_	I-cesDoc	_	I-p
2209	13795	13796	]	]	NN	_	_	I-cesDoc	_	I-p
2210	13796	13797	)	)	)	_	_	I-cesDoc	_	I-p
2211	13797	13798	.	.	.	_	_	I-cesDoc	_	I-p
2212	13827	13835	Baseline	baseline	NNP	_	_	I-cesDoc	B-head	_
2213	13836	13839	and	and	CC	_	_	I-cesDoc	I-head	_
2214	13840	13850	stimulated	stimulate	VBN	_	_	I-cesDoc	I-head	_
2215	13851	13856	COX-2	cox-2	NNP	_	_	I-cesDoc	I-head	_
2216	13857	13867	expression	expression	NN	_	_	I-cesDoc	I-head	_
2217	13878	13885	Western	western	JJ	_	_	I-cesDoc	_	B-p
2218	13886	13890	blot	blot	NN	_	_	I-cesDoc	_	I-p
2219	13891	13893	in	in	IN	_	_	I-cesDoc	_	I-p
2220	13894	13906	unstimulated	unstimulated	JJ	_	_	I-cesDoc	_	I-p
2221	13907	13918	fibroblasts	fibroblast	NNS	_	_	I-cesDoc	_	I-p
2222	13919	13925	showed	show	VBD	_	_	I-cesDoc	_	I-p
2223	13926	13928	no	no	DT	_	_	I-cesDoc	_	I-p
2224	13939	13949	detectable	detectable	JJ	_	_	I-cesDoc	_	I-p
2225	13950	13955	COX-2	cox-2	NNP	_	_	I-cesDoc	_	I-p
2226	13956	13963	protein	protein	NN	_	_	I-cesDoc	_	I-p
2227	13964	13966	in	in	IN	_	_	I-cesDoc	_	I-p
2228	13967	13973	either	either	DT	_	_	I-cesDoc	_	I-p
2229	13974	13979	group	group	NN	_	_	I-cesDoc	_	I-p
2230	13980	13982	of	of	IN	_	_	I-cesDoc	_	I-p
2231	13983	13988	cells	cell	NNS	_	_	I-cesDoc	_	I-p
2232	13988	13989	,	,	,	_	_	I-cesDoc	_	I-p
2233	13990	13995	while	while	IN	_	_	I-cesDoc	_	I-p
2234	14006	14011	IL-1?	il-1?	NNP	_	_	I-cesDoc	_	I-p
2235	14012	14025	significantly	significantly	RB	_	_	I-cesDoc	_	I-p
2236	14026	14033	induced	induce	VBD	_	_	I-cesDoc	_	I-p
2237	14034	14039	COX-2	cox-2	NNP	_	_	I-cesDoc	_	I-p
2238	14040	14042	to	to	TO	_	_	I-cesDoc	_	I-p
2239	14043	14044	a	a	DT	_	_	I-cesDoc	_	I-p
2240	14045	14052	similar	similar	JJ	_	_	I-cesDoc	_	I-p
2241	14053	14059	degree	degree	NN	_	_	I-cesDoc	_	I-p
2242	14060	14062	in	in	IN	_	_	I-cesDoc	_	I-p
2243	14073	14076	IPF	ipf	NNP	_	_	I-cesDoc	_	I-p
2244	14077	14080	and	and	CC	_	_	I-cesDoc	_	I-p
2245	14081	14087	normal	normal	JJ	_	_	I-cesDoc	_	I-p
2246	14088	14092	lung	lung	NN	_	_	I-cesDoc	_	I-p
2247	14093	14104	fibroblasts	fibroblast	NNS	_	_	I-cesDoc	_	I-p
2248	14105	14106	(	(	(	_	_	I-cesDoc	_	I-p
2249	14106	14110	Fig.	Fig.	NN	_	_	I-cesDoc	_	I-p
2250	14111	14112	3	3	CD	_	_	I-cesDoc	_	I-p
2251	14112	14113	)	)	)	_	_	I-cesDoc	_	I-p
2252	14113	14114	.	.	.	_	_	I-cesDoc	_	I-p
2253	14115	14123	Northern	northern	NNP	_	_	I-cesDoc	_	I-p
2254	14124	14128	blot	blot	NN	_	_	I-cesDoc	_	I-p
2255	14139	14145	showed	show	VBD	_	_	I-cesDoc	_	I-p
2256	14146	14153	minimal	minimal	JJ	_	_	I-cesDoc	_	I-p
2257	14154	14159	COX-2	cox-2	NNP	_	_	I-cesDoc	_	I-p
2258	14160	14164	mRNA	mrna	NN	_	_	I-cesDoc	_	I-p
2259	14165	14167	in	in	IN	_	_	I-cesDoc	_	I-p
2260	14168	14180	unstimulated	unstimulated	JJ	_	_	I-cesDoc	_	I-p
2261	14181	14186	cells	cell	NNS	_	_	I-cesDoc	_	I-p
2262	14187	14190	and	and	CC	_	_	I-cesDoc	_	I-p
2263	14201	14212	significant	significant	JJ	_	_	I-cesDoc	_	I-p
2264	14213	14225	upregulation	upregulation	NN	_	_	I-cesDoc	_	I-p
2265	14226	14228	of	of	IN	_	_	I-cesDoc	_	I-p
2266	14229	14234	COX-2	cox-2	NNP	_	_	I-cesDoc	_	I-p
2267	14235	14239	mRNA	mrna	NN	_	_	I-cesDoc	_	I-p
2268	14240	14250	expression	expression	NN	_	_	I-cesDoc	_	I-p
2269	14251	14255	when	when	WRB	_	_	I-cesDoc	_	I-p
2270	14266	14276	stimulated	stimulate	VBN	_	_	I-cesDoc	_	I-p
2271	14277	14281	with	with	IN	_	_	I-cesDoc	_	I-p
2272	14282	14287	IL-1?	il-1?	NNP	_	_	I-cesDoc	_	I-p
2273	14288	14290	in	in	IN	_	_	I-cesDoc	_	I-p
2274	14291	14295	both	both	DT	_	_	I-cesDoc	_	I-p
2275	14296	14302	HF-IPF	hf-ipf	NNP	_	_	I-cesDoc	_	I-p
2276	14303	14306	and	and	CC	_	_	I-cesDoc	_	I-p
2277	14307	14312	HF-NL	hf-nl	NNP	_	_	I-cesDoc	_	I-p
2278	14313	14314	(	(	(	_	_	I-cesDoc	_	I-p
2279	14314	14318	Fig.	Fig.	NN	_	_	I-cesDoc	_	I-p
2280	14329	14330	4	4	CD	_	_	I-cesDoc	_	I-p
2281	14330	14331	)	)	)	_	_	I-cesDoc	_	I-p
2282	14331	14332	.	.	.	_	_	I-cesDoc	_	I-p
2283	14364	14374	Discussion	discussion	NNP	_	_	I-cesDoc	B-head	_
2284	14383	14390	Several	several	JJ	_	_	I-cesDoc	_	B-p
2285	14391	14398	factors	factor	NNS	_	_	I-cesDoc	_	I-p
2286	14399	14407	modulate	modulate	VBP	_	_	I-cesDoc	_	I-p
2287	14408	14418	fibroblast	fibroblast	NN	_	_	I-cesDoc	_	I-p
2288	14419	14432	proliferation	proliferation	NN	_	_	I-cesDoc	_	I-p
2289	14433	14436	and	and	CC	_	_	I-cesDoc	_	I-p
2290	14445	14453	collagen	collagen	NN	_	_	I-cesDoc	_	I-p
2291	14454	14464	production	production	NN	_	_	I-cesDoc	_	I-p
2292	14464	14465	,	,	,	_	_	I-cesDoc	_	I-p
2293	14466	14475	including	include	VBG	_	_	I-cesDoc	_	I-p
2294	14476	14485	mitogenic	mitogenic	JJ	_	_	I-cesDoc	_	I-p
2295	14486	14495	cytokines	cytokine	NNS	_	_	I-cesDoc	_	I-p
2296	14496	14497	(	(	(	_	_	I-cesDoc	_	I-p
2297	14497	14501	e.g.	e.g.	NN	_	_	I-cesDoc	_	I-p
2298	14501	14502	,	,	,	_	_	I-cesDoc	_	I-p
2299	14511	14523	transforming	transform	VBG	_	_	I-cesDoc	_	I-p
2300	14524	14530	growth	growth	NN	_	_	I-cesDoc	_	I-p
2301	14531	14537	factor	factor	NN	_	_	I-cesDoc	_	I-p
2302	14538	14539	?	?	NN	_	_	I-cesDoc	_	I-p
2303	14540	14541	[	[	NN	_	_	I-cesDoc	_	I-p
2304	14541	14545	TGF?	tgf?	NNP	_	_	I-cesDoc	_	I-p
2305	14545	14546	]	]	NN	_	_	I-cesDoc	_	I-p
2306	14546	14547	,	,	,	_	_	I-cesDoc	_	I-p
2307	14548	14556	platelet	platelet	NN	_	_	I-cesDoc	_	I-p
2308	14556	14557	-	-	-	_	_	I-cesDoc	_	I-p
2309	14557	14564	derived	derive	VBN	_	_	I-cesDoc	_	I-p
2310	14573	14579	growth	growth	NN	_	_	I-cesDoc	_	I-p
2311	14580	14586	factor	factor	NN	_	_	I-cesDoc	_	I-p
2312	14587	14588	[	[	NN	_	_	I-cesDoc	_	I-p
2313	14588	14592	PDGF	pdgf	NNP	_	_	I-cesDoc	_	I-p
2314	14592	14593	]	]	NN	_	_	I-cesDoc	_	I-p
2315	14593	14594	,	,	,	_	_	I-cesDoc	_	I-p
2316	14595	14600	basic	basic	JJ	_	_	I-cesDoc	_	I-p
2317	14601	14611	fibroblast	fibroblast	NN	_	_	I-cesDoc	_	I-p
2318	14612	14618	growth	growth	NN	_	_	I-cesDoc	_	I-p
2319	14619	14625	factor	factor	NN	_	_	I-cesDoc	_	I-p
2320	14634	14635	[	[	NN	_	_	I-cesDoc	_	I-p
2321	14635	14639	bFGF	bfgf	NN	_	_	I-cesDoc	_	I-p
2322	14639	14640	]	]	NN	_	_	I-cesDoc	_	I-p
2323	14640	14641	)	)	)	_	_	I-cesDoc	_	I-p
2324	14641	14642	,	,	,	_	_	I-cesDoc	_	I-p
2325	14643	14654	eicosanoids	eicosanoid	NNS	_	_	I-cesDoc	_	I-p
2326	14655	14656	(	(	(	_	_	I-cesDoc	_	I-p
2327	14656	14660	i.e.	i.e.	NN	_	_	I-cesDoc	_	I-p
2328	14660	14661	,	,	,	_	_	I-cesDoc	_	I-p
2329	14662	14665	PGE	pge	NNP	_	_	I-cesDoc	_	I-p
2330	14675	14676	2	2	CD	_	_	I-cesDoc	_	I-p
2331	14677	14678	,	,	,	_	_	I-cesDoc	_	I-p
2332	14679	14682	TXB	txb	NNP	_	_	I-cesDoc	_	I-p
2333	14692	14693	2	2	CD	_	_	I-cesDoc	_	I-p
2334	14694	14695	,	,	,	_	_	I-cesDoc	_	I-p
2335	14696	14699	and	and	CC	_	_	I-cesDoc	_	I-p
2336	14700	14703	PGI	pgi	NNP	_	_	I-cesDoc	_	I-p
2337	14713	14714	2	2	CD	_	_	I-cesDoc	_	I-p
2338	14715	14716	)	)	)	_	_	I-cesDoc	_	I-p
2339	14716	14717	,	,	,	_	_	I-cesDoc	_	I-p
2340	14718	14721	and	and	CC	_	_	I-cesDoc	_	I-p
2341	14722	14736	antifibrogenic	antifibrogenic	JJ	_	_	I-cesDoc	_	I-p
2342	14737	14746	cytokines	cytokine	NNS	_	_	I-cesDoc	_	I-p
2343	14747	14748	(	(	(	_	_	I-cesDoc	_	I-p
2344	14748	14752	e.g.	e.g.	NN	_	_	I-cesDoc	_	I-p
2345	14761	14766	IFN-?	ifn-?	NNP	_	_	I-cesDoc	_	I-p
2346	14766	14767	)	)	)	_	_	I-cesDoc	_	I-p
2347	14768	14769	[	[	NN	_	_	I-cesDoc	_	I-p
2348	14770	14771	1	1	CD	_	_	I-cesDoc	_	I-p
2349	14772	14773	2	2	CD	_	_	I-cesDoc	_	I-p
2350	14774	14775	3	3	CD	_	_	I-cesDoc	_	I-p
2351	14776	14777	]	]	NN	_	_	I-cesDoc	_	I-p
2352	14778	14779	.	.	.	_	_	I-cesDoc	_	I-p
2353	14780	14782	It	it	PRP	_	_	I-cesDoc	_	I-p
2354	14783	14785	is	be	VBZ	_	_	I-cesDoc	_	I-p
2355	14786	14790	very	very	RB	_	_	I-cesDoc	_	I-p
2356	14791	14797	likely	likely	JJ	_	_	I-cesDoc	_	I-p
2357	14798	14802	that	that	IN	_	_	I-cesDoc	_	I-p
2358	14803	14804	a	a	DT	_	_	I-cesDoc	_	I-p
2359	14805	14812	complex	complex	JJ	_	_	I-cesDoc	_	I-p
2360	14821	14832	interaction	interaction	NN	_	_	I-cesDoc	_	I-p
2361	14833	14838	among	among	IN	_	_	I-cesDoc	_	I-p
2362	14839	14844	these	these	DT	_	_	I-cesDoc	_	I-p
2363	14845	14852	factors	factor	NNS	_	_	I-cesDoc	_	I-p
2364	14853	14859	exists	exist	VBZ	_	_	I-cesDoc	_	I-p
2365	14860	14862	in	in	IN	_	_	I-cesDoc	_	I-p
2366	14863	14866	the	the	DT	_	_	I-cesDoc	_	I-p
2367	14867	14873	tissue	tissue	NN	_	_	I-cesDoc	_	I-p
2368	14874	14880	repair	repair	NN	_	_	I-cesDoc	_	I-p
2369	14889	14896	process	process	NN	_	_	I-cesDoc	_	I-p
2370	14896	14897	,	,	,	_	_	I-cesDoc	_	I-p
2371	14898	14901	and	and	CC	_	_	I-cesDoc	_	I-p
2372	14902	14904	it	it	PRP	_	_	I-cesDoc	_	I-p
2373	14905	14907	is	be	VBZ	_	_	I-cesDoc	_	I-p
2374	14908	14916	possible	possible	JJ	_	_	I-cesDoc	_	I-p
2375	14917	14921	that	that	IN	_	_	I-cesDoc	_	I-p
2376	14922	14932	pathologic	pathologic	JJ	_	_	I-cesDoc	_	I-p
2377	14933	14941	fibrosis	fibrosis	NNS	_	_	I-cesDoc	_	I-p
2378	14941	14942	,	,	,	_	_	I-cesDoc	_	I-p
2379	14943	14945	as	as	IN	_	_	I-cesDoc	_	I-p
2380	14946	14948	in	in	IN	_	_	I-cesDoc	_	I-p
2381	14957	14960	IPF	ipf	NNP	_	_	I-cesDoc	_	I-p
2382	14960	14961	,	,	,	_	_	I-cesDoc	_	I-p
2383	14962	14969	results	result	VBZ	_	_	I-cesDoc	_	I-p
2384	14970	14974	from	from	IN	_	_	I-cesDoc	_	I-p
2385	14975	14987	phenotypical	phenotypical	JJ	_	_	I-cesDoc	_	I-p
2386	14988	14999	alterations	alteration	NNS	_	_	I-cesDoc	_	I-p
2387	15000	15002	in	in	IN	_	_	I-cesDoc	_	I-p
2388	15003	15014	fibroblasts	fibroblast	NNS	_	_	I-cesDoc	_	I-p
2389	15023	15027	that	that	WDT	_	_	I-cesDoc	_	I-p
2390	15028	15034	affect	affect	VBP	_	_	I-cesDoc	_	I-p
2391	15035	15038	the	the	DT	_	_	I-cesDoc	_	I-p
2392	15039	15040	""	""	''	_	_	I-cesDoc	_	I-p
2393	15040	15046	normal	normal	JJ	_	_	I-cesDoc	_	I-p
2394	15046	15047	""	""	''	_	_	I-cesDoc	_	I-p
2395	15048	15059	interaction	interaction	NN	_	_	I-cesDoc	_	I-p
2396	15060	15062	of	of	IN	_	_	I-cesDoc	_	I-p
2397	15063	15068	these	these	DT	_	_	I-cesDoc	_	I-p
2398	15069	15076	factors	factor	NNS	_	_	I-cesDoc	_	I-p
2399	15076	15077	.	.	.	_	_	I-cesDoc	_	I-p
2400	15086	15089	Our	our	PRP$	_	_	I-cesDoc	_	I-p
2401	15090	15097	results	result	NNS	_	_	I-cesDoc	_	I-p
2402	15098	15102	show	show	VBP	_	_	I-cesDoc	_	I-p
2403	15103	15107	that	that	DT	_	_	I-cesDoc	_	I-p
2404	15108	15119	stimulation	stimulation	NN	_	_	I-cesDoc	_	I-p
2405	15120	15122	of	of	IN	_	_	I-cesDoc	_	I-p
2406	15123	15130	primary	primary	JJ	_	_	I-cesDoc	_	I-p
2407	15131	15139	cultures	culture	NNS	_	_	I-cesDoc	_	I-p
2408	15140	15142	of	of	IN	_	_	I-cesDoc	_	I-p
2409	15151	15156	human	human	JJ	_	_	I-cesDoc	_	I-p
2410	15157	15161	lung	lung	NN	_	_	I-cesDoc	_	I-p
2411	15162	15173	fibroblasts	fibroblast	NNS	_	_	I-cesDoc	_	I-p
2412	15174	15178	with	with	IN	_	_	I-cesDoc	_	I-p
2413	15179	15182	the	the	DT	_	_	I-cesDoc	_	I-p
2414	15183	15191	proximal	proximal	NN	_	_	I-cesDoc	_	I-p
2415	15192	15200	cytokine	cytokine	NN	_	_	I-cesDoc	_	I-p
2416	15201	15206	IL-1?	il-1?	NNP	_	_	I-cesDoc	_	I-p
2417	15215	15226	upregulates	upregulate	NNS	_	_	I-cesDoc	_	I-p
2418	15227	15232	COX-2	cox-2	NNP	_	_	I-cesDoc	_	I-p
2419	15233	15240	protein	protein	NN	_	_	I-cesDoc	_	I-p
2420	15241	15244	and	and	CC	_	_	I-cesDoc	_	I-p
2421	15245	15249	mRNA	mrna	NN	_	_	I-cesDoc	_	I-p
2422	15250	15260	expression	expression	NN	_	_	I-cesDoc	_	I-p
2423	15261	15263	to	to	TO	_	_	I-cesDoc	_	I-p
2424	15264	15265	a	a	DT	_	_	I-cesDoc	_	I-p
2425	15266	15273	similar	similar	JJ	_	_	I-cesDoc	_	I-p
2426	15282	15288	degree	degree	NN	_	_	I-cesDoc	_	I-p
2427	15289	15291	in	in	IN	_	_	I-cesDoc	_	I-p
2428	15292	15298	normal	normal	JJ	_	_	I-cesDoc	_	I-p
2429	15299	15302	and	and	CC	_	_	I-cesDoc	_	I-p
2430	15303	15306	IPF	ipf	NNP	_	_	I-cesDoc	_	I-p
2431	15307	15318	fibroblasts	fibroblast	NNS	_	_	I-cesDoc	_	I-p
2432	15318	15319	.	.	.	_	_	I-cesDoc	_	I-p
2433	15320	15323	TXA	txa	NNP	_	_	I-cesDoc	_	I-p
2434	15333	15334	2	2	CD	_	_	I-cesDoc	_	I-p
2435	15335	15345	production	production	NN	_	_	I-cesDoc	_	I-p
2436	15346	15352	tended	tend	VBD	_	_	I-cesDoc	_	I-p
2437	15353	15355	to	to	TO	_	_	I-cesDoc	_	I-p
2438	15356	15358	be	be	VB	_	_	I-cesDoc	_	I-p
2439	15359	15366	greater	greater	JJR	_	_	I-cesDoc	_	I-p
2440	15367	15369	in	in	IN	_	_	I-cesDoc	_	I-p
2441	15370	15373	IPF	ipf	NNP	_	_	I-cesDoc	_	I-p
2442	15382	15386	than	than	IN	_	_	I-cesDoc	_	I-p
2443	15387	15389	in	in	IN	_	_	I-cesDoc	_	I-p
2444	15390	15396	normal	normal	JJ	_	_	I-cesDoc	_	I-p
2445	15397	15408	fibroblasts	fibroblast	NNS	_	_	I-cesDoc	_	I-p
2446	15409	15411	at	at	IN	_	_	I-cesDoc	_	I-p
2447	15412	15420	baseline	baseline	NN	_	_	I-cesDoc	_	I-p
2448	15420	15421	;	;	:	_	_	I-cesDoc	_	I-p
2449	15422	15426	when	when	WRB	_	_	I-cesDoc	_	I-p
2450	15427	15437	stimulated	stimulate	VBN	_	_	I-cesDoc	_	I-p
2451	15446	15450	with	with	IN	_	_	I-cesDoc	_	I-p
2452	15451	15456	IL-1?	il-1?	NNP	_	_	I-cesDoc	_	I-p
2453	15457	15461	this	this	DT	_	_	I-cesDoc	_	I-p
2454	15462	15472	difference	difference	NN	_	_	I-cesDoc	_	I-p
2455	15473	15479	became	become	VBD	_	_	I-cesDoc	_	I-p
2456	15480	15493	statistically	statistically	RB	_	_	I-cesDoc	_	I-p
2457	15502	15513	significant	significant	JJ	_	_	I-cesDoc	_	I-p
2458	15513	15514	.	.	.	_	_	I-cesDoc	_	I-p
2459	15515	15518	The	the	DT	_	_	I-cesDoc	_	I-p
2460	15519	15524	ratio	ratio	NN	_	_	I-cesDoc	_	I-p
2461	15525	15527	of	of	IN	_	_	I-cesDoc	_	I-p
2462	15528	15531	PGI	pgi	NNP	_	_	I-cesDoc	_	I-p
2463	15541	15542	2	2	CD	_	_	I-cesDoc	_	I-p
2464	15543	15545	to	to	TO	_	_	I-cesDoc	_	I-p
2465	15546	15549	TXA	txa	NNP	_	_	I-cesDoc	_	I-p
2466	15559	15560	2	2	CD	_	_	I-cesDoc	_	I-p
2467	15561	15572	metabolites	metabolite	NNS	_	_	I-cesDoc	_	I-p
2468	15573	15576	was	be	VBD	_	_	I-cesDoc	_	I-p
2469	15577	15582	lower	lower	JJR	_	_	I-cesDoc	_	I-p
2470	15583	15585	in	in	IN	_	_	I-cesDoc	_	I-p
2471	15586	15589	IPF	ipf	NNP	_	_	I-cesDoc	_	I-p
2472	15598	15609	fibroblasts	fibroblast	NNS	_	_	I-cesDoc	_	I-p
2473	15610	15612	at	at	IN	_	_	I-cesDoc	_	I-p
2474	15613	15621	baseline	baseline	NN	_	_	I-cesDoc	_	I-p
2475	15622	15625	and	and	CC	_	_	I-cesDoc	_	I-p
2476	15626	15630	with	with	IN	_	_	I-cesDoc	_	I-p
2477	15631	15636	IL-1?	il-1?	NNP	_	_	I-cesDoc	_	I-p
2478	15637	15648	stimulation	stimulation	NN	_	_	I-cesDoc	_	I-p
2479	15648	15649	.	.	.	_	_	I-cesDoc	_	I-p
2480	15650	15653	The	the	DT	_	_	I-cesDoc	_	I-p
2481	15662	15667	above	above	IN	_	_	I-cesDoc	_	I-p
2482	15668	15675	results	result	NNS	_	_	I-cesDoc	_	I-p
2483	15676	15683	suggest	suggest	VBP	_	_	I-cesDoc	_	I-p
2484	15684	15688	that	that	IN	_	_	I-cesDoc	_	I-p
2485	15689	15690	a	a	DT	_	_	I-cesDoc	_	I-p
2486	15691	15700	decreased	decrease	VBN	_	_	I-cesDoc	_	I-p
2487	15701	15704	PGI	pgi	NNP	_	_	I-cesDoc	_	I-p
2488	15714	15715	2	2	CD	_	_	I-cesDoc	_	I-p
2489	15716	15717	:	:	:	_	_	I-cesDoc	_	I-p
2490	15717	15720	TXA	txa	NNP	_	_	I-cesDoc	_	I-p
2491	15730	15731	2	2	CD	_	_	I-cesDoc	_	I-p
2492	15732	15737	ratio	ratio	NN	_	_	I-cesDoc	_	I-p
2493	15738	15743	could	could	MD	_	_	I-cesDoc	_	I-p
2494	15744	15746	be	be	VB	_	_	I-cesDoc	_	I-p
2495	15747	15748	a	a	DT	_	_	I-cesDoc	_	I-p
2496	15749	15759	phenotypic	phenotypic	JJ	_	_	I-cesDoc	_	I-p
2497	15760	15770	alteration	alteration	NN	_	_	I-cesDoc	_	I-p
2498	15779	15786	present	present	JJ	_	_	I-cesDoc	_	I-p
2499	15787	15789	in	in	IN	_	_	I-cesDoc	_	I-p
2500	15790	15793	IPF	ipf	NNP	_	_	I-cesDoc	_	I-p
2501	15794	15805	fibroblasts	fibroblast	NNS	_	_	I-cesDoc	_	I-p
2502	15805	15806	,	,	,	_	_	I-cesDoc	_	I-p
2503	15807	15816	resulting	result	VBG	_	_	I-cesDoc	_	I-p
2504	15817	15819	in	in	IN	_	_	I-cesDoc	_	I-p
2505	15820	15821	a	a	DT	_	_	I-cesDoc	_	I-p
2506	15822	15826	loss	loss	NN	_	_	I-cesDoc	_	I-p
2507	15827	15829	of	of	IN	_	_	I-cesDoc	_	I-p
2508	15830	15835	their	their	PRP$	_	_	I-cesDoc	_	I-p
2509	15844	15852	capacity	capacity	NN	_	_	I-cesDoc	_	I-p
2510	15853	15855	to	to	TO	_	_	I-cesDoc	_	I-p
2511	15856	15868	autoregulate	autoregulate	NN	_	_	I-cesDoc	_	I-p
2512	15869	15882	proliferation	proliferation	NN	_	_	I-cesDoc	_	I-p
2513	15883	15886	and	and	CC	_	_	I-cesDoc	_	I-p
2514	15887	15900	extracellular	extracellular	NN	_	_	I-cesDoc	_	I-p
2515	15909	15915	matrix	matrix	NN	_	_	I-cesDoc	_	I-p
2516	15916	15926	production	production	NN	_	_	I-cesDoc	_	I-p
2517	15926	15927	.	.	.	_	_	I-cesDoc	_	I-p
2518	15936	15939	The	the	DT	_	_	I-cesDoc	_	I-p
2519	15940	15947	effects	effect	NNS	_	_	I-cesDoc	_	I-p
2520	15948	15950	of	of	IN	_	_	I-cesDoc	_	I-p
2521	15951	15954	PGs	pgs	NNP	_	_	I-cesDoc	_	I-p
2522	15955	15957	on	on	IN	_	_	I-cesDoc	_	I-p
2523	15958	15962	cell	cell	NN	_	_	I-cesDoc	_	I-p
2524	15963	15976	proliferation	proliferation	NN	_	_	I-cesDoc	_	I-p
2525	15977	15980	and	and	CC	_	_	I-cesDoc	_	I-p
2526	15981	15989	collagen	collagen	NN	_	_	I-cesDoc	_	I-p
2527	15998	16008	production	production	NN	_	_	I-cesDoc	_	I-p
2528	16009	16013	have	have	VBP	_	_	I-cesDoc	_	I-p
2529	16014	16018	been	be	VBN	_	_	I-cesDoc	_	I-p
2530	16019	16025	widely	widely	RB	_	_	I-cesDoc	_	I-p
2531	16026	16033	studied	study	VBN	_	_	I-cesDoc	_	I-p
2532	16034	16036	in	in	IN	_	_	I-cesDoc	_	I-p
2533	16037	16046	different	different	JJ	_	_	I-cesDoc	_	I-p
2534	16047	16051	cell	cell	NN	_	_	I-cesDoc	_	I-p
2535	16052	16057	types	type	NNS	_	_	I-cesDoc	_	I-p
2536	16066	16067	[	[	NN	_	_	I-cesDoc	_	I-p
2537	16068	16070	13	13	CD	_	_	I-cesDoc	_	I-p
2538	16071	16073	14	14	CD	_	_	I-cesDoc	_	I-p
2539	16074	16076	15	15	CD	_	_	I-cesDoc	_	I-p
2540	16077	16079	16	16	CD	_	_	I-cesDoc	_	I-p
2541	16080	16082	17	17	CD	_	_	I-cesDoc	_	I-p
2542	16083	16085	26	26	CD	_	_	I-cesDoc	_	I-p
2543	16086	16087	]	]	NN	_	_	I-cesDoc	_	I-p
2544	16088	16089	.	.	.	_	_	I-cesDoc	_	I-p
2545	16090	16093	TXA	txa	NNP	_	_	I-cesDoc	_	I-p
2546	16103	16104	2	2	CD	_	_	I-cesDoc	_	I-p
2547	16105	16108	has	have	VBZ	_	_	I-cesDoc	_	I-p
2548	16109	16113	been	be	VBN	_	_	I-cesDoc	_	I-p
2549	16114	16121	studied	study	VBN	_	_	I-cesDoc	_	I-p
2550	16122	16133	extensively	extensively	RB	_	_	I-cesDoc	_	I-p
2551	16134	16141	because	because	IN	_	_	I-cesDoc	_	I-p
2552	16150	16152	of	of	IN	_	_	I-cesDoc	_	I-p
2553	16153	16156	its	its	PRP$	_	_	I-cesDoc	_	I-p
2554	16157	16165	apparent	apparent	JJ	_	_	I-cesDoc	_	I-p
2555	16166	16170	role	role	NN	_	_	I-cesDoc	_	I-p
2556	16171	16173	in	in	IN	_	_	I-cesDoc	_	I-p
2557	16174	16189	atherosclerosis	atherosclerosis	NNS	_	_	I-cesDoc	_	I-p
2558	16189	16190	,	,	,	_	_	I-cesDoc	_	I-p
2559	16191	16194	due	due	JJ	_	_	I-cesDoc	_	I-p
2560	16195	16197	to	to	TO	_	_	I-cesDoc	_	I-p
2561	16198	16201	its	its	PRP$	_	_	I-cesDoc	_	I-p
2562	16210	16223	prothrombotic	prothrombotic	JJ	_	_	I-cesDoc	_	I-p
2563	16224	16227	and	and	CC	_	_	I-cesDoc	_	I-p
2564	16228	16237	mitogenic	mitogenic	JJ	_	_	I-cesDoc	_	I-p
2565	16238	16248	activities	activity	NNS	_	_	I-cesDoc	_	I-p
2566	16249	16251	on	on	IN	_	_	I-cesDoc	_	I-p
2567	16252	16260	vascular	vascular	NN	_	_	I-cesDoc	_	I-p
2568	16261	16267	smooth	smooth	JJ	_	_	I-cesDoc	_	I-p
2569	16276	16282	muscle	muscle	NN	_	_	I-cesDoc	_	I-p
2570	16283	16288	cells	cell	NNS	_	_	I-cesDoc	_	I-p
2571	16289	16290	[	[	NN	_	_	I-cesDoc	_	I-p
2572	16291	16293	15	15	CD	_	_	I-cesDoc	_	I-p
2573	16294	16296	16	16	CD	_	_	I-cesDoc	_	I-p
2574	16297	16298	]	]	NN	_	_	I-cesDoc	_	I-p
2575	16299	16300	.	.	.	_	_	I-cesDoc	_	I-p
2576	16301	16306	These	these	DT	_	_	I-cesDoc	_	I-p
2577	16307	16316	mitogenic	mitogenic	JJ	_	_	I-cesDoc	_	I-p
2578	16317	16324	effects	effect	NNS	_	_	I-cesDoc	_	I-p
2579	16325	16328	are	be	VBP	_	_	I-cesDoc	_	I-p
2580	16337	16348	potentiated	potentiated	JJ	_	_	I-cesDoc	_	I-p
2581	16349	16351	by	by	IN	_	_	I-cesDoc	_	I-p
2582	16352	16358	growth	growth	NN	_	_	I-cesDoc	_	I-p
2583	16359	16366	factors	factor	NNS	_	_	I-cesDoc	_	I-p
2584	16367	16368	[	[	NN	_	_	I-cesDoc	_	I-p
2585	16369	16371	15	15	CD	_	_	I-cesDoc	_	I-p
2586	16372	16374	16	16	CD	_	_	I-cesDoc	_	I-p
2587	16375	16377	27	27	CD	_	_	I-cesDoc	_	I-p
2588	16378	16380	28	28	CD	_	_	I-cesDoc	_	I-p
2589	16381	16382	]	]	NN	_	_	I-cesDoc	_	I-p
2590	16383	16384	.	.	.	_	_	I-cesDoc	_	I-p
2591	16385	16387	In	in	IN	_	_	I-cesDoc	_	I-p
2592	16388	16396	vascular	vascular	NN	_	_	I-cesDoc	_	I-p
2593	16405	16411	smooth	smooth	JJ	_	_	I-cesDoc	_	I-p
2594	16412	16418	muscle	muscle	NN	_	_	I-cesDoc	_	I-p
2595	16419	16424	cells	cell	NNS	_	_	I-cesDoc	_	I-p
2596	16425	16428	TXA	txa	NNP	_	_	I-cesDoc	_	I-p
2597	16438	16439	2	2	CD	_	_	I-cesDoc	_	I-p
2598	16440	16450	stimulates	stimulate	NNS	_	_	I-cesDoc	_	I-p
2599	16451	16460	synthesis	synthesis	NN	_	_	I-cesDoc	_	I-p
2600	16461	16463	of	of	IN	_	_	I-cesDoc	_	I-p
2601	16464	16468	bFGF	bfgf	NN	_	_	I-cesDoc	_	I-p
2602	16469	16472	and	and	CC	_	_	I-cesDoc	_	I-p
2603	16481	16490	increases	increase	VBZ	_	_	I-cesDoc	_	I-p
2604	16491	16494	the	the	DT	_	_	I-cesDoc	_	I-p
2605	16495	16505	expression	expression	NN	_	_	I-cesDoc	_	I-p
2606	16506	16508	of	of	IN	_	_	I-cesDoc	_	I-p
2607	16509	16512	the	the	DT	_	_	I-cesDoc	_	I-p
2608	16513	16518	proto	proto	JJ	_	_	I-cesDoc	_	I-p
2609	16518	16519	-	-	-	_	_	I-cesDoc	_	I-p
2610	16519	16528	oncogenes	oncogene	NNS	_	_	I-cesDoc	_	I-p
2611	16538	16543	c-fos	c-fos	JJ	_	_	I-cesDoc	_	I-p
2612	16544	16545	,	,	,	_	_	I-cesDoc	_	I-p
2613	16555	16560	c-myc	c-myc	JJ	_	_	I-cesDoc	_	I-p
2614	16561	16562	,	,	,	_	_	I-cesDoc	_	I-p
2615	16563	16566	and	and	CC	_	_	I-cesDoc	_	I-p
2616	16576	16581	egr-1	egr-1	NN	_	_	I-cesDoc	_	I-p
2617	16582	16583	,	,	,	_	_	I-cesDoc	_	I-p
2618	16584	16589	which	which	WDT	_	_	I-cesDoc	_	I-p
2619	16590	16593	are	be	VBP	_	_	I-cesDoc	_	I-p
2620	16594	16604	associated	associate	VBN	_	_	I-cesDoc	_	I-p
2621	16605	16609	with	with	IN	_	_	I-cesDoc	_	I-p
2622	16618	16623	entry	entry	NN	_	_	I-cesDoc	_	I-p
2623	16624	16628	into	into	IN	_	_	I-cesDoc	_	I-p
2624	16629	16632	the	the	DT	_	_	I-cesDoc	_	I-p
2625	16633	16637	cell	cell	NN	_	_	I-cesDoc	_	I-p
2626	16638	16644	growth	growth	NN	_	_	I-cesDoc	_	I-p
2627	16645	16650	cycle	cycle	NN	_	_	I-cesDoc	_	I-p
2628	16651	16652	[	[	NN	_	_	I-cesDoc	_	I-p
2629	16653	16655	15	15	CD	_	_	I-cesDoc	_	I-p
2630	16656	16657	]	]	NN	_	_	I-cesDoc	_	I-p
2631	16658	16659	.	.	.	_	_	I-cesDoc	_	I-p
2632	16660	16662	In	in	IN	_	_	I-cesDoc	_	I-p
2633	16663	16671	addition	addition	NN	_	_	I-cesDoc	_	I-p
2634	16671	16672	,	,	,	_	_	I-cesDoc	_	I-p
2635	16673	16676	TXA	txa	NNP	_	_	I-cesDoc	_	I-p
2636	16686	16687	2	2	CD	_	_	I-cesDoc	_	I-p
2637	16688	16697	increases	increase	NNS	_	_	I-cesDoc	_	I-p
2638	16698	16711	proliferation	proliferation	NN	_	_	I-cesDoc	_	I-p
2639	16712	16714	of	of	IN	_	_	I-cesDoc	_	I-p
2640	16715	16726	fibroblasts	fibroblast	NNS	_	_	I-cesDoc	_	I-p
2641	16735	16736	[	[	NN	_	_	I-cesDoc	_	I-p
2642	16737	16739	13	13	CD	_	_	I-cesDoc	_	I-p
2643	16740	16741	]	]	NN	_	_	I-cesDoc	_	I-p
2644	16742	16745	and	and	CC	_	_	I-cesDoc	_	I-p
2645	16746	16752	smooth	smooth	JJ	_	_	I-cesDoc	_	I-p
2646	16753	16759	muscle	muscle	NN	_	_	I-cesDoc	_	I-p
2647	16759	16760	-	-	-	_	_	I-cesDoc	_	I-p
2648	16760	16764	like	like	IN	_	_	I-cesDoc	_	I-p
2649	16765	16775	glomerular	glomerular	NN	_	_	I-cesDoc	_	I-p
2650	16776	16785	mesangial	mesangial	NN	_	_	I-cesDoc	_	I-p
2651	16786	16791	cells	cell	NNS	_	_	I-cesDoc	_	I-p
2652	16792	16793	[	[	NN	_	_	I-cesDoc	_	I-p
2653	16802	16804	14	14	CD	_	_	I-cesDoc	_	I-p
2654	16805	16806	]	]	NN	_	_	I-cesDoc	_	I-p
2655	16807	16808	.	.	.	_	_	I-cesDoc	_	I-p
2656	16817	16819	On	on	IN	_	_	I-cesDoc	_	I-p
2657	16820	16823	the	the	DT	_	_	I-cesDoc	_	I-p
2658	16824	16829	other	other	JJ	_	_	I-cesDoc	_	I-p
2659	16830	16834	hand	hand	NN	_	_	I-cesDoc	_	I-p
2660	16834	16835	,	,	,	_	_	I-cesDoc	_	I-p
2661	16836	16839	PGI	pgi	NNP	_	_	I-cesDoc	_	I-p
2662	16849	16850	2	2	CD	_	_	I-cesDoc	_	I-p
2663	16851	16860	decreases	decrease	NNS	_	_	I-cesDoc	_	I-p
2664	16861	16869	vascular	vascular	NN	_	_	I-cesDoc	_	I-p
2665	16870	16876	smooth	smooth	JJ	_	_	I-cesDoc	_	I-p
2666	16877	16883	muscle	muscle	NN	_	_	I-cesDoc	_	I-p
2667	16884	16888	cell	cell	NN	_	_	I-cesDoc	_	I-p
2668	16897	16910	proliferation	proliferation	NN	_	_	I-cesDoc	_	I-p
2669	16911	16914	and	and	CC	_	_	I-cesDoc	_	I-p
2670	16915	16923	collagen	collagen	NN	_	_	I-cesDoc	_	I-p
2671	16924	16927	and	and	CC	_	_	I-cesDoc	_	I-p
2672	16928	16946	glycosaminoglycane	glycosaminoglycane	NN	_	_	I-cesDoc	_	I-p
2673	16955	16964	synthesis	synthesis	NN	_	_	I-cesDoc	_	I-p
2674	16964	16965	,	,	,	_	_	I-cesDoc	_	I-p
2675	16966	16969	via	via	IN	_	_	I-cesDoc	_	I-p
2676	16970	16980	activation	activation	NN	_	_	I-cesDoc	_	I-p
2677	16981	16983	of	of	IN	_	_	I-cesDoc	_	I-p
2678	16984	16992	adenylyl	adenylyl	NN	_	_	I-cesDoc	_	I-p
2679	16993	17000	cyclase	cyclase	NN	_	_	I-cesDoc	_	I-p
2680	17001	17004	and	and	CC	_	_	I-cesDoc	_	I-p
2681	17013	17023	subsequent	subsequent	JJ	_	_	I-cesDoc	_	I-p
2682	17024	17034	production	production	NN	_	_	I-cesDoc	_	I-p
2683	17035	17037	of	of	IN	_	_	I-cesDoc	_	I-p
2684	17038	17042	cAMP	camp	NN	_	_	I-cesDoc	_	I-p
2685	17043	17044	[	[	NN	_	_	I-cesDoc	_	I-p
2686	17045	17047	17	17	CD	_	_	I-cesDoc	_	I-p
2687	17048	17049	]	]	NN	_	_	I-cesDoc	_	I-p
2688	17050	17051	.	.	.	_	_	I-cesDoc	_	I-p
2689	17052	17061	Betaprost	betaprost	NNP	_	_	I-cesDoc	_	I-p
2690	17061	17062	,	,	,	_	_	I-cesDoc	_	I-p
2691	17063	17065	an	an	DT	_	_	I-cesDoc	_	I-p
2692	17066	17072	analog	analog	NN	_	_	I-cesDoc	_	I-p
2693	17081	17083	of	of	IN	_	_	I-cesDoc	_	I-p
2694	17084	17087	PGI	pgi	NNP	_	_	I-cesDoc	_	I-p
2695	17097	17098	2	2	CD	_	_	I-cesDoc	_	I-p
2696	17099	17100	,	,	,	_	_	I-cesDoc	_	I-p
2697	17101	17110	decreases	decrease	NNS	_	_	I-cesDoc	_	I-p
2698	17111	17122	procollagen	procollagen	NN	_	_	I-cesDoc	_	I-p
2699	17123	17124	I	i	PRP	_	_	I-cesDoc	_	I-p
2700	17125	17128	and	and	CC	_	_	I-cesDoc	_	I-p
2701	17129	17132	III	iii	NNP	_	_	I-cesDoc	_	I-p
2702	17133	17137	mRNA	mrna	NN	_	_	I-cesDoc	_	I-p
2703	17146	17156	expression	expression	NN	_	_	I-cesDoc	_	I-p
2704	17157	17159	in	in	IN	_	_	I-cesDoc	_	I-p
2705	17160	17167	cardiac	cardiac	JJ	_	_	I-cesDoc	_	I-p
2706	17168	17179	fibroblasts	fibroblast	NNS	_	_	I-cesDoc	_	I-p
2707	17180	17181	[	[	NN	_	_	I-cesDoc	_	I-p
2708	17182	17184	18	18	CD	_	_	I-cesDoc	_	I-p
2709	17185	17186	]	]	NN	_	_	I-cesDoc	_	I-p
2710	17187	17188	.	.	.	_	_	I-cesDoc	_	I-p
2711	17189	17194	These	these	DT	_	_	I-cesDoc	_	I-p
2712	17195	17202	effects	effect	NNS	_	_	I-cesDoc	_	I-p
2713	17211	17214	may	may	MD	_	_	I-cesDoc	_	I-p
2714	17215	17225	counteract	counteract	VB	_	_	I-cesDoc	_	I-p
2715	17226	17229	the	the	DT	_	_	I-cesDoc	_	I-p
2716	17230	17241	profibrotic	profibrotic	JJ	_	_	I-cesDoc	_	I-p
2717	17242	17249	effects	effect	NNS	_	_	I-cesDoc	_	I-p
2718	17250	17254	seen	see	VBN	_	_	I-cesDoc	_	I-p
2719	17255	17259	with	with	IN	_	_	I-cesDoc	_	I-p
2720	17260	17263	TXA	txa	NNP	_	_	I-cesDoc	_	I-p
2721	17273	17274	2	2	CD	_	_	I-cesDoc	_	I-p
2722	17275	17278	and	and	CC	_	_	I-cesDoc	_	I-p
2723	17279	17281	it	it	PRP	_	_	I-cesDoc	_	I-p
2724	17282	17284	is	be	VBZ	_	_	I-cesDoc	_	I-p
2725	17285	17293	possible	possible	JJ	_	_	I-cesDoc	_	I-p
2726	17294	17298	that	that	IN	_	_	I-cesDoc	_	I-p
2727	17299	17301	an	an	DT	_	_	I-cesDoc	_	I-p
2728	17302	17312	alteration	alteration	NN	_	_	I-cesDoc	_	I-p
2729	17321	17323	of	of	IN	_	_	I-cesDoc	_	I-p
2730	17324	17325	a	a	DT	_	_	I-cesDoc	_	I-p
2731	17326	17327	""	""	''	_	_	I-cesDoc	_	I-p
2732	17327	17333	normal	normal	JJ	_	_	I-cesDoc	_	I-p
2733	17333	17334	""	""	''	_	_	I-cesDoc	_	I-p
2734	17335	17346	physiologic	physiologic	JJ	_	_	I-cesDoc	_	I-p
2735	17347	17354	balance	balance	NN	_	_	I-cesDoc	_	I-p
2736	17355	17362	between	between	IN	_	_	I-cesDoc	_	I-p
2737	17363	17366	PGI	pgi	NNP	_	_	I-cesDoc	_	I-p
2738	17376	17377	2	2	CD	_	_	I-cesDoc	_	I-p
2739	17378	17381	and	and	CC	_	_	I-cesDoc	_	I-p
2740	17382	17385	TXA	txa	NNP	_	_	I-cesDoc	_	I-p
2741	17395	17396	2	2	CD	_	_	I-cesDoc	_	I-p
2742	17397	17402	could	could	MD	_	_	I-cesDoc	_	I-p
2743	17403	17411	increase	increase	VB	_	_	I-cesDoc	_	I-p
2744	17412	17420	tendency	tendency	NN	_	_	I-cesDoc	_	I-p
2745	17421	17428	towards	towards	IN	_	_	I-cesDoc	_	I-p
2746	17437	17449	fibrogenesis	fibrogenesis	NNS	_	_	I-cesDoc	_	I-p
2747	17449	17450	.	.	.	_	_	I-cesDoc	_	I-p
2748	17459	17461	It	it	PRP	_	_	I-cesDoc	_	I-p
2749	17462	17464	is	be	VBZ	_	_	I-cesDoc	_	I-p
2750	17465	17474	important	important	JJ	_	_	I-cesDoc	_	I-p
2751	17475	17477	to	to	TO	_	_	I-cesDoc	_	I-p
2752	17478	17485	mention	mention	VB	_	_	I-cesDoc	_	I-p
2753	17486	17490	that	that	IN	_	_	I-cesDoc	_	I-p
2754	17491	17494	our	our	PRP$	_	_	I-cesDoc	_	I-p
2755	17495	17506	experiments	experiment	NNS	_	_	I-cesDoc	_	I-p
2756	17507	17511	were	be	VBD	_	_	I-cesDoc	_	I-p
2757	17520	17529	conducted	conduct	VBN	_	_	I-cesDoc	_	I-p
2758	17530	17532	at	at	IN	_	_	I-cesDoc	_	I-p
2759	17533	17540	similar	similar	JJ	_	_	I-cesDoc	_	I-p
2760	17541	17548	passage	passage	NN	_	_	I-cesDoc	_	I-p
2761	17549	17555	levels	level	NNS	_	_	I-cesDoc	_	I-p
2762	17556	17557	(	(	(	_	_	I-cesDoc	_	I-p
2763	17557	17564	passage	passage	NN	_	_	I-cesDoc	_	I-p
2764	17565	17566	6	6	CD	_	_	I-cesDoc	_	I-p
2765	17567	17569	to	to	TO	_	_	I-cesDoc	_	I-p
2766	17570	17571	8	8	CD	_	_	I-cesDoc	_	I-p
2767	17571	17572	)	)	)	_	_	I-cesDoc	_	I-p
2768	17573	17575	in	in	IN	_	_	I-cesDoc	_	I-p
2769	17584	17588	both	both	DT	_	_	I-cesDoc	_	I-p
2770	17589	17595	groups	group	NNS	_	_	I-cesDoc	_	I-p
2771	17595	17596	,	,	,	_	_	I-cesDoc	_	I-p
2772	17597	17602	since	since	IN	_	_	I-cesDoc	_	I-p
2773	17603	17613	senescence	senescence	NN	_	_	I-cesDoc	_	I-p
2774	17614	17616	of	of	IN	_	_	I-cesDoc	_	I-p
2775	17617	17628	fibroblasts	fibroblast	NNS	_	_	I-cesDoc	_	I-p
2776	17629	17631	is	be	VBZ	_	_	I-cesDoc	_	I-p
2777	17632	17642	associated	associate	VBN	_	_	I-cesDoc	_	I-p
2778	17651	17655	with	with	IN	_	_	I-cesDoc	_	I-p
2779	17656	17657	a	a	DT	_	_	I-cesDoc	_	I-p
2780	17658	17663	shift	shift	NN	_	_	I-cesDoc	_	I-p
2781	17664	17668	from	from	IN	_	_	I-cesDoc	_	I-p
2782	17669	17672	the	the	DT	_	_	I-cesDoc	_	I-p
2783	17673	17685	biosynthesis	biosynthesis	NNS	_	_	I-cesDoc	_	I-p
2784	17686	17688	of	of	IN	_	_	I-cesDoc	_	I-p
2785	17689	17692	PGI	pgi	NNP	_	_	I-cesDoc	_	I-p
2786	17702	17703	2	2	CD	_	_	I-cesDoc	_	I-p
2787	17704	17706	to	to	TO	_	_	I-cesDoc	_	I-p
2788	17707	17710	TXA	txa	NNP	_	_	I-cesDoc	_	I-p
2789	17720	17721	2	2	CD	_	_	I-cesDoc	_	I-p
2790	17722	17723	[	[	NN	_	_	I-cesDoc	_	I-p
2791	17724	17726	24	24	CD	_	_	I-cesDoc	_	I-p
2792	17727	17729	25	25	CD	_	_	I-cesDoc	_	I-p
2793	17730	17731	]	]	NN	_	_	I-cesDoc	_	I-p
2794	17732	17733	.	.	.	_	_	I-cesDoc	_	I-p
2795	17734	17736	It	it	PRP	_	_	I-cesDoc	_	I-p
2796	17737	17739	is	be	VBZ	_	_	I-cesDoc	_	I-p
2797	17740	17748	possible	possible	JJ	_	_	I-cesDoc	_	I-p
2798	17749	17753	that	that	IN	_	_	I-cesDoc	_	I-p
2799	17754	17757	the	the	DT	_	_	I-cesDoc	_	I-p
2800	17766	17776	difference	difference	NN	_	_	I-cesDoc	_	I-p
2801	17777	17781	seen	see	VBN	_	_	I-cesDoc	_	I-p
2802	17782	17784	in	in	IN	_	_	I-cesDoc	_	I-p
2803	17785	17788	our	our	PRP$	_	_	I-cesDoc	_	I-p
2804	17789	17794	study	study	NN	_	_	I-cesDoc	_	I-p
2805	17795	17802	between	between	IN	_	_	I-cesDoc	_	I-p
2806	17803	17809	HF-IPF	hf-ipf	NNP	_	_	I-cesDoc	_	I-p
2807	17810	17813	and	and	CC	_	_	I-cesDoc	_	I-p
2808	17814	17819	HF-NL	hf-nl	NNP	_	_	I-cesDoc	_	I-p
2809	17820	17825	could	could	MD	_	_	I-cesDoc	_	I-p
2810	17834	17840	result	result	VB	_	_	I-cesDoc	_	I-p
2811	17841	17845	from	from	IN	_	_	I-cesDoc	_	I-p
2812	17846	17855	comparing	compare	VBG	_	_	I-cesDoc	_	I-p
2813	17856	17867	fibroblasts	fibroblast	NNS	_	_	I-cesDoc	_	I-p
2814	17868	17870	of	of	IN	_	_	I-cesDoc	_	I-p
2815	17871	17880	different	different	JJ	_	_	I-cesDoc	_	I-p
2816	17881	17885	ages	age	NNS	_	_	I-cesDoc	_	I-p
2817	17885	17886	.	.	.	_	_	I-cesDoc	_	I-p
2818	17887	17893	HF-IPF	hf-ipf	NNP	_	_	I-cesDoc	_	I-p
2819	17902	17907	might	might	MD	_	_	I-cesDoc	_	I-p
2820	17908	17912	have	have	VB	_	_	I-cesDoc	_	I-p
2821	17913	17917	been	be	VBN	_	_	I-cesDoc	_	I-p
2822	17918	17927	harvested	harvest	VBN	_	_	I-cesDoc	_	I-p
2823	17928	17932	from	from	IN	_	_	I-cesDoc	_	I-p
2824	17933	17941	fibrotic	fibrotic	JJ	_	_	I-cesDoc	_	I-p
2825	17942	17949	lesions	lesion	NNS	_	_	I-cesDoc	_	I-p
2826	17950	17955	where	where	WRB	_	_	I-cesDoc	_	I-p
2827	17964	17975	fibroblasts	fibroblast	NNS	_	_	I-cesDoc	_	I-p
2828	17976	17979	had	have	VBD	_	_	I-cesDoc	_	I-p
2829	17980	17990	previously	previously	RB	_	_	I-cesDoc	_	I-p
2830	17991	18000	undergone	undergo	VBN	_	_	I-cesDoc	_	I-p
2831	18001	18002	a	a	DT	_	_	I-cesDoc	_	I-p
2832	18003	18010	greater	greater	JJR	_	_	I-cesDoc	_	I-p
2833	18011	18017	number	number	NN	_	_	I-cesDoc	_	I-p
2834	18018	18020	of	of	IN	_	_	I-cesDoc	_	I-p
2835	18029	18033	cell	cell	NN	_	_	I-cesDoc	_	I-p
2836	18034	18043	divisions	division	NNS	_	_	I-cesDoc	_	I-p
2837	18044	18048	than	than	IN	_	_	I-cesDoc	_	I-p
2838	18049	18054	HF-NL	hf-nl	NNP	_	_	I-cesDoc	_	I-p
2839	18054	18055	,	,	,	_	_	I-cesDoc	_	I-p
2840	18056	18064	obtained	obtain	VBN	_	_	I-cesDoc	_	I-p
2841	18065	18069	from	from	IN	_	_	I-cesDoc	_	I-p
2842	18070	18081	nonfibrotic	nonfibrotic	JJ	_	_	I-cesDoc	_	I-p
2843	18082	18087	lungs	lung	NNS	_	_	I-cesDoc	_	I-p
2844	18087	18088	.	.	.	_	_	I-cesDoc	_	I-p
2845	18097	18105	Although	although	IN	_	_	I-cesDoc	_	I-p
2846	18106	18110	this	this	DT	_	_	I-cesDoc	_	I-p
2847	18111	18113	is	be	VBZ	_	_	I-cesDoc	_	I-p
2848	18114	18115	a	a	DT	_	_	I-cesDoc	_	I-p
2849	18116	18127	possibility	possibility	NN	_	_	I-cesDoc	_	I-p
2850	18127	18128	,	,	,	_	_	I-cesDoc	_	I-p
2851	18129	18132	the	the	DT	_	_	I-cesDoc	_	I-p
2852	18133	18136	age	age	NN	_	_	I-cesDoc	_	I-p
2853	18136	18137	-	-	-	_	_	I-cesDoc	_	I-p
2854	18137	18144	related	relate	VBN	_	_	I-cesDoc	_	I-p
2855	18145	18150	shift	shift	NN	_	_	I-cesDoc	_	I-p
2856	18151	18153	in	in	IN	_	_	I-cesDoc	_	I-p
2857	18154	18156	PG	pg	NNP	_	_	I-cesDoc	_	I-p
2858	18165	18175	production	production	NN	_	_	I-cesDoc	_	I-p
2859	18176	18179	has	have	VBZ	_	_	I-cesDoc	_	I-p
2860	18180	18184	only	only	RB	_	_	I-cesDoc	_	I-p
2861	18185	18189	been	be	VBN	_	_	I-cesDoc	_	I-p
2862	18190	18195	shown	show	VBN	_	_	I-cesDoc	_	I-p
2863	18196	18198	at	at	IN	_	_	I-cesDoc	_	I-p
2864	18199	18203	very	very	RB	_	_	I-cesDoc	_	I-p
2865	18204	18208	high	high	JJ	_	_	I-cesDoc	_	I-p
2866	18209	18213	cell	cell	NN	_	_	I-cesDoc	_	I-p
2867	18214	18222	passages	passage	NNS	_	_	I-cesDoc	_	I-p
2868	18231	18234	and	and	CC	_	_	I-cesDoc	_	I-p
2869	18235	18238	has	have	VBZ	_	_	I-cesDoc	_	I-p
2870	18239	18242	not	not	RB	_	_	I-cesDoc	_	I-p
2871	18243	18247	been	be	VBN	_	_	I-cesDoc	_	I-p
2872	18248	18258	documented	document	VBN	_	_	I-cesDoc	_	I-p
2873	18268	18270	in	in	IN	_	_	I-cesDoc	_	I-p
2874	18271	18275	vivo	vivo	NN	_	_	I-cesDoc	_	I-p
2875	18276	18277	.	.	.	_	_	I-cesDoc	_	I-p
2876	18286	18288	We	we	PRP	_	_	I-cesDoc	_	I-p
2877	18289	18293	also	also	RB	_	_	I-cesDoc	_	I-p
2878	18294	18299	found	find	VBD	_	_	I-cesDoc	_	I-p
2879	18300	18304	that	that	IN	_	_	I-cesDoc	_	I-p
2880	18305	18309	both	both	DT	_	_	I-cesDoc	_	I-p
2881	18310	18316	HF-IPF	hf-ipf	NNP	_	_	I-cesDoc	_	I-p
2882	18317	18320	and	and	CC	_	_	I-cesDoc	_	I-p
2883	18321	18326	HF-NL	hf-nl	NNP	_	_	I-cesDoc	_	I-p
2884	18327	18330	had	have	VBD	_	_	I-cesDoc	_	I-p
2885	18331	18338	similar	similar	JJ	_	_	I-cesDoc	_	I-p
2886	18339	18342	PGE	pge	NNP	_	_	I-cesDoc	_	I-p
2887	18360	18361	2	2	CD	_	_	I-cesDoc	_	B-p
2888	18362	18372	production	production	NN	_	_	I-cesDoc	_	I-p
2889	18373	18375	at	at	IN	_	_	I-cesDoc	_	I-p
2890	18376	18384	baseline	baseline	NN	_	_	I-cesDoc	_	I-p
2891	18384	18385	,	,	,	_	_	I-cesDoc	_	I-p
2892	18386	18389	and	and	CC	_	_	I-cesDoc	_	I-p
2893	18390	18391	a	a	DT	_	_	I-cesDoc	_	I-p
2894	18392	18399	similar	similar	JJ	_	_	I-cesDoc	_	I-p
2895	18408	18416	increase	increase	NN	_	_	I-cesDoc	_	I-p
2896	18417	18421	when	when	WRB	_	_	I-cesDoc	_	I-p
2897	18422	18432	stimulated	stimulate	VBN	_	_	I-cesDoc	_	I-p
2898	18433	18437	with	with	IN	_	_	I-cesDoc	_	I-p
2899	18438	18443	IL-1?	il-1?	NNP	_	_	I-cesDoc	_	I-p
2900	18443	18444	.	.	.	_	_	I-cesDoc	_	I-p
2901	18445	18448	PGE	pge	NNP	_	_	I-cesDoc	_	I-p
2902	18458	18459	2	2	CD	_	_	I-cesDoc	_	I-p
2903	18460	18463	can	can	MD	_	_	I-cesDoc	_	I-p
2904	18464	18472	decrease	decrease	VB	_	_	I-cesDoc	_	I-p
2905	18473	18483	fibroblast	fibroblast	NN	_	_	I-cesDoc	_	I-p
2906	18484	18497	proliferation	proliferation	NN	_	_	I-cesDoc	_	I-p
2907	18506	18509	and	and	CC	_	_	I-cesDoc	_	I-p
2908	18510	18518	collagen	collagen	NN	_	_	I-cesDoc	_	I-p
2909	18519	18528	synthesis	synthesis	NN	_	_	I-cesDoc	_	I-p
2910	18528	18529	,	,	,	_	_	I-cesDoc	_	I-p
2911	18530	18533	and	and	CC	_	_	I-cesDoc	_	I-p
2912	18534	18542	increase	increase	NN	_	_	I-cesDoc	_	I-p
2913	18543	18551	collagen	collagen	NN	_	_	I-cesDoc	_	I-p
2914	18552	18563	degradation	degradation	NN	_	_	I-cesDoc	_	I-p
2915	18564	18565	[	[	NN	_	_	I-cesDoc	_	I-p
2916	18574	18575	5	5	CD	_	_	I-cesDoc	_	I-p
2917	18576	18577	6	6	CD	_	_	I-cesDoc	_	I-p
2918	18578	18579	7	7	CD	_	_	I-cesDoc	_	I-p
2919	18580	18581	8	8	CD	_	_	I-cesDoc	_	I-p
2920	18582	18583	]	]	NN	_	_	I-cesDoc	_	I-p
2921	18584	18585	.	.	.	_	_	I-cesDoc	_	I-p
2922	18594	18600	Recent	recent	JJ	_	_	I-cesDoc	_	I-p
2923	18601	18608	reports	report	NNS	_	_	I-cesDoc	_	I-p
2924	18609	18619	suggesting	suggest	VBG	_	_	I-cesDoc	_	I-p
2925	18620	18629	decreased	decrease	VBN	_	_	I-cesDoc	_	I-p
2926	18630	18635	COX-2	cox-2	NNP	_	_	I-cesDoc	_	I-p
2927	18636	18646	expression	expression	NN	_	_	I-cesDoc	_	I-p
2928	18647	18650	and	and	CC	_	_	I-cesDoc	_	I-p
2929	18659	18662	PGE	pge	NNP	_	_	I-cesDoc	_	I-p
2930	18672	18673	2	2	CD	_	_	I-cesDoc	_	I-p
2931	18674	18684	production	production	NN	_	_	I-cesDoc	_	I-p
2932	18685	18687	in	in	IN	_	_	I-cesDoc	_	I-p
2933	18688	18691	IPF	ipf	NNP	_	_	I-cesDoc	_	I-p
2934	18692	18703	fibroblasts	fibroblast	NNS	_	_	I-cesDoc	_	I-p
2935	18704	18708	have	have	VBP	_	_	I-cesDoc	_	I-p
2936	18717	18725	received	receive	VBN	_	_	I-cesDoc	_	I-p
2937	18726	18737	significant	significant	JJ	_	_	I-cesDoc	_	I-p
2938	18738	18747	attention	attention	NN	_	_	I-cesDoc	_	I-p
2939	18748	18749	[	[	NN	_	_	I-cesDoc	_	I-p
2940	18750	18752	12	12	CD	_	_	I-cesDoc	_	I-p
2941	18753	18755	20	20	CD	_	_	I-cesDoc	_	I-p
2942	18756	18758	21	21	CD	_	_	I-cesDoc	_	I-p
2943	18759	18760	]	]	NN	_	_	I-cesDoc	_	I-p
2944	18761	18762	.	.	.	_	_	I-cesDoc	_	I-p
2945	18763	18765	In	in	IN	_	_	I-cesDoc	_	I-p
2946	18766	18769	our	our	PRP$	_	_	I-cesDoc	_	I-p
2947	18770	18775	study	study	NN	_	_	I-cesDoc	_	I-p
2948	18784	18786	we	we	PRP	_	_	I-cesDoc	_	I-p
2949	18787	18792	found	find	VBD	_	_	I-cesDoc	_	I-p
2950	18793	18797	that	that	IN	_	_	I-cesDoc	_	I-p
2951	18798	18802	both	both	DT	_	_	I-cesDoc	_	I-p
2952	18803	18808	COX-2	cox-2	NNP	_	_	I-cesDoc	_	I-p
2953	18809	18816	protein	protein	NN	_	_	I-cesDoc	_	I-p
2954	18817	18827	expression	expression	NN	_	_	I-cesDoc	_	I-p
2955	18828	18831	and	and	CC	_	_	I-cesDoc	_	I-p
2956	18832	18835	PGE	pge	NNP	_	_	I-cesDoc	_	I-p
2957	18845	18846	2	2	CD	_	_	I-cesDoc	_	I-p
2958	18847	18857	production	production	NN	_	_	I-cesDoc	_	I-p
2959	18858	18862	were	be	VBD	_	_	I-cesDoc	_	I-p
2960	18863	18874	upregulated	upregulated	JJ	_	_	I-cesDoc	_	I-p
2961	18875	18877	to	to	TO	_	_	I-cesDoc	_	I-p
2962	18878	18879	a	a	DT	_	_	I-cesDoc	_	I-p
2963	18888	18895	similar	similar	JJ	_	_	I-cesDoc	_	I-p
2964	18896	18902	degree	degree	NN	_	_	I-cesDoc	_	I-p
2965	18903	18905	in	in	IN	_	_	I-cesDoc	_	I-p
2966	18906	18909	IPF	ipf	NNP	_	_	I-cesDoc	_	I-p
2967	18910	18913	and	and	CC	_	_	I-cesDoc	_	I-p
2968	18914	18920	normal	normal	JJ	_	_	I-cesDoc	_	I-p
2969	18921	18925	lung	lung	NN	_	_	I-cesDoc	_	I-p
2970	18926	18937	fibroblasts	fibroblast	NNS	_	_	I-cesDoc	_	I-p
2971	18937	18938	.	.	.	_	_	I-cesDoc	_	I-p
2972	18939	18941	We	we	PRP	_	_	I-cesDoc	_	I-p
2973	18950	18957	believe	believe	VBP	_	_	I-cesDoc	_	I-p
2974	18958	18962	that	that	IN	_	_	I-cesDoc	_	I-p
2975	18963	18974	differences	difference	NNS	_	_	I-cesDoc	_	I-p
2976	18975	18977	in	in	IN	_	_	I-cesDoc	_	I-p
2977	18978	18989	methodology	methodology	NN	_	_	I-cesDoc	_	I-p
2978	18990	18993	and	and	CC	_	_	I-cesDoc	_	I-p
2979	18994	19001	patient	patient	NN	_	_	I-cesDoc	_	I-p
2980	19010	19019	selection	selection	NN	_	_	I-cesDoc	_	I-p
2981	19020	19023	may	may	MD	_	_	I-cesDoc	_	I-p
2982	19024	19031	explain	explain	VB	_	_	I-cesDoc	_	I-p
2983	19032	19035	the	the	DT	_	_	I-cesDoc	_	I-p
2984	19036	19049	discrepancies	discrepancy	NNS	_	_	I-cesDoc	_	I-p
2985	19050	19054	with	with	IN	_	_	I-cesDoc	_	I-p
2986	19055	19060	other	other	JJ	_	_	I-cesDoc	_	I-p
2987	19061	19068	studies	study	NNS	_	_	I-cesDoc	_	I-p
2988	19068	19069	.	.	.	_	_	I-cesDoc	_	I-p
2989	19078	19086	Vancheri	vancheri	NNP	_	_	I-cesDoc	_	I-p
2990	19087	19090	and	and	CC	_	_	I-cesDoc	_	I-p
2991	19091	19104	collaborators	collaborator	NNS	_	_	I-cesDoc	_	I-p
2992	19105	19106	[	[	NN	_	_	I-cesDoc	_	I-p
2993	19107	19109	20	20	CD	_	_	I-cesDoc	_	I-p
2994	19110	19111	]	]	NN	_	_	I-cesDoc	_	I-p
2995	19112	19117	found	find	VBD	_	_	I-cesDoc	_	I-p
2996	19118	19122	that	that	IN	_	_	I-cesDoc	_	I-p
2997	19131	19147	TNF-?-stimulated	tnf-?-stimulated	NNP	_	_	I-cesDoc	_	I-p
2998	19148	19156	fibrotic	fibrotic	JJ	_	_	I-cesDoc	_	I-p
2999	19157	19161	lung	lung	NN	_	_	I-cesDoc	_	I-p
3000	19162	19173	fibroblasts	fibroblast	NNS	_	_	I-cesDoc	_	I-p
3001	19174	19177	had	have	VBD	_	_	I-cesDoc	_	I-p
3002	19178	19187	decreased	decrease	VBN	_	_	I-cesDoc	_	I-p
3003	19196	19201	COX-2	cox-2	NNP	_	_	I-cesDoc	_	I-p
3004	19202	19212	expression	expression	NN	_	_	I-cesDoc	_	I-p
3005	19213	19216	and	and	CC	_	_	I-cesDoc	_	I-p
3006	19217	19220	PGE	pge	NNP	_	_	I-cesDoc	_	I-p
3007	19230	19231	2	2	CD	_	_	I-cesDoc	_	I-p
3008	19232	19242	production	production	NN	_	_	I-cesDoc	_	I-p
3009	19242	19243	,	,	,	_	_	I-cesDoc	_	I-p
3010	19244	19247	but	but	CC	_	_	I-cesDoc	_	I-p
3011	19248	19252	they	they	PRP	_	_	I-cesDoc	_	I-p
3012	19253	19260	further	further	RBR	_	_	I-cesDoc	_	I-p
3013	19261	19267	showed	show	VBD	_	_	I-cesDoc	_	I-p
3014	19276	19280	that	that	IN	_	_	I-cesDoc	_	I-p
3015	19281	19286	these	these	DT	_	_	I-cesDoc	_	I-p
3016	19287	19295	findings	finding	NNS	_	_	I-cesDoc	_	I-p
3017	19296	19300	were	be	VBD	_	_	I-cesDoc	_	I-p
3018	19301	19302	a	a	DT	_	_	I-cesDoc	_	I-p
3019	19303	19309	result	result	NN	_	_	I-cesDoc	_	I-p
3020	19310	19312	of	of	IN	_	_	I-cesDoc	_	I-p
3021	19313	19322	decreased	decrease	VBD	_	_	I-cesDoc	_	I-p
3022	19323	19333	expression	expression	NN	_	_	I-cesDoc	_	I-p
3023	19342	19344	of	of	IN	_	_	I-cesDoc	_	I-p
3024	19345	19350	TNF-?	tnf-?	NNP	_	_	I-cesDoc	_	I-p
3025	19351	19360	receptors	receptor	NNS	_	_	I-cesDoc	_	I-p
3026	19360	19361	.	.	.	_	_	I-cesDoc	_	I-p
3027	19362	19365	The	the	DT	_	_	I-cesDoc	_	I-p
3028	19366	19372	latter	latter	JJ	_	_	I-cesDoc	_	I-p
3029	19373	19380	finding	finding	NN	_	_	I-cesDoc	_	I-p
3030	19381	19386	would	would	MD	_	_	I-cesDoc	_	I-p
3031	19387	19392	argue	argue	VB	_	_	I-cesDoc	_	I-p
3032	19393	19400	against	against	IN	_	_	I-cesDoc	_	I-p
3033	19409	19410	a	a	DT	_	_	I-cesDoc	_	I-p
3034	19411	19418	primary	primary	JJ	_	_	I-cesDoc	_	I-p
3035	19419	19425	defect	defect	NN	_	_	I-cesDoc	_	I-p
3036	19426	19428	in	in	IN	_	_	I-cesDoc	_	I-p
3037	19429	19434	COX-2	cox-2	NNP	_	_	I-cesDoc	_	I-p
3038	19435	19445	expression	expression	NN	_	_	I-cesDoc	_	I-p
3039	19445	19446	,	,	,	_	_	I-cesDoc	_	I-p
3040	19447	19452	since	since	IN	_	_	I-cesDoc	_	I-p
3041	19453	19455	no	no	DT	_	_	I-cesDoc	_	I-p
3042	19456	19461	other	other	JJ	_	_	I-cesDoc	_	I-p
3043	19470	19478	stimulus	stimulus	NN	_	_	I-cesDoc	_	I-p
3044	19478	19479	,	,	,	_	_	I-cesDoc	_	I-p
3045	19480	19485	other	other	JJ	_	_	I-cesDoc	_	I-p
3046	19486	19490	than	than	IN	_	_	I-cesDoc	_	I-p
3047	19491	19496	TNF-?	tnf-?	NNP	_	_	I-cesDoc	_	I-p
3048	19496	19497	,	,	,	_	_	I-cesDoc	_	I-p
3049	19498	19501	was	be	VBD	_	_	I-cesDoc	_	I-p
3050	19502	19508	tested	test	VBN	_	_	I-cesDoc	_	I-p
3051	19508	19509	.	.	.	_	_	I-cesDoc	_	I-p
3052	19510	19512	In	in	IN	_	_	I-cesDoc	_	I-p
3053	19513	19520	another	another	DT	_	_	I-cesDoc	_	I-p
3054	19521	19526	study	study	NN	_	_	I-cesDoc	_	I-p
3055	19526	19527	,	,	,	_	_	I-cesDoc	_	I-p
3056	19536	19549	Keerthisingam	keerthisingam	NNP	_	_	I-cesDoc	_	I-p
3057	19559	19561	et	et	CC	_	_	I-cesDoc	_	I-p
3058	19562	19565	al.	al.	NN	_	_	I-cesDoc	_	I-p
3059	19566	19567	[	[	NN	_	_	I-cesDoc	_	I-p
3060	19568	19570	21	21	CD	_	_	I-cesDoc	_	I-p
3061	19571	19572	]	]	NN	_	_	I-cesDoc	_	I-p
3062	19573	19581	reported	report	VBD	_	_	I-cesDoc	_	I-p
3063	19582	19586	that	that	IN	_	_	I-cesDoc	_	I-p
3064	19587	19595	fibrotic	fibrotic	JJ	_	_	I-cesDoc	_	I-p
3065	19604	19608	lung	lung	NN	_	_	I-cesDoc	_	I-p
3066	19609	19620	fibroblasts	fibroblast	NNS	_	_	I-cesDoc	_	I-p
3067	19621	19624	had	have	VBD	_	_	I-cesDoc	_	I-p
3068	19625	19634	decreased	decrease	VBN	_	_	I-cesDoc	_	I-p
3069	19635	19640	COX-2	cox-2	NNP	_	_	I-cesDoc	_	I-p
3070	19641	19651	expression	expression	NN	_	_	I-cesDoc	_	I-p
3071	19652	19655	and	and	CC	_	_	I-cesDoc	_	I-p
3072	19656	19659	PGE	pge	NNP	_	_	I-cesDoc	_	I-p
3073	19669	19670	2	2	CD	_	_	I-cesDoc	_	I-p
3074	19671	19681	production	production	NN	_	_	I-cesDoc	_	I-p
3075	19682	19684	in	in	IN	_	_	I-cesDoc	_	I-p
3076	19685	19693	response	response	NN	_	_	I-cesDoc	_	I-p
3077	19694	19696	to	to	TO	_	_	I-cesDoc	_	I-p
3078	19697	19701	TGF?	tgf?	NNP	_	_	I-cesDoc	_	I-p
3079	19710	19721	stimulation	stimulation	NN	_	_	I-cesDoc	_	I-p
3080	19721	19722	.	.	.	_	_	I-cesDoc	_	I-p
3081	19723	19727	This	this	DT	_	_	I-cesDoc	_	I-p
3082	19728	19733	study	study	NN	_	_	I-cesDoc	_	I-p
3083	19734	19742	differed	differ	VBD	_	_	I-cesDoc	_	I-p
3084	19743	19747	from	from	IN	_	_	I-cesDoc	_	I-p
3085	19748	19752	ours	ours	PRP	_	_	I-cesDoc	_	I-p
3086	19753	19755	in	in	IN	_	_	I-cesDoc	_	I-p
3087	19756	19760	that	that	IN	_	_	I-cesDoc	_	I-p
3088	19761	19762	a	a	DT	_	_	I-cesDoc	_	I-p
3089	19771	19780	different	different	JJ	_	_	I-cesDoc	_	I-p
3090	19781	19789	stimulus	stimulus	NN	_	_	I-cesDoc	_	I-p
3091	19790	19793	was	be	VBD	_	_	I-cesDoc	_	I-p
3092	19794	19798	used	use	VBN	_	_	I-cesDoc	_	I-p
3093	19798	19799	.	.	.	_	_	I-cesDoc	_	I-p
3094	19800	19802	Of	of	IN	_	_	I-cesDoc	_	I-p
3095	19803	19815	significance	significance	NN	_	_	I-cesDoc	_	I-p
3096	19816	19818	is	be	VBZ	_	_	I-cesDoc	_	I-p
3097	19819	19822	the	the	DT	_	_	I-cesDoc	_	I-p
3098	19823	19827	fact	fact	NN	_	_	I-cesDoc	_	I-p
3099	19836	19840	that	that	IN	_	_	I-cesDoc	_	I-p
3100	19841	19844	the	the	DT	_	_	I-cesDoc	_	I-p
3101	19845	19850	COX-2	cox-2	NNP	_	_	I-cesDoc	_	I-p
3102	19851	19855	gene	gene	NN	_	_	I-cesDoc	_	I-p
3103	19856	19858	is	be	VBZ	_	_	I-cesDoc	_	I-p
3104	19859	19864	known	know	VBN	_	_	I-cesDoc	_	I-p
3105	19865	19867	to	to	TO	_	_	I-cesDoc	_	I-p
3106	19868	19870	be	be	VB	_	_	I-cesDoc	_	I-p
3107	19871	19876	NF-?B	nf-?b	NNP	_	_	I-cesDoc	_	I-p
3108	19877	19886	dependent	dependent	JJ	_	_	I-cesDoc	_	I-p
3109	19886	19887	,	,	,	_	_	I-cesDoc	_	I-p
3110	19888	19891	and	and	CC	_	_	I-cesDoc	_	I-p
3111	19900	19905	IL-1?	il-1?	NNP	_	_	I-cesDoc	_	I-p
3112	19905	19906	,	,	,	_	_	I-cesDoc	_	I-p
3113	19907	19910	but	but	CC	_	_	I-cesDoc	_	I-p
3114	19911	19914	not	not	RB	_	_	I-cesDoc	_	I-p
3115	19915	19919	TGF?	tgf?	NNP	_	_	I-cesDoc	_	I-p
3116	19919	19920	,	,	,	_	_	I-cesDoc	_	I-p
3117	19921	19923	is	be	VBZ	_	_	I-cesDoc	_	I-p
3118	19924	19925	a	a	DT	_	_	I-cesDoc	_	I-p
3119	19926	19932	potent	potent	JJ	_	_	I-cesDoc	_	I-p
3120	19933	19940	inducer	inducer	NN	_	_	I-cesDoc	_	I-p
3121	19941	19943	of	of	IN	_	_	I-cesDoc	_	I-p
3122	19944	19949	NF-?B	nf-?b	NNP	_	_	I-cesDoc	_	I-p
3123	19958	19968	activation	activation	NN	_	_	I-cesDoc	_	I-p
3124	19968	19969	.	.	.	_	_	I-cesDoc	_	I-p
3125	19970	19975	Hence	hence	RB	_	_	I-cesDoc	_	I-p
3126	19975	19976	,	,	,	_	_	I-cesDoc	_	I-p
3127	19977	19980	the	the	DT	_	_	I-cesDoc	_	I-p
3128	19981	19988	pathway	pathway	NN	_	_	I-cesDoc	_	I-p
3129	19989	19997	involved	involve	VBN	_	_	I-cesDoc	_	I-p
3130	19998	20000	in	in	IN	_	_	I-cesDoc	_	I-p
3131	20001	20004	the	the	DT	_	_	I-cesDoc	_	I-p
3132	20005	20014	induction	induction	NN	_	_	I-cesDoc	_	I-p
3133	20015	20017	of	of	IN	_	_	I-cesDoc	_	I-p
3134	20026	20029	the	the	DT	_	_	I-cesDoc	_	I-p
3135	20030	20035	COX-2	cox-2	NNP	_	_	I-cesDoc	_	I-p
3136	20036	20040	gene	gene	NN	_	_	I-cesDoc	_	I-p
3137	20041	20043	by	by	IN	_	_	I-cesDoc	_	I-p
3138	20044	20049	IL-1?	il-1?	NNP	_	_	I-cesDoc	_	I-p
3139	20050	20053	and	and	CC	_	_	I-cesDoc	_	I-p
3140	20054	20058	TGF?	tgf?	NNP	_	_	I-cesDoc	_	I-p
3141	20059	20062	may	may	MD	_	_	I-cesDoc	_	I-p
3142	20063	20065	be	be	VB	_	_	I-cesDoc	_	I-p
3143	20066	20075	different	different	JJ	_	_	I-cesDoc	_	I-p
3144	20075	20076	.	.	.	_	_	I-cesDoc	_	I-p
3145	20085	20096	Furthermore	furthermore	RB	_	_	I-cesDoc	_	I-p
3146	20096	20097	,	,	,	_	_	I-cesDoc	_	I-p
3147	20098	20099	a	a	DT	_	_	I-cesDoc	_	I-p
3148	20100	20111	significant	significant	JJ	_	_	I-cesDoc	_	I-p
3149	20112	20122	proportion	proportion	NN	_	_	I-cesDoc	_	I-p
3150	20123	20125	of	of	IN	_	_	I-cesDoc	_	I-p
3151	20126	20129	the	the	DT	_	_	I-cesDoc	_	I-p
3152	20130	20141	fibroblasts	fibroblast	NNS	_	_	I-cesDoc	_	I-p
3153	20150	20154	used	use	VBN	_	_	I-cesDoc	_	I-p
3154	20155	20157	in	in	IN	_	_	I-cesDoc	_	I-p
3155	20158	20161	the	the	DT	_	_	I-cesDoc	_	I-p
3156	20162	20167	study	study	NN	_	_	I-cesDoc	_	I-p
3157	20168	20170	by	by	IN	_	_	I-cesDoc	_	I-p
3158	20171	20184	Keerthisingam	keerthisingam	NNP	_	_	I-cesDoc	_	I-p
3159	20194	20196	et	et	CC	_	_	I-cesDoc	_	I-p
3160	20197	20200	al.	al.	NN	_	_	I-cesDoc	_	I-p
3161	20201	20202	[	[	NN	_	_	I-cesDoc	_	I-p
3162	20203	20205	21	21	CD	_	_	I-cesDoc	_	I-p
3163	20206	20207	]	]	NN	_	_	I-cesDoc	_	I-p
3164	20208	20212	were	be	VBD	_	_	I-cesDoc	_	I-p
3165	20213	20221	obtained	obtain	VBN	_	_	I-cesDoc	_	I-p
3166	20222	20226	from	from	IN	_	_	I-cesDoc	_	I-p
3167	20235	20243	patients	patient	NNS	_	_	I-cesDoc	_	I-p
3168	20244	20248	with	with	IN	_	_	I-cesDoc	_	I-p
3169	20249	20257	systemic	systemic	JJ	_	_	I-cesDoc	_	I-p
3170	20258	20267	sclerosis	sclerosis	NN	_	_	I-cesDoc	_	I-p
3171	20267	20268	,	,	,	_	_	I-cesDoc	_	I-p
3172	20269	20274	which	which	WDT	_	_	I-cesDoc	_	I-p
3173	20275	20280	makes	make	VBZ	_	_	I-cesDoc	_	I-p
3174	20281	20286	their	their	PRP$	_	_	I-cesDoc	_	I-p
3175	20295	20305	fibroblast	fibroblast	NN	_	_	I-cesDoc	_	I-p
3176	20306	20316	population	population	NN	_	_	I-cesDoc	_	I-p
3177	20317	20321	more	more	RBR	_	_	I-cesDoc	_	I-p
3178	20322	20335	heterogeneous	heterogeneous	JJ	_	_	I-cesDoc	_	I-p
3179	20335	20336	.	.	.	_	_	I-cesDoc	_	I-p
3180	20345	20352	Wilborn	wilborn	NNP	_	_	I-cesDoc	_	I-p
3181	20362	20364	et	et	CC	_	_	I-cesDoc	_	I-p
3182	20365	20368	al.	al.	NN	_	_	I-cesDoc	_	I-p
3183	20369	20370	[	[	NN	_	_	I-cesDoc	_	I-p
3184	20371	20373	12	12	CD	_	_	I-cesDoc	_	I-p
3185	20374	20375	]	]	NN	_	_	I-cesDoc	_	I-p
3186	20376	20380	also	also	RB	_	_	I-cesDoc	_	I-p
3187	20381	20389	reported	report	VBD	_	_	I-cesDoc	_	I-p
3188	20390	20391	a	a	DT	_	_	I-cesDoc	_	I-p
3189	20400	20409	decreased	decrease	VBN	_	_	I-cesDoc	_	I-p
3190	20410	20420	production	production	NN	_	_	I-cesDoc	_	I-p
3191	20421	20423	of	of	IN	_	_	I-cesDoc	_	I-p
3192	20424	20427	PGE	pge	NNP	_	_	I-cesDoc	_	I-p
3193	20437	20438	2	2	CD	_	_	I-cesDoc	_	I-p
3194	20439	20441	by	by	IN	_	_	I-cesDoc	_	I-p
3195	20442	20458	IL-1?-stimulated	il-1?-stimulated	NNP	_	_	I-cesDoc	_	I-p
3196	20459	20462	IPF	ipf	NNP	_	_	I-cesDoc	_	I-p
3197	20463	20474	fibroblasts	fibroblast	NNS	_	_	I-cesDoc	_	I-p
3198	20474	20475	,	,	,	_	_	I-cesDoc	_	I-p
3199	20484	20487	due	due	JJ	_	_	I-cesDoc	_	I-p
3200	20488	20490	to	to	TO	_	_	I-cesDoc	_	I-p
3201	20491	20500	decreased	decrease	VBD	_	_	I-cesDoc	_	I-p
3202	20501	20506	COX-2	cox-2	NNP	_	_	I-cesDoc	_	I-p
3203	20507	20517	expression	expression	NN	_	_	I-cesDoc	_	I-p
3204	20518	20519	[	[	NN	_	_	I-cesDoc	_	I-p
3205	20520	20522	12	12	CD	_	_	I-cesDoc	_	I-p
3206	20523	20524	]	]	NN	_	_	I-cesDoc	_	I-p
3207	20525	20526	.	.	.	_	_	I-cesDoc	_	I-p
3208	20527	20532	There	there	EX	_	_	I-cesDoc	_	I-p
3209	20533	20535	is	be	VBZ	_	_	I-cesDoc	_	I-p
3210	20536	20537	a	a	DT	_	_	I-cesDoc	_	I-p
3211	20546	20557	possibility	possibility	NN	_	_	I-cesDoc	_	I-p
3212	20558	20562	that	that	DT	_	_	I-cesDoc	_	I-p
3213	20563	20570	patient	patient	NN	_	_	I-cesDoc	_	I-p
3214	20571	20580	selection	selection	NN	_	_	I-cesDoc	_	I-p
3215	20581	20584	may	may	MD	_	_	I-cesDoc	_	I-p
3216	20585	20589	have	have	VB	_	_	I-cesDoc	_	I-p
3217	20590	20598	differed	differ	VBD	_	_	I-cesDoc	_	I-p
3218	20607	20614	between	between	IN	_	_	I-cesDoc	_	I-p
3219	20615	20618	the	the	DT	_	_	I-cesDoc	_	I-p
3220	20619	20622	two	two	CD	_	_	I-cesDoc	_	I-p
3221	20623	20630	studies	study	NNS	_	_	I-cesDoc	_	I-p
3222	20630	20631	.	.	.	_	_	I-cesDoc	_	I-p
3223	20632	20639	However	however	RB	_	_	I-cesDoc	_	I-p
3224	20639	20640	,	,	,	_	_	I-cesDoc	_	I-p
3225	20641	20643	we	we	PRP	_	_	I-cesDoc	_	I-p
3226	20644	20648	feel	feel	VBP	_	_	I-cesDoc	_	I-p
3227	20649	20656	certain	certain	JJ	_	_	I-cesDoc	_	I-p
3228	20657	20661	that	that	IN	_	_	I-cesDoc	_	I-p
3229	20662	20665	the	the	DT	_	_	I-cesDoc	_	I-p
3230	20674	20684	diagnostic	diagnostic	JJ	_	_	I-cesDoc	_	I-p
3231	20685	20693	accuracy	accuracy	NN	_	_	I-cesDoc	_	I-p
3232	20694	20696	of	of	IN	_	_	I-cesDoc	_	I-p
3233	20697	20700	our	our	PRP$	_	_	I-cesDoc	_	I-p
3234	20701	20708	patient	patient	NN	_	_	I-cesDoc	_	I-p
3235	20709	20719	population	population	NN	_	_	I-cesDoc	_	I-p
3236	20720	20723	was	be	VBD	_	_	I-cesDoc	_	I-p
3237	20724	20728	high	high	JJ	_	_	I-cesDoc	_	I-p
3238	20728	20729	,	,	,	_	_	I-cesDoc	_	I-p
3239	20730	20733	due	due	JJ	_	_	I-cesDoc	_	I-p
3240	20742	20744	to	to	TO	_	_	I-cesDoc	_	I-p
3241	20745	20748	the	the	DT	_	_	I-cesDoc	_	I-p
3242	20749	20753	fact	fact	NN	_	_	I-cesDoc	_	I-p
3243	20754	20758	that	that	IN	_	_	I-cesDoc	_	I-p
3244	20759	20760	5	5	CD	_	_	I-cesDoc	_	I-p
3245	20761	20764	out	out	IN	_	_	I-cesDoc	_	I-p
3246	20765	20767	of	of	IN	_	_	I-cesDoc	_	I-p
3247	20768	20769	a	a	DT	_	_	I-cesDoc	_	I-p
3248	20770	20775	total	total	NN	_	_	I-cesDoc	_	I-p
3249	20776	20778	of	of	IN	_	_	I-cesDoc	_	I-p
3250	20779	20780	7	7	CD	_	_	I-cesDoc	_	I-p
3251	20781	20784	IPF	ipf	NNP	_	_	I-cesDoc	_	I-p
3252	20785	20793	subjects	subject	NNS	_	_	I-cesDoc	_	I-p
3253	20802	20810	included	include	VBN	_	_	I-cesDoc	_	I-p
3254	20811	20813	in	in	IN	_	_	I-cesDoc	_	I-p
3255	20814	20817	our	our	PRP$	_	_	I-cesDoc	_	I-p
3256	20818	20823	study	study	NN	_	_	I-cesDoc	_	I-p
3257	20824	20833	underwent	undergo	VBD	_	_	I-cesDoc	_	I-p
3258	20834	20838	lung	lung	NN	_	_	I-cesDoc	_	I-p
3259	20839	20854	transplantation	transplantation	NN	_	_	I-cesDoc	_	I-p
3260	20855	20859	with	with	IN	_	_	I-cesDoc	_	I-p
3261	20868	20880	confirmatory	confirmatory	NN	_	_	I-cesDoc	_	I-p
3262	20881	20890	pathology	pathology	NN	_	_	I-cesDoc	_	I-p
3263	20891	20898	results	result	NNS	_	_	I-cesDoc	_	I-p
3264	20899	20909	consistent	consistent	JJ	_	_	I-cesDoc	_	I-p
3265	20910	20914	with	with	IN	_	_	I-cesDoc	_	I-p
3266	20915	20918	IPF	ipf	NNP	_	_	I-cesDoc	_	I-p
3267	20918	20919	.	.	.	_	_	I-cesDoc	_	I-p
3268	20920	20923	The	the	DT	_	_	I-cesDoc	_	I-p
3269	20932	20937	other	other	JJ	_	_	I-cesDoc	_	I-p
3270	20938	20939	2	2	CD	_	_	I-cesDoc	_	I-p
3271	20940	20948	subjects	subject	NNS	_	_	I-cesDoc	_	I-p
3272	20949	20952	had	have	VBD	_	_	I-cesDoc	_	I-p
3273	20953	20959	biopsy	biopsy	NN	_	_	I-cesDoc	_	I-p
3274	20959	20960	-	-	-	_	_	I-cesDoc	_	I-p
3275	20960	20966	proven	prove	VBN	_	_	I-cesDoc	_	I-p
3276	20967	20970	IPF	ipf	NNP	_	_	I-cesDoc	_	I-p
3277	20970	20971	.	.	.	_	_	I-cesDoc	_	I-p
3278	20972	20974	In	in	IN	_	_	I-cesDoc	_	I-p
3279	20975	20983	addition	addition	NN	_	_	I-cesDoc	_	I-p
3280	20983	20984	,	,	,	_	_	I-cesDoc	_	I-p
3281	20985	20988	our	our	PRP$	_	_	I-cesDoc	_	I-p
3282	20997	21004	results	result	NNS	_	_	I-cesDoc	_	I-p
3283	21005	21009	were	be	VBD	_	_	I-cesDoc	_	I-p
3284	21010	21017	similar	similar	JJ	_	_	I-cesDoc	_	I-p
3285	21018	21022	when	when	WRB	_	_	I-cesDoc	_	I-p
3286	21023	21032	comparing	compare	VBG	_	_	I-cesDoc	_	I-p
3287	21033	21037	lung	lung	NN	_	_	I-cesDoc	_	I-p
3288	21038	21049	fibroblasts	fibroblast	NNS	_	_	I-cesDoc	_	I-p
3289	21058	21066	obtained	obtain	VBN	_	_	I-cesDoc	_	I-p
3290	21067	21071	from	from	IN	_	_	I-cesDoc	_	I-p
3291	21072	21073	5	5	CD	_	_	I-cesDoc	_	I-p
3292	21074	21082	subjects	subject	NNS	_	_	I-cesDoc	_	I-p
3293	21083	21087	with	with	IN	_	_	I-cesDoc	_	I-p
3294	21088	21096	advanced	advanced	JJ	_	_	I-cesDoc	_	I-p
3295	21097	21102	stage	stage	NN	_	_	I-cesDoc	_	I-p
3296	21103	21106	IPF	ipf	NNP	_	_	I-cesDoc	_	I-p
3297	21107	21111	with	with	IN	_	_	I-cesDoc	_	I-p
3298	21112	21117	those	those	DT	_	_	I-cesDoc	_	I-p
3299	21126	21128	of	of	IN	_	_	I-cesDoc	_	I-p
3300	21129	21130	2	2	CD	_	_	I-cesDoc	_	I-p
3301	21131	21139	subjects	subject	NNS	_	_	I-cesDoc	_	I-p
3302	21140	21142	at	at	IN	_	_	I-cesDoc	_	I-p
3303	21143	21145	an	an	DT	_	_	I-cesDoc	_	I-p
3304	21146	21153	earlier	earlier	JJR	_	_	I-cesDoc	_	I-p
3305	21154	21159	stage	stage	NN	_	_	I-cesDoc	_	I-p
3306	21160	21162	of	of	IN	_	_	I-cesDoc	_	I-p
3307	21163	21168	their	their	PRP$	_	_	I-cesDoc	_	I-p
3308	21169	21176	disease	disease	NN	_	_	I-cesDoc	_	I-p
3309	21176	21177	,	,	,	_	_	I-cesDoc	_	I-p
3310	21178	21181	who	who	WP	_	_	I-cesDoc	_	I-p
3311	21182	21185	had	have	VBD	_	_	I-cesDoc	_	I-p
3312	21194	21202	received	receive	VBN	_	_	I-cesDoc	_	I-p
3313	21203	21205	no	no	DT	_	_	I-cesDoc	_	I-p
3314	21206	21213	therapy	therapy	NN	_	_	I-cesDoc	_	I-p
3315	21213	21214	.	.	.	_	_	I-cesDoc	_	I-p
3316	21215	21223	Although	although	IN	_	_	I-cesDoc	_	I-p
3317	21224	21227	the	the	DT	_	_	I-cesDoc	_	I-p
3318	21228	21235	reasons	reason	NNS	_	_	I-cesDoc	_	I-p
3319	21236	21239	for	for	IN	_	_	I-cesDoc	_	I-p
3320	21240	21243	our	our	PRP$	_	_	I-cesDoc	_	I-p
3321	21244	21253	different	different	JJ	_	_	I-cesDoc	_	I-p
3322	21262	21269	results	result	NNS	_	_	I-cesDoc	_	I-p
3323	21270	21273	are	be	VBP	_	_	I-cesDoc	_	I-p
3324	21274	21281	unclear	unclear	JJ	_	_	I-cesDoc	_	I-p
3325	21281	21282	,	,	,	_	_	I-cesDoc	_	I-p
3326	21283	21286	the	the	DT	_	_	I-cesDoc	_	I-p
3327	21287	21291	fact	fact	NN	_	_	I-cesDoc	_	I-p
3328	21292	21296	that	that	IN	_	_	I-cesDoc	_	I-p
3329	21297	21299	we	we	PRP	_	_	I-cesDoc	_	I-p
3330	21300	21305	found	find	VBD	_	_	I-cesDoc	_	I-p
3331	21306	21313	similar	similar	JJ	_	_	I-cesDoc	_	I-p
3332	21314	21319	COX-2	cox-2	NNP	_	_	I-cesDoc	_	I-p
3333	21328	21338	expression	expression	NN	_	_	I-cesDoc	_	I-p
3334	21339	21342	and	and	CC	_	_	I-cesDoc	_	I-p
3335	21343	21346	PGE	pge	NNP	_	_	I-cesDoc	_	I-p
3336	21356	21357	2	2	CD	_	_	I-cesDoc	_	I-p
3337	21358	21368	production	production	NN	_	_	I-cesDoc	_	I-p
3338	21369	21371	in	in	IN	_	_	I-cesDoc	_	I-p
3339	21372	21378	normal	normal	JJ	_	_	I-cesDoc	_	I-p
3340	21379	21382	and	and	CC	_	_	I-cesDoc	_	I-p
3341	21383	21386	IPF	ipf	NNP	_	_	I-cesDoc	_	I-p
3342	21387	21391	lung	lung	NN	_	_	I-cesDoc	_	I-p
3343	21400	21411	fibroblasts	fibroblast	NNS	_	_	I-cesDoc	_	I-p
3344	21412	21420	suggests	suggest	VBZ	_	_	I-cesDoc	_	I-p
3345	21421	21425	that	that	DT	_	_	I-cesDoc	_	I-p
3346	21426	21430	loss	loss	NN	_	_	I-cesDoc	_	I-p
3347	21431	21433	of	of	IN	_	_	I-cesDoc	_	I-p
3348	21434	21439	COX-2	cox-2	NNP	_	_	I-cesDoc	_	I-p
3349	21440	21450	expression	expression	NN	_	_	I-cesDoc	_	I-p
3350	21451	21453	is	be	VBZ	_	_	I-cesDoc	_	I-p
3351	21454	21457	not	not	RB	_	_	I-cesDoc	_	I-p
3352	21458	21459	a	a	DT	_	_	I-cesDoc	_	I-p
3353	21468	21477	universal	universal	JJ	_	_	I-cesDoc	_	I-p
3354	21478	21492	characteristic	characteristic	NN	_	_	I-cesDoc	_	I-p
3355	21493	21495	of	of	IN	_	_	I-cesDoc	_	I-p
3356	21496	21507	fibroblasts	fibroblast	NNS	_	_	I-cesDoc	_	I-p
3357	21508	21516	cultured	cultured	JJ	_	_	I-cesDoc	_	I-p
3358	21517	21521	from	from	IN	_	_	I-cesDoc	_	I-p
3359	21522	21525	the	the	DT	_	_	I-cesDoc	_	I-p
3360	21534	21539	lungs	lung	NNS	_	_	I-cesDoc	_	I-p
3361	21540	21542	of	of	IN	_	_	I-cesDoc	_	I-p
3362	21543	21551	subjects	subject	NNS	_	_	I-cesDoc	_	I-p
3363	21552	21556	with	with	IN	_	_	I-cesDoc	_	I-p
3364	21557	21560	IPF	ipf	NNP	_	_	I-cesDoc	_	I-p
3365	21560	21561	.	.	.	_	_	I-cesDoc	_	I-p
3366	21584	21594	Conclusion	conclusion	NNP	_	_	I-cesDoc	B-head	_
3367	21603	21605	We	we	PRP	_	_	I-cesDoc	_	B-p
3368	21606	21610	have	have	VBP	_	_	I-cesDoc	_	I-p
3369	21611	21616	found	find	VBN	_	_	I-cesDoc	_	I-p
3370	21617	21621	that	that	WDT	_	_	I-cesDoc	_	I-p
3371	21622	21633	fibroblasts	fibroblast	NNS	_	_	I-cesDoc	_	I-p
3372	21634	21642	cultured	cultured	JJ	_	_	I-cesDoc	_	I-p
3373	21643	21647	from	from	IN	_	_	I-cesDoc	_	I-p
3374	21648	21654	normal	normal	JJ	_	_	I-cesDoc	_	I-p
3375	21655	21658	and	and	CC	_	_	I-cesDoc	_	I-p
3376	21667	21670	IPF	ipf	NNP	_	_	I-cesDoc	_	I-p
3377	21671	21676	human	human	JJ	_	_	I-cesDoc	_	I-p
3378	21677	21682	lungs	lung	NNS	_	_	I-cesDoc	_	I-p
3379	21683	21687	have	have	VBP	_	_	I-cesDoc	_	I-p
3380	21688	21689	a	a	DT	_	_	I-cesDoc	_	I-p
3381	21690	21701	significant	significant	JJ	_	_	I-cesDoc	_	I-p
3382	21702	21705	and	and	CC	_	_	I-cesDoc	_	I-p
3383	21706	21713	similar	similar	JJ	_	_	I-cesDoc	_	I-p
3384	21714	21723	induction	induction	NN	_	_	I-cesDoc	_	I-p
3385	21724	21726	of	of	IN	_	_	I-cesDoc	_	I-p
3386	21735	21738	the	the	DT	_	_	I-cesDoc	_	I-p
3387	21739	21744	COX-2	cox-2	NNP	_	_	I-cesDoc	_	I-p
3388	21745	21751	enzyme	enzyme	NN	_	_	I-cesDoc	_	I-p
3389	21752	21756	when	when	WRB	_	_	I-cesDoc	_	I-p
3390	21757	21767	stimulated	stimulate	VBN	_	_	I-cesDoc	_	I-p
3391	21768	21772	with	with	IN	_	_	I-cesDoc	_	I-p
3392	21773	21778	IL-1?	il-1?	NNP	_	_	I-cesDoc	_	I-p
3393	21778	21779	,	,	,	_	_	I-cesDoc	_	I-p
3394	21780	21783	but	but	CC	_	_	I-cesDoc	_	I-p
3395	21784	21788	that	that	IN	_	_	I-cesDoc	_	I-p
3396	21789	21792	IPF	ipf	NNP	_	_	I-cesDoc	_	I-p
3397	21801	21812	fibroblasts	fibroblast	NNS	_	_	I-cesDoc	_	I-p
3398	21813	21821	produced	produce	VBD	_	_	I-cesDoc	_	I-p
3399	21822	21826	more	more	JJR	_	_	I-cesDoc	_	I-p
3400	21827	21838	thromboxane	thromboxane	NN	_	_	I-cesDoc	_	I-p
3401	21839	21842	and	and	CC	_	_	I-cesDoc	_	I-p
3402	21843	21846	had	have	VBD	_	_	I-cesDoc	_	I-p
3403	21847	21848	a	a	DT	_	_	I-cesDoc	_	I-p
3404	21857	21870	significantly	significantly	RB	_	_	I-cesDoc	_	I-p
3405	21871	21876	lower	lower	JJR	_	_	I-cesDoc	_	I-p
3406	21877	21889	prostacyclin	prostacyclin	NN	_	_	I-cesDoc	_	I-p
3407	21889	21890	:	:	:	_	_	I-cesDoc	_	I-p
3408	21890	21901	thromboxane	thromboxane	NN	_	_	I-cesDoc	_	I-p
3409	21902	21907	ratio	ratio	NN	_	_	I-cesDoc	_	I-p
3410	21907	21908	.	.	.	_	_	I-cesDoc	_	I-p
3411	21909	21911	We	we	PRP	_	_	I-cesDoc	_	I-p
3412	21920	21931	hypothesize	hypothesize	NN	_	_	I-cesDoc	_	I-p
3413	21932	21936	that	that	IN	_	_	I-cesDoc	_	I-p
3414	21937	21940	the	the	DT	_	_	I-cesDoc	_	I-p
3415	21941	21946	lower	lower	JJR	_	_	I-cesDoc	_	I-p
3416	21947	21950	PGI	pgi	NNP	_	_	I-cesDoc	_	I-p
3417	21960	21961	2	2	CD	_	_	I-cesDoc	_	I-p
3418	21962	21963	:	:	:	_	_	I-cesDoc	_	I-p
3419	21963	21966	TXA	txa	NNP	_	_	I-cesDoc	_	I-p
3420	21976	21977	2	2	CD	_	_	I-cesDoc	_	I-p
3421	21978	21983	ratio	ratio	NN	_	_	I-cesDoc	_	I-p
3422	21984	21988	seen	see	VBN	_	_	I-cesDoc	_	I-p
3423	21989	21991	in	in	IN	_	_	I-cesDoc	_	I-p
3424	21992	21998	HF-IPF	hf-ipf	NNP	_	_	I-cesDoc	_	I-p
3425	21999	22002	may	may	MD	_	_	I-cesDoc	_	I-p
3426	22003	22005	be	be	VB	_	_	I-cesDoc	_	I-p
3427	22006	22007	a	a	DT	_	_	I-cesDoc	_	I-p
3428	22016	22026	phenotypic	phenotypic	JJ	_	_	I-cesDoc	_	I-p
3429	22027	22037	alteration	alteration	NN	_	_	I-cesDoc	_	I-p
3430	22038	22042	that	that	WDT	_	_	I-cesDoc	_	I-p
3431	22043	22048	plays	play	VBZ	_	_	I-cesDoc	_	I-p
3432	22049	22050	a	a	DT	_	_	I-cesDoc	_	I-p
3433	22051	22055	role	role	NN	_	_	I-cesDoc	_	I-p
3434	22056	22058	in	in	IN	_	_	I-cesDoc	_	I-p
3435	22059	22062	the	the	DT	_	_	I-cesDoc	_	I-p
3436	22063	22075	pathogenesis	pathogenesis	NNS	_	_	I-cesDoc	_	I-p
3437	22084	22086	of	of	IN	_	_	I-cesDoc	_	I-p
3438	22087	22090	IPF	ipf	NNP	_	_	I-cesDoc	_	I-p
3439	22090	22091	.	.	.	_	_	I-cesDoc	_	I-p
3440	22114	22127	Abbreviations	abbreviations	NNP	_	_	I-cesDoc	B-head	_
3441	22136	22139	COX	cox	NNP	_	_	I-cesDoc	_	B-p
3442	22140	22141	=	=	SYM	_	_	I-cesDoc	_	I-p
3443	22142	22156	cyclooxygenase	cyclooxygenase	NN	_	_	I-cesDoc	_	I-p
3444	22156	22157	;	;	:	_	_	I-cesDoc	_	I-p
3445	22158	22160	HF	hf	NNP	_	_	I-cesDoc	_	I-p
3446	22161	22162	=	=	SYM	_	_	I-cesDoc	_	I-p
3447	22163	22168	human	human	JJ	_	_	I-cesDoc	_	I-p
3448	22169	22180	fibroblasts	fibroblast	NNS	_	_	I-cesDoc	_	I-p
3449	22180	22181	;	;	:	_	_	I-cesDoc	_	I-p
3450	22182	22184	NL	nl	NNP	_	_	I-cesDoc	_	I-p
3451	22185	22186	=	=	SYM	_	_	I-cesDoc	_	I-p
3452	22195	22201	normal	normal	JJ	_	_	I-cesDoc	_	I-p
3453	22202	22207	lungs	lung	NNS	_	_	I-cesDoc	_	I-p
3454	22207	22208	;	;	:	_	_	I-cesDoc	_	I-p
3455	22209	22212	IPF	ipf	NNP	_	_	I-cesDoc	_	I-p
3456	22213	22214	=	=	SYM	_	_	I-cesDoc	_	I-p
3457	22215	22225	idiopathic	idiopathic	JJ	_	_	I-cesDoc	_	I-p
3458	22226	22235	pulmonary	pulmonary	JJ	_	_	I-cesDoc	_	I-p
3459	22236	22244	fibrosis	fibrosis	NNS	_	_	I-cesDoc	_	I-p
3460	22244	22245	;	;	:	_	_	I-cesDoc	_	I-p
3461	22246	22249	IFN	ifn	NNP	_	_	I-cesDoc	_	I-p
3462	22250	22251	=	=	SYM	_	_	I-cesDoc	_	I-p
3463	22260	22270	interferon	interferon	NN	_	_	I-cesDoc	_	I-p
3464	22270	22271	;	;	:	_	_	I-cesDoc	_	I-p
3465	22272	22274	IL	il	NNP	_	_	I-cesDoc	_	I-p
3466	22275	22276	=	=	SYM	_	_	I-cesDoc	_	I-p
3467	22277	22288	interleukin	interleukin	NN	_	_	I-cesDoc	_	I-p
3468	22288	22289	;	;	:	_	_	I-cesDoc	_	I-p
3469	22290	22292	PG	pg	NNP	_	_	I-cesDoc	_	I-p
3470	22293	22294	=	=	SYM	_	_	I-cesDoc	_	I-p
3471	22295	22308	prostaglandin	prostaglandin	NN	_	_	I-cesDoc	_	I-p
3472	22308	22309	;	;	:	_	_	I-cesDoc	_	I-p
3473	22310	22312	TX	tx	NNP	_	_	I-cesDoc	_	I-p
3474	22313	22314	=	=	SYM	_	_	I-cesDoc	_	I-p
3475	22323	22334	thromboxane	thromboxane	NN	_	_	I-cesDoc	_	I-p
3476	22334	22335	;	;	:	_	_	I-cesDoc	_	I-p
3477	22336	22339	PGI	pgi	NNP	_	_	I-cesDoc	_	I-p
3478	22349	22350	2	2	CD	_	_	I-cesDoc	_	I-p
3479	22351	22352	=	=	SYM	_	_	I-cesDoc	_	I-p
3480	22353	22365	prostacyclin	prostacyclin	NN	_	_	I-cesDoc	_	I-p
3481	22365	22366	.	.	.	_	_	I-cesDoc	_	I-p

